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Three protein targets are used in malaria rapid diagnostic tests (RDTs). These are Plasmodium 
falciparum histidine rich protein 2, Plasmodium lactate dehydrogenase and aldolase. A thrust 
of research in RDTs is to improve on their specificity and sensitivity. In this study the current 
diagnostic target, P. falciparum lactate dehydrogenase (PfLDH) was compared to a new target 
glyceraldehyde-3-phosphate dehydrogenase (PfGAPDH) that was identified based on 
transcriptional data. These proteins are conserved amongst all Plasmodium species, with 
minor amino acid sequence variations which were evaluated as possible species-specific 
peptide epitopes for PfLDH: LISDAELEAIFDRC and PfGAPDH: 
CADGFLLIGEKKVSVFA; CAEKDPSQIPWGKCQV, where common peptides were 
identified as pan-malarial epitopes for pLDH: APGKSDKEWNRDDLC and pGAPDH: 
CKDDTPIYVMGINH. The chosen peptides were located on the surface of their predicted 3D 
crystal structure models. Antibodies were raised against these peptides in chickens (IgY) and 
affinity purified.  
PfLDH and PfGAPDH were recombinantly expressed in E. coli BL21(DE3) cells and their 
coding inserts confirmed by sequencing. The recombinant proteins were detected in Western 
blots with specific anti-His6 tag antibodies at approximately 35 kD (PfLDH ~ 36 kD and 
PfGAPDH ~ 39 kD) which compared with their expected values. Both recombinant proteins 
were found to form tetramers in solution and were used to raise IgY antibodies for 
comparison of PheroidsTM and Freund’s adjuvants. PheroidsTM, like Freund’s appeared to 
exhibit a depot effect, however Freund’s adjuvant gave higher affinity purified IgY yields. 
The anti-recombinant and anti-peptide IgY specifically detected their respective recombinant 
and native antigens and did not cross-react with other human blood proteins. 
Immunoprecipitation detected higher levels of PfGAPDH to PfLDH in P. falciparum culture 
lysates. A double antibody sandwich ELISA detected 17.3 ng/ml PfLDH and 138.5 ng/ml 
PfGAPDH at 1% parasitemia in in vitro cultures, however this needs to be further evaluated.  
These findings suggest PfGAPDH to be at least as good a protein target as PfLDH for malaria 
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Introduction and Literature Review 
 
1.1 An overview of malaria 
Malaria is caused by a eukaryotic parasite from the genus Plasmodium (Miller et al., 1994; 
Bannister et al., 2000), and is transmitted by the Anopheles mosquito (Kiszewski et al., 2004). 
Malaria caused an estimated 1 million deaths worldwide out of 247 million reported cases in 
2006 (WHO The Global Burden of Disease, 2008). The disease is especially severe in 
children under the age of 5, claiming a child’s life nearly every 30 seconds, totalling 
approximately 700,000 deaths each year (Black et al., 2003;WHO The Global Burden of 
Disease, 2008; WHO malaria fact sheet no. 94, January 2009). In endemic countries adults 
develop natural immunity against malaria. However, this is non-sterilizing, meaning that 
individuals remain susceptible to infection but remain asymptomatic, making them important 
reservoirs of malaria (Hafalla et al., 2011; Miller et al., 1994). 
Progress on an anti-malarial vaccine has proven slow although various strategies are being 
investigated ranging from anti-protein or sub-unit vaccines to using attenuated whole 
parasites (Friesen et al., 2010; Nussenzweig et al., 1967). Some groups believe a humoral 
immune response should suffice for sterile immunity, while others have demonstrated the 
need for stimulation of both humoral and innate immune systems as reviewed by Anders 
(2011) and Good (2011). Until a vaccine is found, diagnosis and anti-malarial drugs remain 
the main tools in the treatment of a malaria infection.  
 
1.1.1 The malaria life cycle 
It was initially believed that malaria was caused by inhaling bad air, which in Italian translates 
to “mal aria”. Since then it was discovered that the parasite life cycle is divided between a 
human host and a mosquito vector. The first microscopic record of the red blood cell stage of 
the parasite was made by Laveran in 1880. The vector responsible for transmitting avian 
malaria was identified as the female Anopheles mosquito by Ross in 1897, which quickly lead 















Sexual cycle in Anopheles mosquito 
Asexual cycle in human 
Salivary 
gland 
Tissue / liver stage 
infecting Hepatocytes 1 to 
2 weeks 
(Hypnozoites) 
Asexual red blood cell 
stage 48-72 hours 
(Merozoites) 
Asexual cycle in oocyst producing 
2000 - 4000 sporozoites in 2 weeks 
10-1000 gametocytes 




1900. The  human liver stage of  the  infe ction wa s only identifie d in 1948 b y S hortt a nd 




Figure1.1 The m alaria life cycle, hig hlighting t he a sexual red b lood ce ll stage as t he t arget f or 
diagnostics.  
The approximate numbers o f p arasites per s tage were taken f rom (Antia et a l., 2008; Baldacci and Menard, 
2004; Fujioka and Aikawa, 2002; Kappe et al., 2010; Miller et al., 1994; Smith and Craig, 2005). The boxed red 
blood cell stage is responsible for disease symptoms and is the stage targeted for diagnostics. (adapted from R.D. 
Barnes). 
 
Female mosquitoes require blood as a source of protein for egg production, and produce eggs 
throughout their life. This means they feed regularly, which makes them an ideal vector for 
transmission of  mala ria from one host  to another. T he f emale Anopheles mosquito inj ects 
salivary fluid containing anti-coagulants into the blood as part of its feeding process (Miller et 
al., 1994). If infected it injects malarial sporozoites with its saliva into host tissue or directly 
into the blood (Baldacci and Menard, 2004). Around 10 to 100 sporozoites are injected per 
mosquito bite (Baldacci and Menard, 2004; Kappe et al., 2010) and this marks the start of the 
life cycle within the human host.  
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Sporozoites migrate to the liver within 60 minutes either by entering the blood stream or the 
lymphatic system by active gliding motility (Baldacci and Menard, 2004; Kebaier et al., 
2009) and invade liver hepatocytes (Baldacci and Menard, 2004; Miller et al., 1994). At this 
stage the parasites mature into schizonts, or they remain dormant in which case they are 
referred to as hypnozoites. The schizonts eventually occupy the entire cytoplasm of a 
hepatocyte, at which stage the hepatocyte bursts and releases thousands of merozoites (10,000 
to 30,000) into the host blood stream (Fujioka and Aikawa, 2002; Miller et al., 1994). This 
completes the liver stage of the infection except in the case of P. vivax and P. ovale as these 
have dormant liver stages referred to as hypnozoites (Fujioka and Aikawa, 2002).  
The next stage takes place in the red blood cell stage and has a 48 to 72 hour cycle, depending 
on the species of Plasmodium (see Table 1.1). For each successful merozoite that infects a red 
blood cell, 8 to 32 new merozoites are formed (Antia et al., 2008; Baldacci and Menard, 
2004; Collins and Jeffery, 2005), and given the short turn-over time in the red cell, the 
parasitemia increases rapidly. This erythrocytic stage is responsible for the symptoms in the 
patient and is targeted for diagnosis (Antia et al., 2008; Baldacci and Menard, 2004; Miller et 
al., 1994; Murray et al., 2008). The time taken for the expression of disease symptoms after 
the initial infective bite is referred to as the incubation period and ranges between 12 to 28 
days dependent on the species of Plasmodium and the number of sporozoites initially injected. 
The greater the numbers of infective sporozoites the faster the symptoms appear. After 3 to 10 
red blood cell cycles of the infection the first male and female gametocytes appear. The life 
cycle returns to the mosquito vector when both male and female gametocytes are ingested by 
a female Anopheles mosquito on its next blood meal where the gametocytes mature into male 
and female gametes (Fujioka and Aikawa, 2002).  
This starts the sexual cycle of the parasite within the mosquito where the gametes form a 
zygote. The zygote becomes a motile ookinete approximately 18 hours after feeding, and 
passes through the stomach wall, settling in the mid gut as a sessile oocyst. Within 10 to 24 
days dependent on the ambient temperature and the species of Anopheles and Plasmodium, 
2000 to 4000 sporozoites are produced within the oocyst (Fujioka and Aikawa, 2002). These 
then become actively motile and migrate to the salivary gland of the mosquito until its next 
blood meal, upon which the life cycle is completed. 
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1.1.2 Which malaria species infect humans? 
Only 5 out of over 100 species of Plasmodium infect humans (Suh et al., 2004). These are 
Plasmodium falciparum; P. vivax; P. ovale; P. malariae and P. knowlesi (Daneshvar et al., 
2009; Sabbatani et al., 2010). P. knowlesi is common to monkeys, and has only recently been 
accepted as a naturally infective human species (Cox-Singh et al., 2008; Lee et al., 2009; 
Singh et al., 2004; van Hellemond et al., 2009).  
P. knowlesi was first isolated from long-tailed macaques in India in 1931, and was shown to 
be infectious to humans by blood passage in 1932 (Lee et al., 2009). The first case of a 
natural P. knowlesi infection in humans was reported in 1965 in Pahang (Malaysia) (Chin et 
al., 1965). The first full description of P. ovale was published in 1922 (Collins and Jeffery, 
2005). Humans are the only natural host of this species and the Donaldson strain was used as 
a treatment of neurosyphilis before the advent of penicillin. The first separate description of 
P. vivax and P. malariae was done by Grassi and Feletti in 1890 (Collins and Jeffery, 2007). 
The malignant tertian malaria was named P. falciparum by Welch and Thayer in 1897. 
Each of these species has slightly different life cycle characteristics as summarized in Table 
1.1. P. falciparum has by far the most aggressive infective characteristics of the 5 species 
infectious to man and leads to the most deaths (Suh et al., 2004). Little is known of the P. 
knowlesi infection characteristics in man, but the short erythrocytic cycle suggests it to cause 
severe and rapid progression of disease, as well as daily fever spikes (Ng et al., 2008). P. 
knowlesi has been shown to share symptoms with P. falciparum and P. vivax and fatal cases 
have been reported (Daneshvar et al., 2009; Sabbatani et al., 2010).  
Table 1.1 Life cycle characteristics of the 5 human infective Plasmodium species. 
 
 
The life cycle data was assembled from the following sources: Chin et al., 1965; Daneshvar et al., 2009; Fujioka 
and Aikawa, 2002; Lee et al., 2009; Murray et al., 2008. Abbreviations used: rbc. = red blood cell(s); NA = not 
currently available.  
  P. falciparum P. vivax P. ovale P. malariae P. knowlesi 
Pre-erythrocytic cycle (days) 5 to 6 8 9 13 NA 
Dormant liver stage no yes yes no no 
Merozoite number released 
per infected hepatocyte 30,000 10,000 15,000 10,000 NA 
Rbc cycle (hours) 48 48 49 72 24 
Maximum number of 
merozoites per rbc 32 24 20 14 16 
Average parasitemia / µl 20 to 500,000 20,000 9000 6000 NA 
Maximum parasitemia / µl 2,000,000 100,000 100,000 20,000 > 100,000 
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The WHO defined severe malaria in 2000 as a patient who shows one or more of the 
following symptoms: prostration (patient cannot sit up without help); impaired consciousness; 
difficulty breathing or pulmonary edema; seizures; collapse of blood circulation and abnormal 
bleeding; jaundice; haemoglobinuria and severe anemia (< 15 % hematocrit). In severe 
malaria, even with proper treatment, the mortality rate exceeds 20 % (Antia et al., 2008; Suh 
et al., 2004). These effects are due to high parasite numbers in the blood and in the case of P. 
falciparum, parasite sequestration also occurs (Baldacci and Menard, 2004; David et al., 
1983; Suh et al., 2004). Sequestration is a phenomenon unique to P. falciparum. As the 
parasite matures within the red blood cell it exports HRP-2 and EMP1 (among other proteins) 
to the surface of the infected red blood cell which form visible knobs on the surface of the cell 
(Bannister et al., 2000). These cause the infected red blood cells to adhere to each other as 
well as uninfected red blood cells, described as rosetting (Leitgeb et al., 2011). The infected 
red blood cells also adhere to endothelial cells lining arterioles. This results in cerebral 
malaria and organ failures in severe malaria (David et al., 1983; Leitgeb et al., 2011).  
 
Only P. vivax and P. ovale have liver dormant stages as seen in Table 1.1 (Perkins and Bell, 
2008). These stages are not susceptible to drugs targeting the blood stage therefore drugs 
targeting hypnozoites are additionally required to clear all stages of these species. As a result 
diagnostic tests have to differentiate between the species of malaria responsible for infection 
to allow appropriate treatment and to avoid a possible relapse. This task is further complicated 
as co-infections of different malaria species are common (Chuangchaiya et al., 2009; Murray 
et al., 2008). Hypnozoites can often emerge from the liver and cause relapse up to two years 
after clearance of the initial blood stage infection (Fujioka and Aikawa, 2002). 
 
1.1.3 Where is malaria found? 
As mentioned before, all 5 species are transmitted by the Anopheles mosquito vector 
(Kiszewski et al., 2004) and as a result malaria endemic regions overlap with the Anopheles 
mosquito’s natural habitat (Hay et al., 2009). P. knowlesi is transmitted by Anopheles latens 
and An. leucospherus which feed on humans as well as macaque monkeys (Anderios, 2009, 
Sabbatani et al., 2010, Van den Eede et al., 2010,).  Anopheles latens is predominantly found 
in South-East Asian countries, where An. leucospherus is more wide spread and has been 






An. darlingi;                   
An. pseudopunctipennis; 
An. aquasalis;                
An. albimanus 
An. culicifacies;    
An. fluviatilis;       
An. dirus;              
An. anthropophagus; 
An. sinensis;        
(An. latens and An. 
leucosphyrus) 
An. acconitus; An. punctulatu; 
An. ludlowae; An. flavirostris;      
(An. leucosphyrus); An. dirus; 
An. balabacensis; An. farauti   
An. maculatus; An. minimus;      
An. subpictus;  
An. sundaicus;      
An. koliensis;                            
and malaria distribution are illustrated in Figure 1.2. This shows that malaria is endemic to the 
tropics. Currently an estimated 1.38 bil lion people live in high-risk mala ria endemic a reas, 
and a re a ffected by the disease, excluding th e m illions of travellers visiting thes e countries 





Figure1.2 Global malaria distribution, including primary Anopheles mosquito vectors. 
Key to  the malaria prevalence is as follows, where % values indicate the proportion o f the human population 
likely to be affected by malaria:  malaria free;  0.1 %;  0 – 5 %;  > 5 - < 40 %;   > 40 % (Hay et 
al., 2009). Primary vectors were defined as: species that feed on humans; frequently contained sporozoites and 
were more prevalent than other species (Kiszewski et a l., 2004). The An. la tens and An. leucosphyrus species 
were listed in brackets as these are the main P. knowlesi vectors responsible for transmission between macaque 
monkeys and humans (Daneshvar et al., 2010; Sabbatani et al., 2010). 
 
From Figure 1.2, it is clear that Sub-Saharan Africa and some East-Asian countries have the 
highest malaria burden. Of the 1.38 bil lion, people living in high-risk endemic areas, 0.041 
billion are in the Americas; 0.657 billion in Africa and 0.686 billion in central and south east 
Asia. Africa has the highest risk of P. falciparum infection accounting for 90 %  all fatalities 
and amounts to an estimated annual loss of around 12 billion US Dollars in Africa alone (Hay 
et al ., 2009; Suh et al ., 2004). An important factor for malaria severity is  that most  tropical 
countries are sti ll de veloping a nd ha ve va st rural areas which lac k adequate he althcare 
infrastructure. As such diagnosis in these areas has to be “low-tech”, simple to perform and 





1.1.4 What is the effect of malaria on South Africa? 
Due to changing climate patterns, the distribution of the Anopheles vector may spread more to 
the east and south-east coast of South Africa (Tonnang et al., 2010). Figure 1.3 shown here, 
depicts the current distribution a nd wor st case sc enarios of  c limate c hange on the An. 
arabiensis and An. gambiae distributions in South Africa. These two species are seen as the 
major vectors within Sub-Saharan Africa and form part of the An. gambiae complex (Betson 






Figure1.3 The prese nt and f uture dis tribution models o f t he t wo major Sub-Saharan Af rican 
Anopheles vectors. 
The key i ndicates d istribution o f Anopheles vectors, with g reen b eing lo w p opulations and b rown b eing high 
populations (    ). E ach map h ad in dividual values per co lour, which were omitted h ere for 
simplicity. (A and C) show present conditions where (B and D) show the change in distribution after a  4 ºC rise 
in temperature and a 20 % increase in summer rains with a 20 % decrease in winter rains. The maps were taken 
from (Tonnang et al., 2010). 
 
The north -eastern r egions of S outh Africa h ave the highest risks of malaria tra nsmission 
especially a long the bor der with Mozambique. In 2006 the estimated po pulation at risk of  
malaria inf ection in South Africa (inc luding Lesotho and S waziland) totalled 6.15 mi llion 
people (Teklehaimanot et al ., 2007) . The im plementation of  indoor residual spraying usin g 
diclorodiphenyltrichloroethane (DDT) and malaria treatment with artemether-lumefantrine in 
2003 has reduced malaria cases in the KwaZulu-Natal province by more than 99 % from over 
30,000 cases be tween 1 991 and 1992  to a round 300 a nnual cases (Duffy and Mutabingwa, 
2005). South Africa is  for tunate, in that it  h as better he alth care in frastructure and is 
economically stron ger than man y other  A frican c ountries, and a s such is better suited t o 
implement malaria control measures.  
This is an example of the successful implementation of combined control measures. Malaria 
was also eradicated fr om North America a nd Europe b y dr aining sw amps and lar ge s cale 
Anopheles arabiensis Anopheles gambiae 
A B C D 
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spraying of insecticides. These control measures are still implemented in Florida and in 
Australia today (Rozendaal, 1997).  
 
1.1.5 Malaria vector control 
The main methods of vector control include insecticide treated bed nets and indoor residual 
spraying. Only a limited number of insecticides are available for indoor residual spraying (12 
in total from 4 classes, organochlorides; organophosphates; carbamates and pyrethroids), 
where only pyrethroids have been approved for treatment of bed nets (Betson et al., 2009). 
Reduced susceptibility of mosquitoes has been reported since mid-1950, and resistance to all 
4 classes of insecticide have been recorded in Africa (Betson et al., 2009; Blanford et al., 
2011). This is due to a pyrethroid knockdown resistance (kdr) mutation in An. gambiae 
(Martinez-Torres et al., 1998). 
The use of alternate vector control measures, such as bio-control methods are being developed 
against Anopheles. These include entomopathogenic soil-borne fungi such as Beauveria 
bassiana and Metarhizium anisopliae, which are found worldwide (Blanford et al., 2011; 
Kanzok and Jacobs-Lorena, 2006). These infect and kill mosquitoes within 2 weeks, which 
corresponds to the time taken for the development of infective malaria sporozoites within the 
mosquito (Blanford et al., 2011; Fujioka and Aikawa, 2002). Both fungi are currently used as 
bio-control agents against termites and aphids (Khetan, 2000). The downfall with current 
formulations is that the viability of spores decreased by 63 % in 3 weeks after spraying. This 
will have to be improved for large scale implementation. No resistance has been reported in 
Anopheles against these agents so far, although cases of reduced susceptibility have been 
observed (Kanzok and Jacobs-Lorena, 2006). Even where mosquitoes develop resistance 
against these agents, it is unlikely that the same population would develop resistance against 
insecticides and vice versa for insecticide resistant populations. Thus by rotational use of 
insecticides and entomopathogenic fungi, vector control could become a lot more effective 
(Blanford et al., 2011). 
Encounters between humans and Anopheles mosquito vectors are almost inevitable, especially 
in cases where people work or hunt in forests, or work in agricultural plantations.  For this 
reason transmission remains a very real threat and occurs frequently in spite of vector control 
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measures, especially in malaria endemic countries and effective treatment with antimalarial 
drugs is essential. 
 
1.1.6 Treatment of malaria 
The classical treatment strategy adopted in malaria endemic countries since the discovery and 
development of chloroquine in the 1930-1940’s was: “fever equals malaria unless proven 
otherwise” (Perkins and Bell, 2008). The majority of fever cases in the tropics were therefore 
treated with chloroquine. This “liberal” use of chloroquine has resulted in the development of 
resistant strains of malaria as summarised in Table 1.2 (Okiro and Snow, 2010; Perkins and 
Bell, 2008).  
 
Table 1.2 Stages targeted by antimalarial drugs and geographical regions in which drug resistance 





species Distribution of resistance 






All P. falciparum endemic regions except: 
Mexico, Dominican Republic, Haiti, 
Central America west and north of the 
Panama Canal, Argentina, North Africa, 
most of the Middle East and China.  
P. vivax resistance: Oceania, Myanmar, 
Guyana, Colombia and Brazil 
Mefloquine / quinine Blood  P. falciparum Thai borders with Cambodia and Myanmar 
Pyrimethamine / 
chlorproguanil; Sulfadixine 
Blood P. falciparum  
Artemisinin Blood and 
gametocyte 
  
Primaquine Liver and 
gametocyte 
P. vivax Oceania, Southeast Asia and Somalia 





  Fatty acid synthesis inhibitors Liver 
   
Data was collected from: Lalloo et al., (2007); Kappe et al., (2010); Suh et al., (2004); Peterson et al., (1998); 
Kublin et al., (2002). 
 
Malaria treatment is dependent on the infecting species of malaria as well as the geographical 
region in which the infection was contracted. The species is important due to the presence of 
liver dormant stages or hypnozoites in both P. vivax and P. ovale infections as mentioned 
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previously in Table 1.1. To clear hypnozoites, a 14-day course of primaquine is required to 
avoid relapse (Lalloo et al., 2007). The geographical region is important as resistant strains 
have been identified in specific areas of the world as shown in Table 1.2 and alternate drug 
treatments have been recommended accordingly (Lalloo et al., 2007; Kappe et al., 2010; Suh 
et al., 2004;). 
Protein transporters involved in drug resistance have been identified in P. falciparum. These 
include the chloroquine resistance transporter (PfCRT); two ATP-binding cassette (ABC) 
transporter family members called the multidrug resistance protein 1 (PfMDR1) and the 
multidrug resistance-associated protein 1 (PfMRP1). Single nucleotide polymorphisms 
change the specificity of the ABC proteins, stopping transport of drugs into the parasite 
cytosol and thereby making the parasite resistant to the drug. Studying these A/T-rich and 
transmembrane proteins of malaria is difficult due to expression difficulties (Koenderink et 
al., 2010).  
To counter drug resistance “Treatment of Malaria (Guidelines for Clinicians)” was published 
by the centre for disease control in 2007 and more recently “Guidelines for the treatment of 
malaria 2010” (Reyburn H., 2010), both emphasizing the need for a parasitological diagnosis 
of malaria before treatment. The WHO has recommended artemisinin combination therapy 
(ACT) in drug resistant areas. This includes quinoline compounds or derivatives such as 
amodiaquine and mefloquine. These drugs prevent haematin polymerisation into haemozoin. 
As the parasite degrades haemoglobin the ferriprotoporphyrin groups accumulate (Bannister 
et al., 2000) and kill the parasite by inhibiting metabolic enzymes such as glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and lactate dehydrogenase (LDH) (Campanale et al., 
2003; Egan and Ncokazi, 2005; Penna-Coutinho et al., 2011). Pyrimethamine and proguanil 
are also incorporated and inhibit the tetrahydrofolic acid cycle, resulting in the inhibition of 
DNA synthesis (Kappe et al., 2010). Artemisinin itself has been shown to reduce gametocyte 
formation as well as reducing their infectivity to mosquitoes as reviewed by Golenser et al., 
(2006). Artemisinin is hypothesised to interfere with a calcium ion transporter called 
sarcoplasmic / endoplasmic calcium ATPase (SERCA) Golenser et al., (2006). 
Development of drug resistance remains a constant challenge in the treatment of malaria. 
There have been recent reports of reduced artemisinin susceptibility as well as artesunate-
mefloquine resistance in Cambodia which are concerning, however these have yet to be 
confirmed (Akler et al., 2007; Koenderink et al., 2010). For this reason it is essential that 
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diagnostic tests allow clinicians to monitor patients while treating them. An increase in 
parasitemia during treatment would therefore suggest treatment failure and alternate 
treatments could be lifesaving. The increased cost of combination therapies has also made 
diagnosis before treatment more essential, while this will also curb the “liberal” use of 
antimalarials, as has been the case with chloroquine (Perkins and Bell, 2008). 
 
1.2 Malaria diagnosis 
1.2.1 What are the main factors impacting malaria diagnosis? 
The important points highlighting the need for malaria diagnosis so far were: 
 Malaria causes severe disease and there is currently no available vaccine. 
 Patients only seek medical attention once disease symptoms appear, which is during the 
red blood cell stage of malaria, making this the stage targeted for diagnostics. 
 There are 5 species of malaria infective to humans, 2 of which have dormant liver stages 
that require alternative treatments to avoid relapse, therefore they have to be 
differentiated by diagnosis. 
 Malaria is endemic to the tropics and rural areas of developing countries are worst 
affected. In this setting diagnostic tests have to be “low tech”, quick and easy to perform 
and interpret. 
 Although South Africa has implemented a successful prevention program, climate change 
models predict a spread in the prevalence of the Anopheles vector, thus diagnosis in 
South Africa will also become more important.  
 Vector control methods are effective, however, insecticide resistance in mosquitoes is 
increasing and there is still a risk of exposure “out of reach” of control measures, 
therefore transmission remains a risk and makes treatment essential. 
 Increasing malarial drug resistance has forced the implementation of combination 
therapies. With the increasing cost of treatment and efforts to curb the spread of anti-
malarial drug resistance, it has become important to diagnose malaria before treatment.  
 Diagnostic tests should ideally be able to track disease progress, which will aid in 
assessing treatment success, which can be lifesaving in drug resistant regions. 
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1.2.2 Criteria for comparison of diagnostic tests 
Before d escribing th e di fferent diagnostic tests available, definitions of the criteria us ed to 
compare thes e tests are important. These a re spe cificity, se nsitivity and li mits of de tection. 
Specificity refers to the a ccuracy of the  pa rticular test to correctly id entify th e infe cting 
species of Plasmodium (Murray et al., 2008). Sensitivity refers to the ability of the particular 
test to correctly d etect infection out of a  tot al number of  posi tive a nd ne gative sa mples 
(Murray et al., 2008). Both specificity and sensitivity are usually expressed as percentages in 
terms of the total number of sa mples diagnosed correctly o ut of the overall number  of  test  
samples. Finally, the limit of detection refers to the lowest level of infection in terms of % 
parasitemia or parasites per microliter of blood that the method can detect. Microscopy is still 
the gold standard for comparison although some groups additionally use PCR as a standard 
(Murray et al., 2008). 
 
1.2.3 A closer look at the red blood cell stage as the target for diagnosis 
Due to the nature of the parasite life-cycle, diagnosis focuses on the red blood cell stage of the 
infection, which was boxed in Figure 1.1 and is shown in more detail in Figure 1.4. This stage 
has the highest pa rasite c ount throughout the  li fecycle a nd is responsible for dise ase 
symptoms as described before (Antia et al., 2008; Baldacci and Menard, 2004; Miller et al ., 
1994).  
 
Figure1.4 Maturation of t he re d blood cell stage (erythrocytic s chizogony) o f t he Plasmodium 
falciparum  parasite. 
The diagram was b ased o n descriptions from B annister et a l., (2000) a nd depicts th e progress o f the P. 
falciparum parasite through it s 4 8 hour r ed blood ce ll cycle, f rom the initial i nvading merozoite s tage, to  t he 
mature late trophozoite s tage known as the schizont.  depicts the parasite, which during the ring stage has a 




From the initial infection of a red blood cell, a merozoite undergoes several morphologically 
distinct changes until maturation (Bannister et al., 2000), followed by rupture of the red blood 
cell. These different stages can be identified under a light microscope (see section 1.3.3) and 
are used in diagnosis of the species of malaria. This is done by comparison of different 
morphological characteristics of the parasites at each stage in the red blood cell cycle as 
summarised in Table 1.4. Once the merozoite invades the red blood cell, which is a rapid 
process, taking at most a few minutes, it enters its trophozoite stage (Bannister et al., 2000).  
The first of these is the ring-stage (Bannister et al., 2000), which has a characteristic vacuole 
in the centre of the parasite. At around 26 hours post-invasion of the red blood cell the first 
pigments of haemozoin appear, which is yet another characteristic that has been exploited for 
diagnosis (see section 1.3.5). The morphology of the parasite assumes an early trophozoite 
stage in which it has a single nucleus and a large cytoplasm with no vacuole (Bannister et al., 
2000). At 38 hours post invasion the morphology assumes that of a schizont, which has 
multiple nuclei, and multiple merozoites are produced. The number of merozoites released is 
also dependent on the species of malaria, with the number ranging from 14 to 32 as shown in 
Table 1.1 (Antia et al., 2008).  
Upon completion of one erythrocytic cycle the red blood cells rupture and release the 
parasites into the blood stream. This causes disease symptoms, where fever is the first of these 
(Miller et al., 1994). The time taken from initial infection to the presentation of symptoms is 
known as the incubation period (Suh et al., 2004). In the field this is of little use as the 
clinician will have no idea as to when the patient was initially bitten. Clinical diagnosis of 
malaria is therefore based on the time between fever episodes (see 1.3.1). 
 
1.3 How is malaria diagnosed? 
1.3.1 Clinical diagnosis 
Rupturing infected red blood cells release parasites into the blood stream resulting in fever as 
was shown by Golgi in 1886 and reviewed by Miller et al., (1994). Fever was used for 
diagnosis because it is the earliest symptom to present during a malaria infection (Antia et al., 
2008). The red blood cell cycles of the 5 species of human malaria differ in length. As a result 
the time between fever episodes is different as shown in Table 1.3.  
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Table 1.3 Characteristic fevers of the 5 human malaria species. 
The data were taken from Collins and Jeffery, (2005); Daneshvar et al., (2009); Sabbatani et al., (2010).  
 
As was shown by Källander et al., in 2004, fever is a common symptom of pneumonia and 
other tropical diseases and as a diagnostic for malaria it is less than 20 to 30 % accurate 
(Gwer et al., 2007; Perkins and Bell, 2008). Clinical diagnosis is highly presumptive as a 
result, but has had success as demonstrated by Kidane and Morrow in 2000 and Sirima et al., 
in 2003, reporting a 40 % reduction in mortality and reduced risk of severe disease in children 
under five years old. Treatment of children exhibiting overlapping disease symptoms using 
both antimalarials and antibiotics, known as an integrated management of childhood illness 
(IMCI), was described by Gove in 1997 to improve the success of presumptive treatment.  
In African children alone the annual number of fever episodes was estimated to around 870 
million (Snow et al., 2003). Presumptive treatment inevitably leads to high rates of 
misdiagnosis and several negative consequences. These included: 1) the treatment of the 
wrong disease resulting in the onset of severe disease and death and 2) an increased frequency 
of drug resistance due to the “liberal” use of antimalarial drugs (Murray et al., 2008; Perkins 
and Bell, 2010).  
More accurate diagnostic techniques have been developed, each with its advantages and 






 P. vivax P. ovale P. malariae P. falciparum P. knowlesi 
Erythrocytic cycle (hours) 48 49 72 48 24 
Time between fevers (days) 2 2 3-4 2 1 
Fever description tertian tertian quartan tertian daily 
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Table 1.4 Parameters of the main malaria diagnostic tests. 
Parameter Microscopy Fluorescence PCR RDTs 
Sensitivity 
(parasites / µl) 
50 ≥ 100 ≤ 5 100 to 200 
Specific yes no yes yes 
Quantification yes no no possible 




yes yes yes no (kit format) 
Expertise level moderate-high moderate high low 
Cost / test R1 - R3.20 R0.60 - R13.60 R20.00 R4.40 - R12.00 
 
Data w ere taken f rom Demas et a l., (2011); Ma kler et a l., (1998); M oody (2002); P erkins and Bell ( 2008); 
Wongsrichanalai et al., (2007). 
 
1.3.3 Microscopy 
Microscopy is based on  the visual detection a nd identific ation of  mala ria pa rasites in red 
blood cells. This is usually done using Giemsa staining, where Wright’s or Field’s stains are 
alternative methods.  All three methods stain DN A, take advantage of  the  terminal nature of  
the mature red blood cell, which does not contain DNA, and the parasites are easily visible 





Figure1.5 View of a thin blood smear showing Giemsa stained red blood cell stages of P. falciparum 
using light microscopy. 
Early trophozoites (ring stage) are visible in (A), followed by a mature schizont in (B) and a gametocyte in (C). 
The images were taken from Suh et al., (2004). 
 
Slides are pr epared e ither as thick or  thi n bloo d films. In the case of  thi ck smea rs the re d 
blood cells are stained but not fixed and are concentrated by a factor of 20 to 30 on the slide. 
Alternatively the thin film preparations are fixed with methanol and then stained. Thick films 
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are more suited to gross quantification, whereas thin films are usually used for identifying the 
infecting species of malaria and more accurate quantification (Moody, 2002). 
Calculating the parasite load or % parasitemia of the patient, which is a measure of the extent 
of infection, allows the clinician to track response to treatment (Murray et al., 2008). The 
most common method of determining parasite load is to count the number of parasites and 
white blood cells in a thick film preparation. The number of parasites in relation to 200 white 
blood cells is extrapolated by multiplying by 40, which assumes that a normal blood sample 
has approximately 8000 white blood cells per microliter (Makler et al., 1998; Moody, 2002). 
Alternatively % parasitemia is estimated using thin film preparations. This is done by 
counting the total number of parasites seen in 10,000 red blood cells or 40 fields of view 
using a normal light microscope at 100X magnification. It is then assumed that 1 µl of blood 
contains an estimated 5 x 106 red blood cells. The following equation is therefore used: 1 % 
parasitemia = 5000 parasites/µl of blood (Moody, 2002). 
In naïve patients, symptoms will start to appear at around 100 parasites/µl (0.0002 % 
parasitemia) whereas in immune patients symptoms are expressed around 2500 to 30,000 
parasites/µl (0.05-0.7 % parasitemia). Severe malaria generally occurs in patients with a 
parasitemia greater than 5 % (Miller et al., 1994; Murray et al., 2008; Suh et al., 2004). Since 
patients will only seek treatment after the presence of symptoms, the sensitivity of 
microscopy at around 50 parasites per microliter (Table 1.4) makes this a good diagnostic 
method. It is also a very simple protocol to follow, which is why it is still regarded as the gold 
standard for comparison of new alternate diagnostic tests (Moody, 2002). 
Various visual characteristics are used to identify the different species of malaria, which is 
summarised in Table 1.5. These are usually viewed in thin film microscope slides. In the case 
of P. falciparum only ring stages are usually visible due to sequestration of late trophozoites 
(Bannister et al., 2000; David et al., 1983). Only P. vivax and P. ovale visibly enlarge the red 
blood cell and characteristic stippling of the red blood cell cytoplasm also known as 






Table 1.5 Differentiating features of the 5 Plasmodial species infecting humans. 
 
P. falciparum P. vivax P. ovale P. malariae P. knowlesi 
Parasites / red blood 
cell 
multiple single single single multiple 
Size of red blood cell normal enlarged enlarged with 
fimbriated ends 
normal normal 
Typical asexual  red 
blood cell stages 
present and shape 
predominant ring 






















Gametocytes  banana / sickle 
shaped  
present present present present 
Other characteristics Knobs on red 






Fine stippling of 
red blood cells 
Fine stippling of 
red blood cells 
 
Data taken from: Anderios et al., (2009); David et al., (1983); Gkrania-Klotsas and Lever (2007); Lee et al., 
(2009).  
 
Microscopy based diagnosis of malaria is a case where “practice makes perfect” and the level 
of experience affects both the specificity and sensitivity of the method. For example P. 
knowlesi resembles P. malariae morphologically during late stages of infection (mature 
trophozoites, schizonts and gametocytes), where early ring stages resemble those of P. 
falciparum (Anderios et al., 2009; Lee et al., 2009). Since co-infections of different malaria 
species are also possible, correctly identifying the individual species in such cases is even 
more challenging (Chuangchaiya et al., 2009). 
Microscopy also requires electricity which often not available in a field setting and it can take 
up to 60 minutes to prepare slides. It is still the cheapest method available in terms of cost per 
test, although the microscope itself is a large initial cost.  
 
1.3.4 Fluorescence microscopy 
Fluorescence microscopy is another method used to visualise the parasite by staining DNA. 
Two fluorochromes are commercially available, namely acridine orange and 
benzothiocarboxypurine, which are excited at 490 nm and emit an apple green or yellow 









Figure1.6 A representation of f luorescence microscopy s howing det ection of P. f alciparum 
trophozoites. 
The image in (A) was stained with acridine orange and that in (B) was stained with benzothiocarboxypurine. The 
images were taken from Moody (2002). 
 
Acridine or ange is not specific to living pa rasites and stains all D NA c ontaining c ells. An 
alternative method called the quantitative buff y coat method separates parasites from white  
blood cells using a  c apillary tube, making it  e asier to differentiate the two (Mood y, 2002) . 
Acridine orange is toxic, making its handling and safe disposal problematic (Moody, 2002). 
Alternatively b enzothiocarboxypurine is used to identify vi able parasites as it de pends on 
active adsorption through the parasite membrane to stain the DNA. It also does not stain white 
blood cells a s stron gly as a cridine orange does (Moody, 2002) . Rhodamine-123 is an 
alternative d ye used  for  parasite viabili ty, but it is not commercially available. Rhodamine-
123 is a c ationic permeant dye which s electively accumulates inside the parasite due  to its 
high membrane potential (Moody, 2002). Fluorescence microscopy is not quantitative and can 
thus not be used to track infe ctions during d rug tr eatment. Differentiating the sp ecies of 
malaria is difficult with fluorescence a nd thi s method is not preferred for  thi s purpose 
(Moody, 2002) . This method also requires electricity, a lthough filter s have been developed 
enabling the use of sunlight (Moody, 2002). A portable battery powered assay was developed 
(CyScope®) and showe d g ood se nsitivity, but a hig h ra te of  fa lse positives and re quires 






1.3.5 Detection of haemozoin 
The malaria parasite digests haemoglobin as a source of amino acids within a lysosome-type 
body called a food vacuole (Bannister et al., 2000; Olszewski et al., 2011). As a by-product of 
haemoglobin catalysis large amount of free haem is produced, which is toxic as it inhibits 
various enzymes and also results in the generation of free radicals. The parasite therefore 
polymerises haem into a compound known as haemozoin or malaria pigment and stores it in 
the food vacuole (Dostert et al., 2009). Haemozoin accumulates to visually detectable levels 
as a black or brown pigment in late trophozoites, as was illustrated in Figure 1.4 (Bannister et 
al., 2000).  
Besides being visible under the microscope in thin blood films, haemozoin can also be 
detected in white blood cells of infected patients. Following lysis of an infected red blood cell 
the haemozoin is released into the blood stream (Dostert et al., 2009). These particles are then 
phagocytosed by white blood cells (Hänscheid et al., 2001). Haemozoin was detected in white 
blood cells using a cell analyser / counter due to the depolarising properties of the pigment 
and gave 95 % sensitivity and 88 % specificity in comparison to microscopy (Hänscheid et 
al., 2001).  
 
1.3.6 Molecular diagnosis 
PCR involves either single or multiplex methods, detecting malarial DNA (Demas et al., 
2011). This method traditionally uses the small-subunit ribosomal RNA (18S rRNA) or 
circumsporozoite genes as targets (Ng et al., 2008). Pvr47 and Pfr364 have also been 
identified as alternate targets (Demas et al., 2011). Nested or reverse transcription PCR allows 
differentiation of the Plasmodial species. The use of fluorescein or radiolabeled probes allows 
detection, or alternatively samples are run and visualised on agarose gels with ethidium 
bromide. Nested PCR to detect malaria infections using saliva and urine samples is also 
possible (Buppan et al., 2010). 
PCR takes a long time, between 2-3 hours to complete and requires a sterile lab environment 
and technical competence for reliable results, making it unsuitable for field clinics. It is an 
essential technique for studies of drug resistance, however and blood samples can be dried 
and stored on filter paper for later analysis (Moody, 2002). 
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Alternative methods have been developed to simplify the PCR reactions, which include loop-
mediated and helicase dependent isothermal amplification reactions. Both methods still 
require a 95 ºC DNA denaturation step as well as subsequent incubations at 37 or 65 ºC 
respectively (Notomi et al., 2000; Vincent et al., 2004). The loop mediated isothermal 
amplification has been used to detect a human P. knowlesi infection of < 0.01 % parasitemia 
and was performed in less than an hour (Lau et al., 2011). The high cost and expertise 
required remain a deterrent for use of PCR in the field.  
 
1.3.7 Serodiagnosis 
These methods entail the detection of antibodies in serum. Antibodies are usually produced 
within one week of onset of the red blood cell stage of the infection. At the same time 
however these antibodies may persist for up to a year after clearance of infection (She et al., 
2007). This is impractical as it is not clear if antibodies in serum are against a current or past 
infection, especially in endemic countries where populations may often have persistent low 
level infections and thus constant levels of antibodies (Makler et al., 1998). The assay is 
based on a direct ELISA format in which ELISA plates are coated with the target malarial 
antigen, such as merozoite-surface protein in the case of the Newmarket Malaria EIA test 
(She et al., 2007). The reverse of this assay would be to detect the immunogenic antigens of 
the malaria parasite by raising antibodies against these antigens and using them to capture and 
detect these antigens. 
 
1.3.8 Antigen based diagnosis 
Antigen based diagnosis relies on the specificity of antibodies for their target antigen. An 
antibody is used to capture its target antigen out of solution, followed by a second antibody 
for detection such as in a double antibody sandwich (DAS) ELISA for example. Alternatively 
if the target antigen is an enzyme, then the enzyme activity of the target antigen can be 
measured such as the immunocapture malarial LDH assay described by (Makler et al., 1998). 
ELISA based methods are complex to perform and require some expertise as well as being 
laboratory based techniques and taking a few hours to perform.  
21 
 
The setting in field hospitals requires diagnostic tests to be “low tech”, quick to perform and 
easy to interpret. Malaria rapid diagnostic tests were thus developed in the 1990’s and were 
designed to allow for “point of care” diagnosis and treatment (Perkins and Bell, 2008). 
 
1.4 Immunochromatographic tests or rapid diagnostic tests  
1.4.1 Basic principle of RDTs 







Figure1.7 Basic outline of a simple rapid diagnostic test (RDT), both top and side view. 
 
RDTs are antibody based diagnostic tests which exploit the interaction between an antibody 
and it s specific antigen, for the detection of  mala ria. The re a re va rious tests on the market 
today, and all make use of a colloidal gold labelled detection antibody which is prepared in a 
lysis buffer and mixed with the test blood sample. If the test sample is infected with malaria, 
then the d etection antibody will bind to it s specific malarial antigen. This solution is then 
added to one end of the test strip (the end on the left in Figure 1.7), and migrates up the strip 
by capillary action. On the other end of the strip are two b ands of capture antibodies which 
are fix ed to the nitrocellulose strip (the e nd on the right in Figure 1.7 ). The  first capture 
antibody binds a separate epitope on the same malarial antigen as the detection antibody. As 
the l ysed malaria posi tive sa mple mi grates up the strip, the a ntigen-detection-antibody 
complex is  bound by t he c apture a ntibody. T he c olloidal g old particles a ttached to the 
detection antibody then form the test line. Any unbound detection antibody migrates further 
up the strip and is captured by the second antibody (control antibody) fixed to the test strip 
Side view 
Top view 




and forms a control line. The second line shows that the test sample has moved completely 
across the strip and that the test is working (Makler et al., 1998; Murray et al., 2008).  
 
1.4.2 Malarial RDT target proteins and examples of commercially available tests 
More involved tests have since been developed based on the basic outline in Figure 1.7. These 
allow differentiation between malaria species, and include up to four line detection. The 
antigens targeted for diagnosis are histidine rich protein 2 (HRP-2) which is specific to P. 
falciparum. These tests include Paracheck Pf®; ParaHIT f® and ParaSight-F for example 
(Murray et al., 2008). Two other proteins commonly used include lactate dehydrogenase 
(LDH) and aldolase, which are both metabolic enzymes conserved among all 5 species of 
human malaria. Tests targeting LDH alone include OptiMAL® or OptiMAL-IT® tests. Other 
tests detect HRP-2 as a P. falciparum specific target, and detect LDH as a pan-malarial target, 
such as the CARESTARTTM test, or alternatively tests target aldolase such as the  
BinaxNOW® test for example (Ashley et al., 2009; Khairnar, 2009; Murray et al., 2008). 
 
1.4.3 Problems associated with RDTs 
Problems associated with malaria RDTs can be divided into practical problems with their 
implementation, or problems associated with the diagnostic target antigen used in RDTs.  
 
1.4.3.1 Practical problems associated with the use of RDTs 
False negative test results 
The tropical setting of malaria endemic areas exposes RDTs to temperatures ranging from 35 
to 60 ºC (Jorgensen et al., 2006). An assay by Chiodini et al., in 2007 showed LDH based 
tests to be more heat-susceptible than HRP-2 based tests and the biggest concern was that 
tests showed positive control lines but no test lines, thus giving false negative results. They 
highlighted the need for a cold chain to supply RDTs to field clinics, which is also required 





False positive test results 
Buffer vials are often lost in the field and often saline, distilled water or tap water are used 
instead. This was assessed by Gillet et al., in 2010, who found that RDTs gave false positive 
reactions in such cases. This could be rectified by supplying multiple buffer vials per kit as 
opposed to a single vial. 
 
1.4.3.2 Problems associated with the diagnostic target antigen 
False negative test results 
The prozone effect, also known as the high dose hook phenomenon causes false negatives or 
faint positive tests at high parasitemia due to excessive antigen concentrations. The capture 
antibody fixed to the test strip binds more “free” antigen from solution than antigens bound 
by the detection antibody, thus resulting in a low signal. This affected HRP-2 based tests and 
not LDH tests in a study by Gillet et al., in 2009. HRP-2 levels have been quantified to 
approximately 6:1 in comparison to LDH (Martin et al., 2009), explaining why HRP-2 based 
tests are prone to this phenomenon. The prozone effect can be avoided by simple dilution of 
the test sample. 
Both gene deletions and antigenic variation (variation in the amino acid composition of the 
target antigen) have been reported for HRP-2 (Baker et al., 2010; Gamboa et al., 2010;  Lee et 
al., 2006a) and resulted in false negative test results. Sequence analyses of LDH and aldolase 
from malaria field isolates showed both proteins to be conserved among malaria species (Lee 
et al., 2006b) thus tests targeting these antigens were not affected. 
 
False positive test results 
False positive results are common in HRP-2 based tests after drug treatment and clearance of 
infection as HRP-2 persists in serum for between 14 to 28 days (Iqbal et al., 2004; Kodisinghe 
et al., 1997; Murray et al., 2008; Tjitra et al., 2001). LDH and aldolase based tests revert back 
to negative within 2 to 7 days, as both antigens have shorter half-lives and are involved in 
parasite metabolism, thus their presence indicate a current infection (Ashley et al., 2009; Iqbal 
et al., 2004, Murray et al., 2008). All three antigens are produced during the gametocyte stage 
of the infection thus low levels of the proteins may persist if gametes are present (Murray et 




Cross reactivity reactions have been recorded with RDTs and Rheumatoid factor or anti-
nuclear antibodies, giving false positive results. Rheumatoid factors are autoantibodies raised 
against the Fc portion of IgG molecules and react with the mouse IgG isotype monoclonal 
antibodies often used in RDTs (Iqbal et al., 2000). The Fc portion (fragment crystalline) of 
IgG molecules consists of the carboxyl termini of the heavy chains and is involved in the 
activation of complement by binding effector molecules or immune cell Fc receptors (Delves 
et al., 2006).  
 
Another issue was cross-reaction of RDTs between malarial species. This has only been 
recorded for LDH and aldolase based RDTs, since HRP-2 is only expressed by P. falciparum. 
P. falciparum-specific as well as P. vivax-specific LDH based RDTs cross-reacted and 
detected P. knowlesi (Kawai et al., 2009; McCutchan et al., 2008). Six out of nine P. vivax-
specific LDH based RDTs also cross-reacted and detected high parasitemia (> 2 %) P. 
falciparum infections (Maltha et al., 2010). 
 
Quality assurance of malaria RDTs 
To improve confidence in RDTs, quality assurance is very important and has also been 
recommended by the WHO (WHO, 2008). These measures include buying RDTs from 
manufacturers with evidence of good manufacturing practice as well as “in the field testing” 
of RDTs. Positive controls have been developed which make use of recombinant antigens or 
peptides reconstituted in uninfected blood (Lon et al., 2005, Murray et al., 2008). 
Alternatively Versteeg and Mens in 2009 used dried infected blood spots as positive controls, 
and found this format to work best for HRP-2 based tests due to the stability of the antigen. 
The purpose of positive controls is not only to give a positive result on the RDT, but also to 
ensure RDT sensitivity is maintained after delivery to the field (Lon et al., 2005; McMorrow 
et al., 2008). 
 
1.4.3.3 Further development and advantages of RDTs 
Finding alternatives to blood for diagnosis was investigated by Rodriguez-del Valle et al., in 
1991 and Wilson et al., in 2008 who found detectible levels of protein antigens in urine and 
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saliva samples of infected patients. This may address safety issues surrounding diagnosis 
using blood samples from patients, as well as avoiding cultural objections to blood collection 
in some rural populations. 
RDTs also serve as diagnostic records for the patients, as isolation of DNA for PCR reactions 
is also possible (Ishengoma et al., 2011; Veron and Carme, 2006). This would allow for more 
accurate mapping of disease prevalence, as well as subsequent analyses of resistance markers 
within a certain malaria area for example, which are invaluable data for controlling malaria 
(Bisoffi et al., 2009). 
 
1.4.4 Improving malaria RDTs 
Detection of asymptomatic infections is essential for the elimination of malaria. This requires 
detection of parasite loads of < 100 / µl which may act as reservoirs of malaria (Hafalla et al., 
2011; Harris et al., 2010; Miller et al., 1994). The current malaria RDTs will have to be 
improved in order to allow for such low detection. This will also allow for earlier detection 
and treatment of infections which may be lifesaving.  
Strategies to improve the limits of detection of RDTs are based on the identification of new 
antigenic targets that are present at higher concentrations than the current targets. This would 
allow RDTs to detect infections at lower parasite loads. 
 
1.4.4.1 GAPDH as an alternative RDT target antigen to LDH 
According to transcriptional data from Le Roch et al., (2003) P. falciparum GAPDH 
(PfGAPDH) messenger RNA (mRNA) levels are around 3 to 4 times higher than P. 
falciparum LDH (PfLDH) levels (Figure 1.8). This is suggestive of higher protein levels of 
PfGAPDH to PfLDH since proteins are usually translated immediately from mRNA in the 
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Figure 1.8 Comparative mRNA levels o f g lyceraldehyde-3-phosphate dehy drogenase ( PfGAPDH) 
and lactate dehydrogenase (PfLDH). 
The mRNA levels of PfGAPDH and PfLDH were plotted for the different red blood cell stages of P. falciparum 
3D7 parasites. T he data was taken from Le R och et a l., (2003). The red blood ce ll stages were annotated as 
follows: M (merozoite); ER (early ring); LR (late ring); ET (early trophozoite); LT (late trophozoite); ES (early 
schizont); LS (late schizont). * The mRNA levels were assigned arbitrary units. 
 
There are onl y s emi-quantitative da ta a vailable on the re lative p rotein levels of PfGAPDH 
and PfLDH.  Th ese d ata suggest increasing protein leve ls during the development of the  
erythrocytic stage, sim ilar to the increasing mR NA lev els ( Aebersold and Mann, 2003 ; 
Lasonder et al., 2002; Nirmalan et al., 2004; Smit et al., 2009).  
Targeting metabolic proteins for diagnosis has the advantage, at least in theory, of  allowing 
the RDTs to monitor the treatment of infection. This was shown with RDTs using LDH as the 
target antigen, where they returned to negative within 2 to 7 days after clearance of infection 
(Iqbal et al., 2004, Murray et al., 2008).  
GAPDH is similar to LDH in that both  pr oteins are de hydrogenase enzymes involved in  
glycolysis (Berwal et al., 2008; Daubenberger et al., 2000; Satchell et al., 2005). Structurally 
both pr oteins form tetra mers in solut ion, whe re the size of the native PfLDH monomer is  
approximately 34.4 kD and that of  the PfGAPDH monomer is approximately 36 kD (Berwal 
et al., 2008; Daubenberger et al., 2000; PlsamoDB; Satchell et al., 2005). Both proteins bind 
NAD+(H) N -terminally thus sharing a  c ommon dinucle otide bindi ng domain known as a 
Rossman fold for this purpose (Akinyi et al., 2008; Daubenberger et al., 2000; Granchi et al., 
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respective substrates (Granchi et al ., 2010; Daubenberger et al ., 2000; Akinyi et al ., 2008) . 








Figure 1.9 Basic glycolytic reactions involving GAPDH and LDH, producing 2 ATP molecules and 
recycling NAD+(H). 
The figure was p repared ac cording to  th e description o f glycolysis b y Vo et and Vo et, 2 004. Glu cose is a 6– 
carbon sugar, thus its catalysis results in 2 of each of the 3–carbon moieties shown in the figure.  
 
The parasite relies primarily on g lycolysis for energy production (Daubenberger et al., 2000; 
Granchi et al ., 2010; Olszewski et al ., 2011 ; Satchell et al ., 200 5), where the ra te of  
glycolysis in an infe cted re d blood cell is between 50 to 100 ti mes greater than that of  an 
uninfected c ell (Daubenberger et al ., 2000; Gomez et al ., 1997 ; Olszewski et al ., 2011) . 
Glycolysis entails the breakdown of glucose (6 carbon sugar) into two molecules of pyruvate 
(3- carbon moi ety), which is then c onverted to two L-lactate mol ecules by LDH in an 
anaerobic homol actic fe rmentation pathway in the malaria parasite (Berwal et al., 2008; 
Daubenberger et al., 2000; Granchi et al., 2010). This pathway requires two ATP molecules 
(energy investment) to generate 4 m olecules of  ATP, thus yielding two ATP molecules per 
glucose molecule. GAPDH reduces NAD+ to NADH and LDH then oxidises NADH to NAD+ 
allowing GAPDH to catalyse further reactions. This is important as the NADH/NAD+ ratio is 
maintained within the cell. 
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Both GAPDH and LDH have been assessed as drug targets, where both are inhibited by 
ferriprotoporphyrin (unpolymerised haeme) as mentioned earlier in the introduction 
(Campanale et al., 2003; Egan and Ncokazi, 2005; Penna-Coutinho et al., 2011).  
GAPDH has been shown to be involved in alternate roles besides glycolysis. Daubenberger et 
al., (2003) showed the N-terminal domain of PfGAPDH to be involved in membrane 
recruitment by binding Rab2. This suggested that PfGAPDH may be involved in vesicle 
transport within the parasite, by interacting with Rab2, tubulin and actin (Tristan et al., 2010). 
Alternative functions of mammalian GAPDH also include association with mitochondria 
during stressed cellular conditions, thereby mediating cell death. Alternatively GAPDH has 
also been located in the nucleus where it is involved in DNA repair or transcription as well as 
telomere protection and cell cycle regulation and cell death (Tristan et al., 2010). These 
alternate roles may explain the higher mRNA levels of PfGAPDH in comparison to PfLDH 
(Le Roch et al., 2003). 
PfGAPDH shares 63.5 % sequence identity with its human red blood cell counterpart 
(Daubenberger et al., 2003). One of the major differences between human and Plasmodial 
GAPDH is the presence of a two amino acid (K194; G195) insert within a structural region 
called the S-loop (residue 188 to 203) in the Plasmodial protein (Satchell et al., 2005). The S-
loop separates the Rossman folds of the adjacent subunits in the tetrameric form of the 
enzyme (Akinyi et al., 2008). Another difference is a substitution of two amino acids (L187; 
V188 for K187; T188) in the same region of the Plasmodial protein. These changes are 
thought to be responsible for the ferriprotoporphyrin susceptibility of the Plasmodial protein 








1.5 Aims and objectives of the current study 
A wide range of diagnostic methods can be used to diagnose malaria, each with their 
individual advantages and disadvantages. An ideal RDT should be easy to perform and 
interpret and have adequate sensitivity and specificity to allow for rapid and correct treatment 
of patients that present with malaria-like symptoms (Makler et al., 1998; Moody, 2002; 
Murray et al., 2008). 
One of the methods of addressing sensitivity of RDTs is by identifying protein targets which 
are more abundant than the present targets. This would lower the limit of detection of the test 
and in so doing should increase the sensitivity. Thus the first aim was to identify a new 
diagnostic target, using transcriptional data from Le Roch et al., (2003) as a starting point 
(Figure 1.8). GAPDH was identified as a possible new target. 
Another issue with RDTs is cross reactivity with Rheumatoid factor and anti-nuclear 
antibodies as a result of cross reaction with Fc portions of mammalian IgG (Gillet et al., 2009; 
Iqbal et al., 2000). The second aim was to use polyclonal antibodies raised in chickens (IgY), 
which lack an Fc portion and thus should not cross react with these factors (Schade et al., 
1991, 1993). Since monoclonal antibodies are preferred for RDTs due to their high 
specificity, the polyclonal IgY antibodies raised here were raised against specific peptide 
epitopes to improve their specificity. An alternative adjuvant called PheroidsTM was also 
assessed in comparison to Freund’s adjuvant, with an aim to improve IgY yields, or to reduce 
stress on the experimental animals as Freund’s is known to cause hypersensitivity reactions 
(Wilson-Welder et al., 2009; Reed et al., 2008).  
The objectives of the current study were therefore to: 
 Recombinantly express and affinity purify both PfGAPDH and PfLDH (Chapter 3). 
 Identify specific immunogenic peptide epitopes on the surface of both PfGAPDH and 
PfLDH and to raise and affinity purify polyclonal IgY antibodies against both the whole 
recombinant proteins as well as the selected peptides and measure final yields for 
comparison of adjuvants (Chapter 4). 
 To compare the levels of the current RDT target PfLDH to that of PfGAPDH within 




Materials and Methods 
 
This chapter describes the molecular, biochemical, immunochemical and bioinformatics 
methods used in this study.  
2.1 Materials 
2.1.1 Equipment  
Poly Prep® affinity column, Mini Protean II™ vertical PAGE unit and the VersaDoc™ 
imaging system were purchased from BioRad (California, USA). Orbital shaking incubator 
was purchased from New Brunswick Scientific (New Jersey, USA). Ultraspec 2100pro 
UV/visible spectrophotometer was purchased from GE Healthcare (Buckinghamshire, 
England). VersaMax™ ELISA plate reader was purchased from Molecular Devices 
Corporation (California, USA). Avanti™ J-26 XPI centrifuge was from Beckman Coulter 
(California, USA). GeneAmp™ PCR thermocyler was from Applied Biosystems (California, 
USA). BIOER Lifepro thermal cycler was purchased from United Scientific (Pty) Ltd. 
(Johannesburg, RSA). Virosonic™ cell disruptor was purchased from VirTis (New York, 
USA). Edwards One Stage 5 A.C. pump from GEC. Machines Ltd. (Newcastle, UK). Micro 
Tube Peristaltic pump MP-3 from EYELA Tokyo Rikakikai co. Ltd. (Tokyo, Japan). 
2.1.2 Reagents  
Ethidium bromide (EtBr), β-mercarptoethanol, 4-chloro-1-naphthol, acrylamide, ampicillin, 
Biomax® X-ray film, bisacrylamide, bromophenol blue, Coomassie Brilliant Blue G-250, 
Coomassie Brilliant Blue R-250, Ellman’s Reagent, formamide, Freund’s complete adjuvant 
(FCA), Freund’s incomplete adjuvant (FIA), glycine, isopropyl thioglucopyranoside (IPTG), 
L-cysteine, kanamycin, maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), ovalbumin, 
p-iodophenol, luminol, ponceau S, rabbit albumin (RA), saponin, Sephadex G-25, Sephadex 
G-10, Sephacryl S200, N,N,N’,N’-tetramethylethylenediamine (TEMED), Triton X-100, 
tryptone, Tween-20, and yeast extract were purchased from Sigma-Aldrich-Fluka (Steinheim, 
Germany). Bovine serum albumin (BSA) was purchased from Roche (Mannheim, Germany). 
The following were purchased from Fermentas (Vilinius, Lithuania): agarose, DNA 
MassRuler™, 10mM dNTP mix, EcoR1, Pst1, Nde1, Xho 1, molecular biology grade DTT, 
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Buffer O™ and an unstained protein molecular weight marker, containing: 116 kD β-
galactosidase; 66.2 kD bovine serum albumin; 45 kD ovalbumin; 35 kD lactate 
dehydrogenase; 25 kD REase Bsp981; 18.4 kD β-lactoglobulin and 14.4 kD lysozyme. 
Molecular biology reagents were purchased from Solis Biodyne (Tartu, Estonia), which 
included the 10× PCR buffer (MgCl2 and detergent-free), PCR MgCl2 stock solution (25mM) 
and Taq polymerase. The Escherichia coli host cells, plasmids and antibodies purchased from 
Novagen (Damstadt, Germany) were: BL21(DE3) (glycerol stock), pET-23a and pET-28a 
plasmids; mouse monoclonal anti-His-Tag IgG and peroxidase conjugated sheep monoclonal 
anti mouse IgG. Polyethylene glycol 6000 (PEG 6000) was purchased from Merck 
Biosciences (Damstadt, Germany). 2,2’-azino-bis(3-ethybenzothiazolinesulfonate) (ABTS) 
was purchased from Boehringer (Mannheim, Germany). SulfoLink™ and AminoLinkTM 
coupling gels and Snake skin™ dialysis membrane were purchased from Pierce Perbio 
Science (Erembodegem, Belgium). Hybond-C™ Extra nitrocellulose membrane purchased 
from GE Healthcare (Buckinghamshire, England). Peroxidase-conjugated rabbit anti-IgY, 
peroxidase-conjugated rabbit ant-mouse IgG antibodies were from Jackson Immunochemicals 
(Pennsylvania, USA). TALON® cobalt metal affinity resin was from Clontech Laboratories 
Inc. (California, USA). Synthetic peptides for lactate dehydrogenase and glyceraldehyde-3-
phosphate dehydrogenase proteins were synthesized by GL Biochem (Shanghai, China). Nunc 
Maxi Sorp™ 96-well ELISA plates were from Nunc products (Roskilde, Denmark). DNA 
purification kit was purchased from PEQLAB Biotechnologie (Erlangen, Germany).  
 
2.2 Molecular biology methods 
These methods include expression and purification of the recombinant proteins used in this 
study. Both expression vectors were provided and the plasmid vectors and expression hosts 
are described first.  
 
2.2.1 Expression vectors/plasmids and E. coli hosts 
Escherichia coli BL21(DE3) was used as the expression host, where the plasmids used were 
as follows: For recombinant Plasmodium falciparum lactate dehydrogenase (rPfLDH) a 
pKK223-3 plasmid vector was used, whereas a pET-15(b) plasmid expression vector was 
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used for recombinant P. falciparum glyceraldehyde-3-phosphate dehydrogenase 
(rPfGAPDH). The plasmid vectors were shown in the Figures 2.1 and 2.2. 
Figure 2.1 rPfLDH expression plasmid vector map (pKK223-3 vector). 
The vector map depicts the restriction sites available for inserting the desired coding sequence. The PfLDH 
sequence was inserted between the PstI and EcoRI restriction sites. The vector codes for Ampicillin resistance, 
which is used as the selective maker for transformed cells. The size of the plasmid without insert was 4.6 kb as 
shown in the centre of the map. 
 
The PfLDH sequence was inserted between the EcoRI (base 4582) and PstI (base 4564) sites 
in the pKK223-3 plasmid shown in Figure 2.1, where the size of the plasmid without an insert 
was 4.6 kb. The PfGAPDH sequence was inserted between the XhoI (base 324) and NdeI 





Figure 2.2 pET-15(b) expression plasmid vector map. 
The vector map depicts the restriction sites available for inserting the desired coding sequence. The PfGAPDH 
sequence was inserted between the XhoI and NdeI restriction sites. The vector codes for Ampicillin resistance, 
which is used as the selective maker for transformed cells. The size of the plasmid without an insert was given as 
5.7 kb as shown in the centre of the map. 
 
2.2.2 Vector verification 
This includes several molecular techniques which were performed on overnight (16 hour) 
culture samples of the respective E. coli BL21(DE3) transformed hosts. The overnight 






2.2.2.1 Agarose gel electrophoresis 
For 1 % (w/v) agarose gels with dimensions of 7 x 6.5 cm gels 0.3 g agarose was dissolved in 
30 ml TAE buffer (2M Tris; 50 mM EDTA; 0.95 M glacial acetic acid, pH 8.0) and heated in 
a microwave until the agarose had completely melted. Once the agarose solution cooled 
sufficiently, ethidium bromide (1 % (w/v) ethidium bromide in TAE buffer) was added to a 
final concentration of around 0.7 µg/ml, and the solution was poured into the gel casting tray 
and allowed to solidify at RT. Samples were prepared by diluting 5:1 in Fermentas sample 
loading buffer (0.25 % (w/v) bromophenol blue and 40 % (w/v) sucrose in TAE buffer). Gels 
were visualised under UV light and images captured using a VersaDocTM gel imaging system. 
Sizes of bands in base pairs (bp) were extrapolated from a graph of relative distance travelled 
from the well to log of the band size in bp of DNA standards run on the same gel. 
2.2.2.2 Plasmid isolation 
The 10 ml overnight (16 hour) culture grown at 37 ºC was centrifuged (1210 x g, 4 ºC, 5 min) 
and the supernatant discarded. The pellet was suspended in 200 µl GTE solution (25 mM Tris; 
1 mM EDTA; 50 mM glucose at pH 8.0) and left at room temperature (RT) for 5 min and 
transferred to a microfuge tube, to which 2 µl RNase A (10 mg/ml in 10 mM Tris; 1 mM 
EDTA at pH 8.0) and 400 µl NaOH/SDS solution (200 mM NaOH; 35 mM SDS) was added 
and left on ice for 5 min to allow cell lysis. Thereafter 300 µl potassium acetate (3 M 
potassium acetate at pH 4.8, titrated with glacial acetic acid) was added and mixed thoroughly 
and placed on ice for 5 min. At this stage a coarse white precipitate of cell debris and 
chromosomal DNA formed, after which the sample was centrifuged (17530 x g, RT, 5 min) 
and 800 µl of the supernatant was transferred to a fresh tube. Six hundred microliters 
isopropanol was added and mixed thoroughly, and the sample was left on ice for 30 min, after 
which it was centrifuged (17530 x g, RT, 5 min) to pellet the plasmid DNA. The pellet was 
then washed with ice cold 70% (v/v) ethanol and centrifuged (17530 x g, RT, 5 min), with the 
final plasmid pellet suspended in 50 µl TE buffer (10 mM Tris; 1 mM EDTA at pH 8.0) and 






2.2.2.3 Restriction digest 
Restriction digests were performed on plasmid DNA isolated as mentioned in 2.2.2.2.  
For single restriction the isolated plasmid DNA was digested at 37 ºC for 2 hours by 
preparing the following reaction mixture: 10 µl isolated plasmid DNA; 0.5 µl restriction 
endonuclease (5 units); 2 µl 10 x digestion buffer and the solution was made up to 20 µl with 
MiliQ dH2O. For double digests a suitable digestion buffer was chosen and the amount of 
each restriction endonuclease added was adjusted based on its activity within the chosen 
buffer (Fermentas restriction endonuclease buffers), and the digest time was left as 2 hours at 
37 ºC. For the P. falciparum LDH vector (pKK223-3) a double digest using EcoRI and PstI 
was performed to drop out the insert. In the case of the P. falciparum GAPDH vector (pET-
15(b)) a double digest using NdeI and XhoI was attempted. 
 
2.2.2.4 Polymerase Chain Reaction 
Colony polymerase chain reaction (PCR) was performed to verify the presence of the insert 
within the expression host.  
Single colonies were used to inoculate 5 ml LB media and cultured overnight (16 hours) at 37 
°C. After centrifugation (1210 x g, RT, 5 min) the supernatant was discarded and the pellet 
suspended in 500 μl MiliQ dH2O. Two microliters of this suspension was then removed and 
diluted further in 50 µl MiliQ dH2O. After boiling for 5 min, the samples were centrifuged 
(17530 x g, RT, 10 min), and 3 μl of the supernatant was transferred to a PCR tube and used 
as the template in the PCR reaction. The reaction mixture was completed by addition of the 
following: 1 μl forward and reverse primers; 0.25 µl Taq polymerase (5 units / µl); 2 μl 
MgCl2 (25 mM); 0.8 µl dNTPs; 2 μl 10 x PCR buffer (MgCl2 free) and made up to 20 µl with 
MiliQ dH2O. The reaction conditions were represented in Figure 2.4 below and a total of 30 
cycles were run per reaction. 
The specific annealing temperature of the primers used differed per reaction, and were 
optimised using gradient PCR if required. The primers were listed in Table 2.1, with the 
























Figure 2.3 PCR cycle conditions. 
The conditions were standard for all P CR reactions performed, except in the case of the annealing temperature 
“x” of the specific primers used, which were optimised if required.  
 
Table 2.1 Primer sequences and annealing temperatures. 
Primer  Sequence Annealing temp. (ºC) 
T7 promoter primer #69348-3 TAATACGACTCACTATAGGG 55 
T7 terminator primer #69337-3 GCTAGTTATTGCTCAGCGG 55 
pLDH forward control primer GGATCTGGTATGATTGGAGGTGTTATGGCC 65 
pLDH reverse control primer TTCGATTACTTGTTCTACACCATTACCACC 65 
 
2.2.2.5 Sequencing 
Plasmid DNA wa s isol ated as de scribed in 2.2.2.2 and se nt for se quencing to Central 
Analytical Facilities at Stellenbosch University. The PfLDH sequencing was done using the 
pLDH pr imers from Table 2.1, whereas T7 promoter a nd terminator specific pr imers were 
supplied b y Central Ana lytical F acilities at S tellenbosch University for the PfGAPDH 
reactions.  Consensus s equences were then identified using  the forward and re verse 
sequences, and analysed by alignment using clustalW to assess their sequence identit y with 
the corresponding coding sequences found in PlasmoDB.  
 
2.2.3  Expression 
Glycerol stocks (overnight culture pellets (centrifuged 4000 x  g, 4 ºC, 10 min) suspended in 
850 µl PBS (137 mM NaCl; 3 mM KCl; 7 mM Na2HPO4; 1.5 mM KH2PO4 at pH 7.2) 150 µl 
glycerol (50 % (v/v))) of the respective expression vectors were 3-way streaked onto LB agar 
(1 % (w/v) tryptone; 0.5 %  (w/v) yeast extract; 85 mM NaCl; 11 m M glucose; 1.5 % (w/v) 
bacto-agar prepared in dH2O and autoclaved) plates and incubated overnight (16 hours) at 37 
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ºC. Single colonies were picked to inoculate 10 ml LB broth (1 % (w/v) tryptone; 0.5 % (w/v) 
yeast extract; 85 mM NaCl; 11 mM glucose; 1.5 % (w/v) prepared in dH2O and autoclaved) 
and incubated overnight at 37 ºC. These cultures were then used to inoculate large LB broth 
preparations (expression culture) using 1/100 dilutions of the overnight cultures. All LB broth 
and agar was supplemented with ampicillin (50 mg/ml stock prepared in dH2O and filter 
sterilised) to a final concentration of 50 µg/ml, and the expression cultures were re-
supplemented with ampicillin every 2 hours to maintain selective pressure for transformed E. 
coli hosts. The expression cultures were monitored until absorbance values at 600 nm (A600) 
of between 0.5-0.6 were reached (exponential growth phase of cultures), upon which 
expression was induced for 4 hours by supplementing with IPTG (0.1 M in dH2O and filter 
sterilised) to a final concentration of 0.3 mM. Cultures were then centrifuged (4000 x g, 4 ºC, 
10 min)  and suspended in 5 % of their original volume in resuspension buffer (50 mM 
NaH2PO4; 300 mM NaCl at pH 7.0 or pH 8.0) after which they were further processed for 
affinity purification of recombinant proteins or stored at -20 ºC until further use. 
 
2.2.4  Affinity purification 
Following vector verification, the recombinant proteins were expressed and passed over a 
TALON (Co2+) affinity matrix, allowing the His6-tagged recombinant proteins to be purified 
as described below. 
The pelleted culture samples prepared as in 2.2.3 were suspended to 5 % of their original 
culture volume in wash buffer and lysed using 4 x 30 sec sonication steps (0.6-0.8 Watts). 
Samples were then centrifuged (12000 x g, 4 ºC, 20 min)  and 10 ml of the supernatant was 
incubated for 20 min with 1 ml of a packed TALON (Co2+) affinity resin (i.e. 2 ml of 50 % 
slurry). The resin was equilibrated earlier by washing twice with 10 ml wash buffer (50 mM 
NaH2PO4; 300 mM NaCl; 10 mM Imidazole; 0.02 % (w/v) NaN3 at pH 7.0 or 8.0), with a 5 
min centrifugation step at 1210 x g after each wash and removal of the supernatant buffer. 
After the incubation with the sample, the resin was washed twice with wash buffer as 
described above. The resin was then transferred to a column and the bound recombinant 
protein was eluted using 5 ml elution buffer (same as wash buffer except for the addition of 
250 mM Imidazole as opposed to 10 mM). Eluants were analysed by measuring A280 values, 
and protein concentration was determined by Bradford method as described in 2.3.1. The 





















min, followed by a 10 ml wash with dH2O and storage at 4 ºC in storage buffer (20 % (v/v) 
ethanol; 0.1 % (w/v) NaN3 prepared in dH2O). 
 
2.3 Biochemical techniques 
This section outlines the different biochemical techniques used to examine both the 
recombinant and native Plasmodium proteins.  
 
2.3.1 Bradford 
This method was performed according to (Bradford, 1976). In order to obtain a standard 
curve, the 1mg/ml bovine serum albumin (BSA) stock solution was used to prepare BSA 
standards (0-50 µg) in triplicate. These were made up to 100 µl with dH2O after which 900 µl 
Bradford dye (0.12 % (w/v) Coomassie brilliant blue G-250 dissolved in 500 ml of a 2 % 
(v/v) perchloric acid solution) was added to each sample and vortexed. Samples were left to 
stand for 15 min after which their absorbance at 595 nm (A595) was read and plotted against 
BSA concentration. Unknown samples were prepared in the same way as the standard 
samples in that an appropriate dilution of the unknown was prepared which allowed the 








Figure 2.4 Bradford standard curve.  




2.3.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis  
Discontinuous SDS-PAGE as described by (Laemmli, 1970) was used to assess protein size 
and purity and was performed as follows. 
Gels were prepared according to Table 2.2. The buffers were named A through E for 
simplicity of the table and were as follows: A (4.1 M acrylamide and 52 mM N,N’-
methylenebisacrylamide); B (1.5 M Tris buffer at pH 8.8); C (495 mM Tris buffer at pH 6.8); 
D (1 % (w/v) SDS solution in dH2O) and E (10 % (w/v) ammonium persulfate solution in 
dH2O). Gels were set using a Bio-Rad Mini PROTEAN II® vertical slab apparatus, consisting 
of 4 glass plates (two with dimensions of 81.5 mm x 101.5 mm and two 72.5 mm x 101.5 
mm); two 10 or 15 well combs; four spacer plates and a gel-casting stand with casting gaskets 
and plate cassettes. The gel-casting unit was assembled according to manufacturer’s 
instructions after cleaning plates with detergent and rinsing under dH2O, giving final gels of 
approximately 1.5 mm width.  
 
Table 2.2 Running and stacking gel recipes for SDS-PAGE. 
 12.5 % 
Running gel 
4 %     
Stacking gel  









D 70 µl 
E 35 µl 
dH2O 4.3ml 
TEMED 15 µl 
 
After addition of TEMED, the un-polymerised running gel solution was mixed and 6.6 ml of 
this was poured into the gel cassette between the glass plates and overlaid with 200 µl dH2O. 
This allows the gels to set properly, as oxidation would otherwise inhibit gel polymerisation. 
Once set, the water was decanted and the freshly prepared stacking gel solution was overlaid 
to the top of the glass plates. The 10 or 15 well comb was then inserted immediately and the 
stacking gel was allowed to set. Samples to be run on the gel were prepared as follows: 
samples were diluted 1:1 in 50 % (v/v) sample buffer for non-reducing gels (2.5 ml solution 
C; 2 ml glycerol; 4 ml solution D; with few grains of bromophenol blue to colour the buffer). 
For reducing gels β-mercaptoethanol was added 1:10 to the sample buffer before mixing with 
the samples. After loading the samples the gels were run at 20 mA per gel in tank buffer (25 
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mM Tris; 192 mM glycine and 1 % (v/v) solution D) until the dye front had migrated to 
within 0.5 to 1 cm from the bottom of the gel. The gels were then removed immediately and 
stained with Coomassie stain (45 % (v/v) methanol; 10 % (v/v) acetic acid; 0.25 % (w/v) 
Coomassie brilliant blue R-250) and destained with several changes of destain I (50 % (v/v) 
methanol and 10 % (v/v) acetic acid) and left in destain II (5 % (v/v) methanol and 7 % (v/v) 
acetic acid) until the gels had swollen back to their original size. The sizes of protein bands 
were determined by extrapolation from a graph of log molecular weight of molecular weight 
standards run on the same gel, against their relative mobility (Rf values).  
 
2.3.3 Sliver staining 
Glassware used for staining was meticulously cleaned with detergent and then rinsed with 
fixing solution (50 % (v/v) methanol; 12 % (v/v) acetic acid and 0.5 % (v/v) formaldehyde) 
and allowed to dry. SDS-PAGE gels were transferred to glass petri dishes and fixed for 1 hour 
or overnight (16 hours). All incubations and washes were performed on a rocker. The gels 
were washed 3 times with wash solution (50 % (v/v) ethanol) after fixing, and then left in pre-
treatment solution (4 mg/ml Na2S2O3.5H2O) for 1 min and 15 sec. Gels were then washed 3 
times with dH2O, 20 sec per wash and then left in impregnation solution (0.2 % (v/v) AgNO3; 
0.3 % (v/v) formaldehyde prepared just before use) for 20 min. Gels were washed 3 times 
with dH2O, 20 sec per wash and then incubated with developing solution (566 mM Na2CO3; 
0.2 % (v/v) formaldehyde; 2 % (v/v) pretreatment solution) until first bands appeared. The 
developing solution was then replaced with dH2O and bands were allowed to develop until the 
intensity was satisfactory, at which time the gels were incubated in stop solution (50 % (v/v) 
methanol; 12 % (v/v) acetic acid) for 10 min, and stored in 50% (v/v) methanol. 
 
2.3.4 Molecular Exclusion Chromatography 
Sephacryl S200 resin was packed using dH2O to a final column volume of approximately 309 
ml. This was done using a peristaltic pump at half to maximum flow rate. Once packed the 
column was washed using half the column volume cleaning buffer (0.2 M NaOH). The MEC 
buffer (50 mM NaH2PO4; 150 mM NaCl at pH 8.0) was always degassed for 45 min at 4 °C 
prior to use, using an Edwards One Stage 5 A.C. pump, and all further working solutions were 
cooled to 4 °C prior to use. The column was then equilibrated with twice the column volume 
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MEC buffer at a set flow rate of 1 ml/min. For calibration of the column, the molecular 
weight standards were prepared to a final volume of 3 ml as follows: 6 mg blue dextran (2000 
kD), and 15 mg each of sheep IgG (150 kD), bovine serum albumin (68 kD), ovalbumin (45 
kD), and myoglobin (18.8 kD). The parameters for running the column were set to a flow rate 
of 1 ml/min and collection of 4 ml eluents. The absorbance at 280 nm (A280) was read for 
each eluent fraction, to give a calibration curve of A280 plotted against elution volume (ml). 
After calibration the rPfLDH (5.6 mg) and rPfRDP (3.8 mg) samples were prepared to a final 
volume of 4 ml and run over the column using the same parameters. 
 
2.4 Bioinformatics 
This section describes the in silico work done in identifying peptide epitopes for each of the 
target proteins, PfLDH and PfGAPDH. 
 
2.4.1 Sequence alignments 
Alignments DNA coding sequences as well as primary protein amino acid sequences were 
done using clustalW2 (www.ebi.ac.uk/Tools/msa/clustalw2/). The sequences were obtained 
either from NCBI (www.ncbi.org/) or PlasmoDB (www.plasmodb.org/) as indicated in text. 
 
2.4.2 3D modelling 
3D protein models were downloaded from the Swiss model repository 
(http://swissmodel.expasy.org/repository/) and manipulated with Deep view Swiss pdb viewer 
downloaded from (http://www.expasy.org/spdbv/).   
 
2.4.3 Predict7TM 
Predict 7TM was used for analysis of protein primary amino acid sequences in order to identify 
immunogenic peptides on the surface of the target proteins PfLDH and PfGAPDH, which 
were used to raise antibodies in chickens. Graphs were generated, plotting peptide 




2.5 Immunochemical techniques 
The methods included in this section centre around the production and use of antibodies, in 
particular chicken antibodies (IgY).   
 
2.5.1 Western blot 
This method follows on from the SDS-PAGE method described in 2.3.2. After running 
protein samples on an SDS-PAGE gel, the proteins were transferred onto a nitrocellulose 
membrane. This was done by sandwiching the gel and nitrocellulose between two pairs of 
blotting paper and one set of sponges in a blotting cassette. The gels and nitrocellulose were 
soaked in blotting buffer (50 mM Tris; 192 mM glycine; 20 % (v/v) methanol) for 10 min 
prior to preparing the sandwich, and the nitrocellulose was carefully rolled onto the gel to 
avoid trapping air bubbles. The cassettes were inserted into the cassette holder and placed in 
the blotting tank, after which they were immersed in blotting buffer. Electrophoretic transfer 
was carried out overnight at 20 mA. The nitrocellulose pieces were then carefully removed 
and blocked with 10 ml of a 5 % (w/v) low fat milk powder in TBS (20 mM Tris; 200 mM 
NaCl at pH 7.4) solution for 1 hour. The nitrocellulose strips were then washed 3 times in 10 
ml TBS for 5 min per wash. Primary antibody solutions were prepared in .05 % (w/v) BSA-
TBS solutions as specified and nitrocellulose strips were incubated for 2 hours with these 
solutions, followed by 3 washes in TBS as described before. The nitrocellulose strips were 
then incubated for 1 hour with secondary antibody solution 1/12000 (unless stated otherwise) 
in 0.5 % (w/v) BSA-TBS, followed by three washes in TBS as described before. Finally the 
nitrocellulose strips were developed for 10 to 30 min using 2 ml of a substrate stock solution 
(0.3 % (w/v) 4-chloro-1-naphthol in methanol) diluted in 8 ml TBS containing 4 µl H2O2. 
After developing the nitrocellulose strips were washed with dH2O and left to dry. 
 
2.5.2 Enhanced chemiluminescence 
The procedure follows that of Western blotting, except that TTBS (0.1 % (v/v) Tween 20 
added to the TBS buffer as described in 2.5.1) is used and the blocking is done with 8 % (w/v) 
low fat milk powder in TTBS, and wash steps are increased to 8 min per wash. After blocking 
for 1 hour and washing 3 times 8 min with TTBS, the blots were incubated with primary 
antibody overnight (16 hours) at 4 ºC with rocking. The primary and secondary antibodies 
43 
 
were prepared in 0.5 % (w/v) BSA-TTBS to the desired concentrations, which were both 
optimised. Detection of the chemiluminescent signal was done in a dark room fitted with red 
lights. Film paper was used for detection, and blots were sandwiched between two sheets of 
plastic overheads and the MWM were traced. The chemiluminescent reagent was then 
prepared by mixing 50 µl of a luminol stock solution (40 mg/ml luminol in 1 % (v/v) DMSO), 
25 µl of a p-iodophenol stock (0.1 M p-iodophenol in 1 ml DMSO) and 10 ml 0.1 M Tris-HCl 
pH 8.5 buffer directly onto the blots and the overhead sheets were folded slowly over the blot. 
Care was taken not to trap air bubbles and the blots were placed into an ECL exposure 
cassette. The film paper was then carefully laid on top of the blots and the exposure cassette 
was closed for the exposure time which was optimised. The film paper was then quickly 
removed and incubated in developing and fixing solution for 5 min and 2 min respectively. 
The film was then rinsed with water and left to dry.  
 
2.5.3 Immunoprecipitation 
Protein G beads were centrifuged (3000 x g, RT, 2 min), suspended in IP buffer (50 mM Tris; 
150 mM NaCl; 0.1 % (v/v) Triton X-100 at pH 8.0) and washed for 30 min on a rocker. They 
were then centrifuged again (3000 x g, RT, 2 min) and suspended in their original volume 
with IP buffer. All sample incubations were done at room temperature (RT) with rocking. 
Parasite lysate samples (1 ml) were pre cleared by incubating with 20 µl protein G slurry for 
30 min, centrifuged (3000 x g, RT, 2 min) and the pre-clarified supernatant samples were 
transferred to new eppendorfs. These samples were then incubated with 25 µg primary IgY 
antibody for 2 hours, followed by an hour incubation with 10 µg secondary / bridging 
antibody (rabbit anti-chicken IgY). Fifty microliters of the washed protein G beads were then 
added to the samples and incubated for one hour. Finally the samples were underlayed with 
200 µl 1M sucrose and centrifuged (3000 x g, RT, 5 min). The supernatant samples were then 
either discarded, or in the case of sequential immunoprecipitation experiments they were 
transferred to new eppendorfs. The immunoprecipitation procedure was then repeated with a 
different primary antibody. The final precipitated pellets were washed twice by suspending 
the samples in 1 ml IP buffer and centrifuging (3000 x g, RT, 2 min), after which they were 




2.5.4 ELISA (direct and double antibody sandwich) 
2.5.4.1 Direct ELISA method 
Antigen concentrations were prepared to 1 µg / ml in PBS (137 mM NaCl; 3 mM KCl; 7 mM 
Na2HPO4; 1.5 mM KH2PO4 at pH 7.2) and 150 µl was pipetted to each well. The plates were 
incubated overnight at 4 ºC to allow coating of the wells. All wash steps were done with 0.1 
% (v/v) PBS-Tween 20 and repeated 3 times and all incubations subsequent to coating were 
done at 37 ºC except with substrate which was left at room temperature. After coating the 
plates were washed and then blocked with 200 µl 0.5 % (w/v) BSA-PBS per well and 
incubated for 1 hour. After a wash step the plates were incubated for 2 hours with 100 µl of 
the antigen-specific primary antibody and washed again. They were then incubated with 120 
µl of the rabbit-anti-chicken HRPO antibody diluted 1/15000 for 1 hour and washed. All 
antibody solutions were prepared in 0.5 % (w/v) BSA-PBS. Finally the plates were incubated 
with 150 µl substrate (0.05 % (w/v) ABTS; 0.0015 % (v/v) H2O2) prepared in a 0.15 M citrate 
phosphate buffer at pH 5.0 per well and left to develop in the dark at room temperature for 30 
min. The plates were then read immediately in an ELISA-plate reader at 405 nm. Background 
controls included: no antigen (or no coat), no primary antibody and no detection antibody. All 
results were corrected for background. Positive controls included a no blocking control. 
Additional controls were stated in text where applicable. 
2.5.4.2 Double antibody sandwich ELISA method 
Plates were coated with 150 µl of an antigen-specific capture antibody at a concentration of 1 
µg / ml prepared in PBS and incubated overnight at 4 ºC. All other antibody solutions were 
prepared in 0.5 % (w/v) BSA-PBS As in the direct ELISA method, all subsequent incubation 
steps were done at 37 ºC and all wash steps were repeated 3 times with 0.1 % (v/v) PBS-
Tween 20. After coating plates were washed and incubated with 0.5 % (w/v) BSA-PBS for 1 
hour and washed. 150 µl of the antigen-containing sample was then loaded per well at the 
desired concentration which had to be optimised to avoid the prozone effect. Recombinant 
protein solutions were prepared in 0.5 % (w/v) BSA-PBS and used to prepare antigen 
standard curves. Plates were incubated for 2 hours, washed and then incubated with 150 µl of 
a detection antigen-specific antibody linked to HRPO diluted 1/200 for 2 hours and washed 
again. 150 µl substrate solution was added per well and the plates were incubated in the dark 
for 30 min at room temperature, after which they were immediately read in an ELISA-plate 
reader at 405 nm. Background controls included: no antigen, no capture antibody and no 
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detection antibody. All results were corrected for background. Positive controls included a no 
blocking control. Additional controls were stated in text where applicable. 
 
2.5.5 Coupling peptides to rabbit albumin 
Four milligrams of the target peptide was dissolved in 50 µl DMSO and made up to 500 µl in 
reducing buffer (100 mM Tris; 1 mM EDTA; 0.02 % (w/v) NaN3 at pH 8.0), after which 500 
µl 10 mM DTT solut ion (10 mM DTT in reducing buffer) was added and the solution was 
mixed and incubated at 37 ºC in a water bath for 90 min.  
The ratio of peptide to carrier is 40:1, therefore the mass of  rabbit albumin (RA) required for 
coupling was calculated as follows, where the molar mass of rabbit albumin is 68.2 kD:  
 
The ra tio of  carrier to MBS is 1:40, therefore t he mass of  MBS required for  coupling w as 
calculated as follows, where the molar mass of MBS is 314.26 g / mol. 
 
The calculated amounts of RA were dissolved in 500 µl PBS and the MBS was dissolved in 
200 µl Dimethyl formazan (DMF) and 300  µl PBS. Once dissolved the two solut ions were 
combined and left to stand at room temperature for 30 min. This incubation was timed to start 
30 min into the peptide incubation. 
Two MEC columns were equilibrated with MEC buff er (100 mM NaH2PO4; 0.02 %  (w/v) 
NaN3 at pH 7.0) . A Sephadex G-10 column was used to separate the reduced peptide from 
DTT, and the eluted 1 ml fractions were assessed for reduced peptide by adding 10 µl eluent 
to 10 µl Ellman’s reagent (4 mg/ml) prepared fresh in Ellman’s buffer (100 mM Tris; 1 mM 
EDTA; 0.1 %  (w /v) SDS a t pH 8.0). Ye llow reactions indicated reduced pe ptide e luents. 
These were retained and used for coupling to the MBS activated RA carrier. The activated RA 
carrier was prepared by running it over a Sephadex G-25 column after the 30 min incubation 
68200 x         x 
1 
40 
4 x 10-3 g (peptide) 
    Mr peptide 
x 1000 = carrier (mg) 
314.26 x 40 x 
carrier (mg) 
    68200 
x 1000 = MBS (mg) 
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at room temperature with MBS as explained above. 1 ml fractions were collected and by 
measuring A280 values those fractions with A280 values greater than 0.3 were pooled and 
combined with the reduced peptide fractions eluted off the Sephadex G-10 column. This 
mixture was then left to stand at room temperature for 3 hours with gentle stirring. The 
resulting peptide-carrier conjugate solution was then split into 4 aliquots and stored at -20 ºC 
until required for immunisation. 
 
2.5.6 Chicken immunisation 
(Ethics number 36/11 Animal) 
Fifty micrograms recombinant protein was used per immunisation per chicken. Alternatively 
4 mg of a prepared peptide conjugate sample was used for the whole immunisation schedule 
for one chicken, the sample was split into 4 aliquots that is. The samples for immunisation 
were prepared in PBS and were mixed 1:1 with the respective adjuvant used either Freund’s 
or PheroidsTM. In the case of Freund’s adjuvant, the complete adjuvant (FCA) containing heat 
killed Mycobacterium was used for primary immunisations and the incomplete adjuvant (FIA) 
without Mycobacterium was used for booster immunisations. All samples were prepared by 
trituration with a syringe, where the Freund’s adjuvant samples eventually formed water in oil 
emulsions. In the case of using PheroidsTM as the adjuvant, the samples were triturated for the 
same time it took for the Freund’s samples to be prepared. Chickens were given intramuscular 
immunisations into each chest muscle, where the immunisation sites were sterilised with 70 % 
(v/v) ethanol prior to immunisation.  
 
2.5.7 IgY isolation  
The method for isolation of chicken antibodies (IgY) was followed as described by Polson et 
al., (1985). 
Chicken eggs were collected on a daily basis and stored at 4 ºC until use. They were cracked 
and the yolk was retained while washing the egg white off under running water to remove all 
the albumin. The yolk sac was then pierced with a needle and the yolk was collected into a 
measuring cylinder to determine the volume. Two volumes of isolation buffer (100 mM 
NaH2PO4; 0.02 % (w/v) NaN3 at pH 7.6) were then added to increase the sample volume to 
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three times the initial yolk volume. PEG (Mr 6000) was then added to a final concentration of 
3.5 % (w/v) and the solution was stirred gently until the PEG dissolved completely. The 
solution was then centrifuged (4420 x g, 4 ºC, 30 min), which removed the precipitated 
vitellin fraction and the supernatant was decanted and filtered through cotton wool. The PEG 
concentration of the supernatant was then increased to 12 % (w/v) and stirred gently until 
completely dissolved. In this case the sample was centrifuged (12000 x g, 4 ºC, 10 min) and 
the precipitate was retained and dissolved in a volume of isolation buffer equal to that of the 
filtrate. The PEG concentration was again brought to 12 % (w/v) and allowed to dissolve 
completely with gentle stirring. The sample was then centrifuged (12000 x g, 4 ºC, 10 min) 
and the final pellet was dissolved in 1/6 of the initial yolk volume in storage buffer and stored 
at 4 ºC.   
 
2.5.8 Preparation of affinity matrices for antibody purification 
2.5.8.1 AminoLinkTM 
AminoLinkTM was used when whole protein antigens were to be used for preparation of 
affinity columns, as outlined below. 
Five milligrams of the protein to be coupled was dialysed against coupling buffer (100mM 
NaH2PO4; 0.05 % (w/v) NaN3 at pH7.2). The AminoLinkTM resin was poured into a mini-
column and the storage buffer was drained after the resin had settled. The resin was then 
equilibrated with 6 ml coupling buffer and drained. The dialysed protein solution was then 
added (2-4 ml) and 0.1 ml was retained to determine the coupling efficiency of the protein to 
the column. Forty microliters cyanoborohydride solution (5M NaCNBH3; 1M NaOH) was 
added, and the column was mixed end-over-end for 6 hours at room temperature. The column 
was then drained of buffer and an eluent sample was retained to determine the coupling 
efficiency of the protein to the column. The column was then washed with 4 ml coupling 
buffer after which 2 ml quenching buffer (1M Tris-HCl at pH 7.4) was added with 40µl 
cyanoborohydride and mixed on an end-over-end mixer for 30 min. The column was then 
drained again and washed with 10 ml wash solution (100mM NaH2PO4; 0.2% (w/v) NaN3 at 





SulfoLinkTM resin was used for producing peptide-linked affinity columns, linking the 
peptides via terminal Cysteine residues.  
Five milligrams of the peptide to be coupled was dissolved in 100 µl DMSO and 400 µl 
general buffer (50 mM Tris-HCl; 50 mM EDTA at pH 8.5), to which 500 µl DTT was added 
and the sample was then incubated for 1.5 hours at 37 ºC (water bath). A Sephadex G-10 
column equilibrated with general buffer was used to separate the reduced peptide from the 
DTT. This was done by collecting 1ml eluents off the column and combining 10 µl of each 
eluent separately with 10 µl Ellmans reagent as described in 2.5.5. The reduced peptides 
reacted with the Ellmans reagent to give a yellow solution. The eluents containing the reduced 
peptide were pooled and added immediately to 1 ml prepared SulfoLinkTM resin and mixed 
for 15 min after which the resin was allowed to stand for 30 min. After 3 washes with general 
buffer (1 column volume each) 1 ml of a 50 mM L-Cysteine solution was added to the resin, 
mixed for 15 min on an end over end mixer and then left to stand for 30 min. The column was 
then drained and washed with 16 column volumes washing buffer followed by 2 column 
volumes of a 0.1 M phosphate buffer at pH 7.6 and stored at 4 ºC until use. 
 
2.5.9 IgY affinity purification 
Crude IgY was isolated from single eggs collected at the end of each week after 
immunisation. Weeks showing high antibody titres were pooled and used for affinity 
purification. The crude IgY was circulated over the column overnight at room temperature. 
The column was then washed with PBS until the A280 of eluting samples dropped down to 
between 0.01-0.02. Eppendorfs were prepared for collection of eluent samples by adding 50 
µl neutralisation buffer (1 M NaH2PO4; 0.02 % (w/v) NaN3 at pH 8.5) to each tube. The 
specific antibodies bound to the antigen on the column were then eluted with a change in pH 
by adding 8 ml elution buffer (100 mM glycine; 0.02 % (w/v) NaN3 at pH 2.8) to the column 
and collection 1 ml eluents. The IgY concentration was then determined by measuring the 
A280 values of the samples and calculated using the extinction coefficient of IgY (Ɛ = 1.25) 
(Coetzer, 1985). Affinity purified samples with A280 values greater than 0.2 were pooled and 




2.5.10 Conjugation of horse radish peroxidase to IgY antibodies 
Eight milligrams of horse radish peroxidase (HRPO) (1360 Units) was dissolved in dH2O. 
Two hundred microliters 0.1 M sodium periodate was added and the solution turned from 
brown to a greenish brown and was stirred gently for 20 min at room temperature. The 
solution was then dialysed overnight (16 hours) at 4 ºC against sodium acetate buffer (0.1 M 
sodium acetate; 0.22 % (v/v) acetic acid at pH 4.4), after which 20 µl sodium carbonate buffer 
(13 ml of a 0.2 M sodium carbonate solution and 37 ml of a 0.2 M sodium hydrogen 
carbonate solution were made up to 200 ml at pH 9.5) was added to raise the pH of the 
solution to between 9-9.5 and 1 ml (8 mg) of the IgY sample to be conjugated was added 
immediately. The antibody-HRPO mixture was inverted every 15 min and left at room 
temperature for a total of 2 hours. Finally 100 µl sodium borohydride solution (4 mg/ml) was 
added to reduce any unbound HRPO and the solution was left to stand for 2 hours at 4 ºC. 
The IgY-HRPO solution was then dialysed against a 0.1 M borate buffer at pH 7.4 after which 
an equal volume of 60% (v/v) glycerol solution (prepared in borate buffer) was added and the 
















Expression and characterisation of recombinant PfLDH and PfGAPDH  
 
3.1 Introduction 
Current rapid diagnostic tests (RDTs) are based on three malarial proteins found in the 
parasite cytoplasm. These include histidine-rich protein 2 (HRP-2), lactate dehydrogenase 
(LDH) and aldolase (Murray et al., 2008, Murray and Bennett, 2009). HRP-2 is used for the 
detection of Plasmodium falciparum infection as it is only expressed by this species (Murray 
et al., 2008). Tests that use HRP-2 exclusively include Paracheck Pf®; ParaHIT f® and 
ParaSight-F for example (Murray et al., 2008).  
There are currently 5 malaria species that infect humans including P. falciparum, P. vivax, P. 
ovale, P. malariae and P. knowlesi. P. knowlesi was recently added as a recognised human 
infective species, transmitted by the mosquito vector Anopheles latens which is parasitic to 
both humans and monkeys (Anderios, 2009, Daneshvar et al., 2009, Lee et al., 2009, 
Sabbatani et al., 2010, Van den Eede et al., 2010, van Hellemond et al., 2009). Due to co-
infections with P. falciparum and other malaria species RDTs have to be able to detect and 
differentiate between these species. With co-infections, drug therapies are required to target 
each infecting malarial species and to avoid relapse (Chuangchaiya et al., 2009; Murray et al., 
2008). Alternate protein targets to HRP-2, such as the glycolytic enzymes LDH and aldolase, 
which are common to all malaria species, are therefore used for diagnosis to detect mixed 
infections (Murray et al., 2008). RDTs either target LDH alone (OptiMAL® or OptiMAL-IT® 
tests), or HRP-2 in combination with either LDH (CARESTARTTM), or with aldolase 
(BinaxNOW® test) to detect mixed infections (Ashley et al., 2009; Khairnar, 2009; Murray et 
al., 2008).  
HRP-2 is secreted and is also found in knob-like protrusions present on the parasitized red 
blood cell membrane (Howard et al., 1986). There have been reports of false negative 
diagnoses of P. falciparum infection using HRP-2 as a target due to HRP-2 gene deletions. 
Isolates in Peru have been shown to have the HRP-2 gene deleted (Gamboa et al., 2010). 
Variation in amino acid composition of HRP-2 (known as antigenic variation) has also been 
reported to affect detection (Baker et al., 2010, Lee et al., 2006a). Sequence analysis of LDH 
and aldolase from malaria field isolates has shown that the amino acid sequence in these 
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proteins does not undergo antigenic variation, unlike HRP-2 (Lee et al., 2006b) which should 
allow for a more consistent detection of infections. 
Another aim for RDTs is to monitor treatment, allowing clinicians to adjust or alter drug 
treatments based on the efficacy of the drug. This is hampered for tests based on HRP-2 as the 
protein persists in serum for 14 to 28 days after the parasitemia is cleared (Iqbal et al., 2004; 
Kodisinghe et al., 1997; Murray et al., 2008; Tjitra et al., 2001). This is not the case with 
LDH and aldolase due to their short half-life. Both LDH and aldolase are involved in 
metabolism and are thus associated with living parasites (Iqbal et al., 2004, Murray et al., 
2008). LDH based tests (CareStartTM and OptiMAL-IT®) reverted back to negative within 2 
and 7 days respectively after drug clearance of infection (Ashley et al., 2009). The only 
possible drawback is that all 3 antigens are also produced in the gametocyte stage of the 
parasite, however due to the low gametocyte numbers in comparison to the asexual stages, 
parasite clearance could still be monitored using LDH and aldolase (Murray et al., 2008, 
Tjitra et al., 2001).  
Tracking the clearance of infection has become an important factor for the treatment of 
malaria as well as other tropical diseases. The early symptoms of malaria infections overlap 
with those of other tropical diseases and therefore these infections are often mistaken for 
malaria and treated as such (Gwer et al., 2007, Källander et al., 2004). An estimated one third 
of children displaying malaria-like symptoms end up testing negative for malaria and 
misdiagnoses are often fatal due to incorrect treatment. Outlines for clinicians have been 
provided by the centre for disease control (Lalloo et al., 2007) encouraging diagnosis before 
treatment (Lalloo et al., 2007). Confidence in malaria RDTs is still lacking however, as 
argued by Bisoffi et al., (2009) with clinicians reverting to presumptive treatment of malaria 
in the case of a negative test.  
To improve confidence in RDTs, quality assurance is very important and has also been 
recommended by the WHO (WHO, 2008). These measures include buying RDTs from 
manufacturers with evidence of good manufacturing practice as well as “in the field testing” 
of RDTs. One of the methods for testing RDTs in the field was by inclusion of a positive 
control. This would entail the use of recombinant antigens or peptides reconstituted in 
uninfected blood (Lon et al., 2005, Murray et al., 2008). Alternatively Versteeg and Mens in 
2009 used dried infected blood spots as positive controls, where they found this format to 
work best for HRP-2 based tests due to the stability of the antigen, but to be less effective for 
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LDH and aldolase based tests. Further work has to be done on the heat stability of positive 
controls and on optimisation of antigen concentrations that will allow for exclusion of RDTs 
that lack appropriate sensitivity (Lon et al., 2005).  
Two malarial metabolic proteins were selected for studying as diagnostic targets. The proteins 
were Plasmodial LDH and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Both LDH 
and GAPDH are key conserved metabolic enzymes, making them ideal targets for diagnostics 
(Daubenberger et al., 2000; Lee et al., 2006b). Both P. falciparum proteins were 
recombinantly expressed and the recombinant proteins were characterised using SDS-PAGE, 
Western blotting and molecular exclusion chromatography. The purified recombinant proteins 

















3.2.1 Confirmation of the identity of the coding sequences cloned for the expression of 
P. falciparum LDH and GAPDH 
E. coli BL21(DE3) cells were tr ansformed with either a  p KK223-3 ve ctor containing th e 
coding gene for PfLDH (Pf(K1) strain), or with a pET-15b vector containing the coding gene 
for PfGAPDH ( Pf(3D7) strain). These we re kindly pr ovided b y P rofessor R.L. B rady 









Figure 3.1  Confirmation of t he r PfLDH g ene insert in the pK K223-3 plasmid by  EcoRI a nd PstI 
restriction digestion and PCR amplification. 
Samples were run on 1% (w/v) agarose gels in the presence of ethidium bromide with the co -migrating DNA 
ladder sizes labelled on the left in kilo base pairs (kb) and bands of interest on the right. EcoRI and PstI digests 
of purified rPfLDH plasmid DNA (pKK223-3 vector) were shown in (A) and the samples were run as follows: 
lane 1 undigested; lane 2 EcoRI digest; lane 3 PstI digest; lane 4 EcoRI and PstI double digest. PCR products 
were run in (B) as follows: lane 1 colony PCR; lane 2 PCR with purified plasmid and lane 3 no template control.
 
Figure 3.1 (A) shows results for the digestion of  the pKK223-3 vector containing the LDH 
gene with EcoRI and PstI restriction endonucleases alone or together. The size of the insert 
was estimated at 950 bp. The vector alone was estimated to be 4.8 kb and to be 5.8 kb with 
the insert. A single 850 bp amplicon was obtained for PCR amplification (Figure 3.1 (B)) as 
expected of the plasmodial LDH.  
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Figure 3.2  Confirmation of the rPfGAPDH gene insert in the pET-15b plasmid by XhoI and NdeI 
restriction digestion and PCR amplification.  
Samples were run on 1% (w/v) agarose gels in the presence of ethidium bromide, with the co-migrating DNA 
ladder sizes labelled in kb on the left of each gel and bands of interest on the right. XhoI and NdeI digests of the 
purified rPfGAPDH plasmid DNA (pET-15b vector) were shown in (A) and the samples were run as follows: 
lane 1 undigested; lane 2 XhoI and lane 3 NdeI digest. Lane 4 NdeI digest of pET-28a; lane 5 undigested pET-
28a. P CR p roducts were run in ( B) as follows: lane 1 co lony P CR r PfGAPDH; lan e 2 colony P CR rP.yoelii 
GAPDH; lane 3 PCR of purified rPfGAPDH plasmid; lane 4 no template control.  
 
A double di gest of the rPfGAPDH plasmi d wa s unsuccessful as NdeI f ailed to digest the 
plasmid (Figure 3.2 (A)). To verify NdeI activity, a single digest of a separate plasmid pET-
28a was performed and was successful as shown in lane 4 of the same gel. XhoI digested the 
plasmid and the linearized plasmid was approximately 1000 bp larger than the v ector alone. 
The P CR re sults (Figure 3.2 (B)) show ed a n a mplicon of around 1 .2 kb. B oth sizes 
corresponded well to that predicted from the base sequence. PET specific primers were used, 
which amplify an additional 322 bp outs ide the expected 1014 bp of  the  inser t DNA. A P. 
yoelii GAPDH insert was amplified fr om a pE T-15b plasmid with the same p ET spe cific 
primers and run in lane 3 (Figure 3.2 (B)) producing an amplicon of around 1.2 kb. 
The inserts were sequenced using both forward and reverse primers, where the same primers 
were used for the LDH se quencing a nd P CR re actions. For the GAPDH sequencing T7  
forward and re verse p rimers were used. Consensus sequences were id entified a nd a ligned 
with the r espective Pf(3D7) coding se quences (Figures 3.3 a nd 3.4 ). B LASTn se arches 
showed 98% and 96%  homol ogy fo r the PfLDH a nd PfGAPDH c onsensus sequences 
respectively (http://www.ncbi.nlm.nih.gov/BLAST/, accessed 15.09.2011).  
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PfLDH           ATGGCACCAAAAGCAAAAATCGTTTTAGTTGGCTCAGGTATGATTGGAGGAGTAATGGCT 60 
Consensus       ATGGCACCAAAAGCAAAAATCGTTTTAGTTGGCTCAGGTATGATTGGTGGTGTAATGGCT 60 
                *********************************************** ** ********* 
 
PfLDH           ACCTTAATTGTTCAGAAAAATTTAGGAGATGTAGTTTTGTTCGATATTGTAAAGAACATG 120 
Consensus       ACTTTAATTGTTCAGAAAAATTTAGGAGATGTAGTTTTGTTCGATATTGTAAAGAACATG 120 
                ** ********************************************************* 
 
PfLDH           CCACATGGAAAAGCTTTAGATACATCTCATACTAATGTTATGGCATATTCAAATTGCAAA 180 
Consensus       CCACATGGAAAAGCTTTAGATACATCTCATACTAATGTTATGGCATATTCAAATTGCAAA 180 
                ************************************************************ 
 
PfLDH           GTAAGTGGTTCAAACACTTATGACGATTTGGCTGGAGCAGATGTAGTAATAGTAACAGCT 240 
Consensus       GTAAGTGGTTCAAACACTTATGACGATTTGGCTGGAGCAGATGTAGTAATAGTAACAGCT 240 
                ************************************************************ 
 
PfLDH           GGATTTACCAAGGCCCCAGGAAAGAGTGACAAAGAATGGAATAGAGATGATTTATTACCA 300 
Consensus       GGATTTACCAAGGCCCCAGGAAAGAGTGACAAAGAATGGAATAGAGATGATTTATTACCA 300 
                ************************************************************ 
 
PfLDH           TTAAACAACAAGATTATGATTGAAATTGGTGGTCATATTAAGAAGAATTGTCCAAATGCT 360 
Consensus       TTAAACAACAAGATTATGATTGAAATTGGTGGTCATATTAAGAAGAATTGTCCAAATGCT 360 
                ************************************************************ 
 
PfLDH           TTTATTATTGTTGTAACAAACCCAGTAGATGTTATGGTACAATTATTACATCAACATTCA 420 
Consensus       TTTATTATTGTTGTAACAAACCCAGTAGATGTTATGGTACAATTATTACATCAACATTCA 420 
                ************************************************************ 
 
PfLDH           GGTGTTCCTAAAAACAAGATTATTGGTTTAGGTGGTGTATTAGATACATCAAGATTGAAG 480 
Consensus       GGTGTTCCTAAAAACAAGATTATTGGTCTAGGTGGTGTATTAGATACATCAAGATTGAAG 480 
                *************************** ******************************** 
 
PfLDH           TATTACATATCTCAGAAATTAAATGTATGCCCAAGAGATGTAAATGCACACATTGTAGGT 540 
Consensus       TATTACATATCTCAGAAATTAAATGTATGCCCAAGAGATGTAAATGCACACATTGTAGGT 540 
                ************************************************************ 
 
PfLDH           GCTCATGGAAATAAAATGGTTCTTTTAAAAAGATACATTACTGTAGGTGGTATCCCTTTA 600 
Consensus       GCTCATGGAAATAAAATGGTTCTTTTAAAAAGATACATTACTGTAGGTGGTATCCCTTTA 600 
                ************************************************************ 
 
PfLDH           CAAGAATTTATTAATAACAAGTTAATTTCTGATGCTGAATTAGAAGCTATATTTGATAGA 660 
Consensus       CAAGAATTTATTAATAACAAGTTAATTTCTGATGCTGAATTAGAAGCTATATTTGATAGA 660 
                ************************************************************ 
 
PfLDH           ACTGTTAATACTGCATTAGAAATTGTAAACTTACATGCATCACCATATGTTGCACCAGCT 720 
Consensus       ACTGTTAATACTGCATTAGAAATTGTAAACTTACATGCATCACCATATGTTGCACCAGCT 720 
                ************************************************************ 
 
PfLDH           GCTGCTATTATCGAAATGGCTGAATCCTACTTAAAAGATTTGAAAAAAGTATTAATTT-G 779 
Consensus       GCTGCTATTATCGAAATGGCTGAATCCTACTTAAAAGATTTGAAAAAAGTATTAATTTTG 780 
                ********************************************************** * 
 
PfLDH           CTCAACCTTGTTAGAAGGACAATATGGACACTCCGATATATTCGGTGGTACACCTG-TTG 838 
Consensus       CTCAACCTTGTTAGAAGGACAATATGGACACTCCGATATATTCCGTGGTACACCTGGTTG 840 
                ******************************************* ************ *** 
 
PfLDH           TTTTAGGTGCTAATGGTGTTGAACAAGTTATCGAATTACAATTAAATAGTGAGGAAAAAG 898 
Consensus       TYTTAGGTGCTAATGGYGTTGAACAAGTTATTCGAATACNATTAAATAGYGAGGAAAAAN 900 
                * ************** **************   * *** ********* *********  
 
PfLDH           CTAAATTTGATGAAGCCATAGCT-GAAACTAAGAGAATGAAGGCATTAGCTTAA 951 
Consensus       CTAAATTTGATGAANCCNTAGCTCAANACTNAGAGAATGAAGGCATTAGCTCAT 954 
                ************** ** *****  * *** ******************** *  
 
Figure 3.3  Alignment of the PfLDH DNA sequence with the LDH coding sequence from the Pf(K1) 
strain. 
Multiple sequence alignment of the PfLDH DNA sequence and the LDH coding sequence from the Pf(K1) strain 
(NCBI ID: DQ198261). Sequence identity was annotated with “*” representing identical residues and blank 
spaces representing no identity. The overall percentage identity between the two sequences was 98 % 





PfGAPDH         ATGGCAGTAACAAAACTTGGAATTAATGGATTTGGTCGTATCGGACGTTTAGTATTTAGA 60 
Consensus       ATGGCAGTAACAAAACTTGGAATTAATGGATTTGGTCGTATCGGACGTTTAGTATTTAGA 60 
                ************************************************************ 
PfGAPDH         GCAGCCTTTGGAAGGAAAGATATCGAAGTAGTTGCTATTAACGACCCATTTATGGACCTT 120 
Consensus       GCAGCCTTTGGAAGGAAAGATATCGAAGTAGTTGCTATTAACGACCCATTTATGGACCTT 120 
                ************************************************************ 
PfGAPDH         AACCACTTATGCTATCTCTTGAAATACGATTCAGTACATGGTCAATTTCCATGTGAGGTA 180 
Consensus       AACCACTTATGCTATCTCTTGAAATACGATTCAGTACATGGTCAATTTCCATGTGAGGTA 180 
                ************************************************************ 
PfGAPDH         ACCCACGCTGATGGATTTTTATTAATCGGAGAAAAGAAAGTCAGTGTTTTTGCTGAAAAG 240 
Consensus       ACCCACGCTGATGGATTTTTATTAATCGGAGAAAAGAAAGTCAGTGTTTTTGCTGAAAAG 240 
                ************************************************************ 
PfGAPDH         GATCCATCTCAAATTCCTTGGGGAAAATGCCAAGTAGATGTTGTATGTGAATCAACTGGT 300 
Consensus       GATCCATCTCAAATTCCTTGGGGAAAATGCCAAGTAGATGTTGTATGTGAATCAACTGGT 300 
                ************************************************************ 
PfGAPDH         GTATTTTTAACCAAAGAATTAGCTAGCAGTCACCTTAAGGGAGGAGCCAAGAAGGTTATT 360 
Consensus       GTATTTTTAACCAAAGAATTAGCTAGCAGTCACCTTAAGGGAGGAGCCAAGAAGGTTATT 360 
                ************************************************************ 
PfGAPDH         ATGTCCGCCCCACCAAAGGATGACACCCCAATTTATGTTATGGGTATTAACCACCACCAA 420 
Consensus       ATGTCCGCCCCACCAAAGGATGACACCCCAATTTATGTTATGGGTATTAACCACCACCAA 420 
                ************************************************************ 
PfGAPDH         TATGATACCAAACAACTTATTGTTTCCAATGCATCATGTACCACAAACTGCTTAGCTCCA 480 
Consensus       TATGATACCAAACAACTTATTGTTTCCAATGCATCATGTACCACAAACTGCTTAGCTCCR 480 
                ***********************************************************  
PfGAPDH         TTAGCTAAAGTTATTAATGATCGTTTTGGAATTGTT-GAAGGTTTAATGACCACCGTTCA 539 
Consensus       TTAGCTAAAGTTATTAATGATCGTTTTGGAATTGKTTGAAGGTTTARTGACCACCGTTCA 540 
                ********************************** * ********* ************* 
PfGAPDH         TGCATCCACTGCTAACCAATTAGTTGTTGATGGTCCATCAAA-GGGTGGTAAGGACTGGA 598 
Consensus       TGCATCCACTGCTAACCAATTAGTTGTTGATGGTCCATCARAAGGGTGGTAAGGACTGGA 600 
                **************************************** * ***************** 
PfGAPDH         GAGCAGGTAGATGTGCATTATCCAACATTATTCCAGCTTCCACTGGTGCAGCTAAAGCTG 658 
Consensus       KAGCAGGTAGATGTSCATTATCCRACATTATTCCR-CTTCCACWGGTGCARCTAAAGCTG 659 
                 ************* ******** **********  ******* ****** ********* 
PfGAPDH         TAGGTAAAGTTTTACCTGAACTTAATGGAAAATTAACAGGTGTAGCTTT-CAGA-GTACC 716 
Consensus       TAGGTAAAGTTTTACCTGAACTTAATGGAAA-TTARCAGGTKTAGCTTTTCAGAAGTACC 718 
                ******************************* *** ***** ******* **** ***** 
PfGAPDH         AATTGGAAC-TGTATCAGTTG-TTGATTTAGTTTGCAGATTAC--AAAAACCAGCAAAAT 772 
Consensus       AATTGGAAMCTGTATYARTTGRTTSATTTASTTTGCARAATAACAAWAARCCAGCAAAAT 778 
                ********  ***** * *** ** ***** ****** * **   * ** ********** 
PfGAPDH         ATGAAGAAG-TTGCTTTAGAAATTAAAAAAGCTGCTGAAGGTCCACTTAAAGGAATCTTA 831 
Consensus       AKGAAGAAGGTTGCTTTAGAAATTWAAAAAGCTGCTGAAGGTCCACTTAAAGGAATCTCA 838 
                * ******* ************** ********************************* * 
PfGAPDH         GGATACACTGAAGATGAAGTTGTTTCTCAAGATTTCGTTCATGATAACAGATCATCAATC 891 
Consensus       GGATACACYGAAGATGAAGTTGTTTCTCAAGATTTCGTTCATGATAACAGATCATCAATC 898 
                ******** *************************************************** 
PfGAPDH         TTTGACATGAAAGCTGGTTTAGCCTTAAACGACAATTTCTTCAAATTAGTTTCATGGTAC 951 
Consensus       TTYGACATGAAAGCTGGTTTAGCCTTAAACGACAATTTCTTCAAATTAGTTTCATGGTRC 958 
                ** ******************************************************* * 
PfGAPDH         GATAATGAATGGGGATACTCAAACCGTGTTCTTGATTTAGCCGTACACATTACTAACAAC 1011 
Consensus       GATAATGAATGGGGATACTCAAMCCGTGTTCTYGATT-AGCCGTACACATTACTAACAAM 1017 
                ********************** ********* **** *********************  
PfGAPDH         TAA 1014 
Consensus       TAA 1020 
                *** 
 
Figure 3.4  Alignment of the PfGAPDH DNA sequence with the GAPDH coding sequence from the 
Pf(3D7) strain. 
Multiple sequence alignment of the PfGAPDH DNA sequence and the GAPDH coding sequence from the 
Pf(3D7) strain (PlasmoDB ID: PF14_0598). Sequence identity was annotated with “*” representing identical 
residues and blank spaces representing no identity. The overall percentage identity between the two sequences 
was 96 % (http://www.ncbi.nlm.nih.gov/BLAST/, accessed 10.01.2012). The symbols “M”, “W”, “R” and “Y” 
denote incompletely specified bases. 
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There were a few nucleotides with no identity between the consensus and coding sequences 
for both PfLDH and PfGAPDH. With the PfGAPDH alignment there were a few insertions as 
well, with the longest being two nucleotides. BLASTp searches of the amino acid sequences 
of LDH and GAPDH orthologs from all the P. falciparum strains revealed 99 % identity 
between the respective orthologs, suggesting that the differences in the nucleotide sequences 
had little effect on the homology between the orthologs. 
 
3.2.2 Optimisation of incubation temperature during expression and buffer pH for 
affinity purification of recombinant PfLDH and PfGAPDH  
Different E. coli culture incubation temperatures were tested for protein expression. An 
overnight culture was grown at 37 ºC and used for the inoculation of fresh broth. These 
cultures were then grown at either 30 or 37 ºC for protein expression. Protein solubility and 
overall charge are dependent on ionic strength and pH of the buffer respectively, and so 
purification conditions compared pH 7.0 and pH 8.0 (50 mM NaH2PO4; 300 mM NaCl). The 
data was recorded in Table 3.1 and showed that the highest protein yields, with a combination 
of incubation temperature and pH for both proteins were obtained at 30 ºC and using isolation 
buffers at pH 8.0.  
 
Table 3.1 The effect of incubation temperature during expression and buffer pH for affinity 
purification rPfLDH and rPfGAPDH. 
 
Yield (µg) 
Sample name rPfLDH rPfGAPDH 
30 ºC at pH 7.0 97.9 32.8 
37 ºC at pH 7.0 68.1 36.5 
30 ºC at pH 8.0 114.5 69.5 
37 ºC at pH 8.0 48.1 46.1 
 
Data represent average values from duplicate experiments using 10 ml LB cultures. 
 
A range of different ionic strengths in the buffer was tested from 50 mM NaCl to 300 mM 





3.2.2.1 Expression and affinity purification of recombinant PfLDH 
The expression of  rPfLDH from 200 ml  cultures was used and high yields of r ecombinant 










Figure 3.5  Expression, pu rification and det ection of r PfLDH with a nti-His a nd a nti-rPfLDH 
antibodies. 
Recombinant PfLDH was expressed at 30ºC and induced with IPTG, and affinity purified with a TALON (Co2+) 
resin i n ph osphate buffer pH  8.0. Protein samples were evaluated o n reducing 12.5% SDS -PAGE g els. T he 
samples were run as follows: lane 1 untransformed E. coli BL21(DE3); lane 2 un-induced and lane 3 induced; 
lane 4 unbound; lane 5-6 washes; lane 7-11 affinity purified rPfLDH eluents; Mw (Molecular weight markers). 
Panels (B) and (C) are Western blots of the Coomassie R-250 stained reference gel (A). (B) was probed with anti 
His-HRPO mouse monoclonal antibody at 1/5000 dilution and (C) with an anti-rPfLDH IgY primary (1 µg/ml) 
and detected with a rabbit-anti-chicken IgY-HRPO secondary antibody at 1/12000. A monomeric as well as a  
dimeric form of rPfLDH was detected as labelled along-side the Western blots. 
 
No rPfLDH was detected in the untransformed BL21(DE3) control (Figure 3.5). There wa s 
“leaky” protein expression observed in the un-induced samples as protein was detected in lane 
2 of panels 3.3B and C. Protein expression increased with induction (lane 3), as shown by the 
increased intensity of the band a t around 36  kD.  The additional ba nd a t around 75  kD was 
detected in (B) and (C) with the most prominent being the 36 kD band. In lanes 7, 8 a nd 9 
there was also detection of  a  doublet of  36  kD and 33 kD, which was possibly a  truncated 
1      Mw 
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2      3      4      5      6      7      8      9      10      11      
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form of rPfLDH. Lower molecular weight products were also detected in (C) which was not 
as evident in (B).  
3.2.2.2 Expression and affinity purification of recombinant PfGAPDH 
The expression of rPfGAPDH from 200 ml cultures was used and high yields of recombinant 










Figure 3.6  Expression, purification and detection of rPfGAPDH with anti-His and anti-rPfGAPDH 
antibodies. 
Recombinant PfGAPDH was expressed at  30ºC and induced with IPTG, and affinity p urified with a TALON 
(Co2+) resin in phosphate buffer pH 8.0. Protein samples were evaluated on reducing 12.5% SDS-PAGE gels. 
The samples were run a s f ollows: lane 1 u ntransformed E . co li BL21(DE3); lane 2 u n-induced an d lane 3  
induced; lane 4 unbound; lane 5-6 washes; lane 7-11 affinity purified rPfLDH eluents; Mw (Molecular weight 
markers). P anels (B) an d ( C) ar e Western b lots o f th e Coomassie R-250 stained r eference g el (A). ( B) was 
probed with anti His-HRPO mouse monoclonal antibody at 1/5000 dilution and (C) with an anti-rPfGAPDH IgY 
primary (1 µg/ml) and detected with a rabbit-anti-chicken IgY-HRPO secondary antibody at 1/12000. 
 
Examination of  r PfGAPDH purif ication steps in Figure 3.6,  showe d r PfGAPDH wa s not 
expressed in the untransformed BL21(DE3) control run in lane 1. A band was detected around 
39 kD in lane 2 (B and C). This was suggestive of “leaky” protein expression. There was a 
clear increased int ensity of  thi s band in lane 3, after expression wa s induced. The re wa s a 
faint band around 80 kD  in lane 8 in (A) which was not detected in the blots. Smaller bands 
were detected in (C) with the anti-rPfGAPDH IgY antibodies which were not detected in the 
anti-His tag Western blot in (B).  
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3.2.3 Assessing tetramer formation of the recombinant PfLDH and PfGAPDH proteins 
by molecular exclusion chromatography 
Both LDH a nd G APDH proteins form tetramers in their native stat e ( Berwal et al ., 2008; 
Daubenberger et al., 2003). To evaluate the quaternary structure of both recombinant His-tag 
proteins, they w ere sub jected to  molecular exclusion (gel filtra tion chromatography) on a  
Sephacryl S200 column (Figures 3.8 and 3.9). The calibration of the Sephacryl S200 column 








Figure 3.7  Sephacryl S200 column calibration profile using five molecular weight standards. 
The Sephacryl S200 co lumn was calibrated with: Blue dextran (2000 kD); sheep IgG (150 kD); bovine serum 
albumin (BSA) (68 kD); ovalbumin (45 kD) and myoglobin (18.8 kD). The column volume was 319 ml and was 
run at a flow rate of 1 ml/min and 80 fractions of 4 ml each were collected. The calibration profile was shown in 
(A). The elution peaks were run o n a reducing 12.5 % S DS-PAGE gel stained with C oomassie R-250 shown 
alongside in (B). The void volume (Vo) was calculated as 144 ml at the elution peak of blue dextran.  
 
There w as a minor overlap of the higher molecular weight protein stan dards as seen in the 
SDS-PAGE gel in Figure 3.7(B), where the prominent bands were of the expected sizes. The 
Sheep IgG standard showed dissociation of the heavy and li ght chains of the IgG molecule 
under reducing conditions. The resulting major protein bands ran at approximately 50 kD and 
27 kD for the heavy and light chains respectively, with incomplete reduction yielding 127 kD; 














































































































Mw 1       1      Mw (kD) 
Peak 1 Peak 1 




















































run over the molecular exclusion chromatography column and the elution profiles were shown 











Figure 3.8  rPfLDH forms tetramers in solution as shown by Sephacryl S200 gel filtration.  
Affinity p urified r PfLDH was run o ver a Sephacryl S200 column. T he rPfLDH elution p rofile was plotted in  
(A), where the column calibration profile was plotted on the primary y-axis. The sizes of the standard proteins 
used for the column calibration were labelled above their respective peaks. The eluents comprising peak 1 in (A) 
were run on a reducing 12.5 % SDS-PAGE gel (B) and detected on a Western blot with anti-rPfLDH IgY and 
secondary rabbit-anti-chicken HRPO antibody at 1/12000 (C). The molecular weight standards (Mw) used were 
labelled on the left of the gels in kilo Daltons (kD).  
 
Recombinant PfLDH ( Figure 3.8 (A )) eluted fr om the Sephacryl S200 c olumn a s a lar ge 
sharp peak estimated to be 140 kD in size. Berwal et al ., (2008) obtained a peak of  around 
145 kD. Peak 1 ha d a shoulder which may have been the dimeric form of the protein which 
would ha ve e luted at around 70 kD. The r emainder of the peaks are m inor and w ere not 
evaluated. Peak 1 was run on an SDS-PAGE gel and blotted as shown in the same figure (B 
and C respectively). The major bands ran at around 36 kD and 75 kD. A minor band was also 
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Figure 3.9  rPfGAPDH forms tetramers in solution as shown by Sephacryl S200 gel filtration. 
Affinity p urified r PfGAPDH was r un o ver a Sephacryl S200 co lumn. T he elution p rofile was p lotted in  ( A), 
where the column calibration profile was plotted on the primary y-axis. The sizes of the standard proteins used 
for the column calibration were labelled above their respective peaks. The eluents comprising peak 1 in (A) were 
run o n a  r educing 1 2.5 % SDS-PAGE gel (B) a nd d etected o n a Western b lot with an ti-rPfGAPDH IgY a nd 
secondary rabbit-anti-chicken HRPO at 1/12000 (C). The molecular weight standards (Mw) used were labelled 
on the left hand side of the gels in kilo Daltons (kD).  
 
Recombinant PfGAPDH (Figure 3.9 ( A)) eluted from the Sephacryl S200 column as a large 
sharp peak estimated to be 140 kD in size. Satchell et al., (2005) obtained a tetramer form of 
around 130 kD. Peak 1 was run on an SDS-PAGE gel and blotted as shown in the same figure 
(B and C respectively). The major bands ran at around 39 kD and 70 kD. A second band was 







Since the expression plasmids were provided, both plasmids were tested to ensure they 
contained the correct coding sequences. The coding sequence for PfLDH is 951 bp in length 
and that of PfGAPDH is 1014 bp (PlasmoDB). The PfLDH insert was approximately 950 bp 
in size, as determined by double restriction digestion, where the PCR amplicon was around 
850 bp. The reason was that the primers used were generic/control primers for Plasmodium 
LDH and this size amplicon was expected after analysis of where they annealed within the 
coding sequence. Following unsuccessful restriction digestion of the PfGAPDH plasmid with 
NdeI due to an apparent loss of the NdeI restriction site, an amplicon of around 1.2 kb was 
obtained for the PCR. This was larger than the literature value for the PfGAPDH coding 
sequence, but was expected, however, as the pET primers should amplify an additional 322 
bp outside of the coding region of the insert.  
The gene inserts were then sequenced and showed high homology to the coding sequences of 
the respective proteins. Slight variation of the sequences may have been due to sequencing 
error. Single nucleotide errors within the Genbank database were assessed by Wesche et al., 
in 2004 who found there to be only approximately 0.1 % (SE 0.012%) error for coding DNA 
entries. Studies by Hill et al., 2000; Kristensen et al., 1992 and Lamperti et al., 1992 found 
errors between 3.1 to 3.6 %. Our sequencing results varied between 2 to 4 % from the coding 
sequences in PlasmoDB and NCBI.  Comparison of the amino acid sequences of the different 
P. falciparum LDH and GAPDH orthologs revealed 99 % sequence identity. This supported 
results found by Lee et al., in 2006 who reported that LDH from field isolates had conserved 
amino acid sequences and did not undergo antigenic variation.   
Some expression parameters were assessed including the temperatures of the bacterial growth 
cultures as well as the pH and ionic strength of the protein isolation buffer. Lower incubation 
temperature of 30ºC compared to 37ºC produced more protein, similar to the result found by 
Schein and Noteborn in 1988, where Berwal et al., (2008) obtained the highest soluble yield 
of rPfLDH using a 15ºC culture incubation temperature. A further aspect of recombinant 
expression that can be optimised, which was not done in this study, is the media. Different 
proteins are expressed at different levels dependent on the media used and this can be 
assessed using a screen as described by Broedel et al., in 2001. The solubility of proteins is 
dependent on their overall charge, which is affected by the pH of the buffer. The pI of 
PfGAPDH is around pH 8.99 and that of PfLDH around pH 8.5 (NCBI; Nirmalan et al, 
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2004), thus at pH 7.0 or 8.0 both proteins would have overall positive charges keeping them 
in solution in a low ionic strength buffer (Voet and Voet, 2004). At the same time for 
purification of His-tag proteins the pKa of imidazole, the side chain of histidine, is important 
as this interacts with the cobalt ion (Co2+) on the affinity resin.  The approximate pKa of 
imidazole is 6.04 (Voet and Voet, 2004). Therefore at a pH of 8.0 it will be neutral and have a 
higher affinity for the positive Co2+ ion than at pH 7.0. This explained the larger purification 
yields for both proteins at pH 8.0 as opposed to pH 7.0. The improved solubility of both 
proteins when dialysed against a higher ionic strength buffer made use of the principle of 
“salting in” of proteins (Voet and Voet, 2004). 
The E. coli BL21(DE3) expression host has several advantages. The E. coli BL21 strain is 
non-pathogenic and does not express ompT and lon proteases, which may digest the 
recombinant protein being expressed. Zymograms testing for protease activity of E. coli 
BL21(DE3) culture lysates were carried out by others in the lab and showed no activity. The 
(DE3) nomenclature means that the T7 RNA polymerase gene was lysogenized into the host 
E. coli BL21 genome (Sorensen and Mortensen, 2005).  
“Leaky” expression was observed with both rPfLDH and rPfGAPDH proteins. This is a 
common phenomenon and is dependent on the promoters in the plasmid as well as the 
composition of the media. The plasmids here make use of either the lac promoter (pET-15b) 
or the tac promoter (pKK223-3), which is a hybrid of the lac and trp promoters (de Boer et 
al., 1983). Both systems require the use of a lysogenized E. coli host strain, such as the 
BL21(DE3) strain used here. Transcription is inhibited in the absence of lactose by the LacI 
repressor, which binds the lac/tac operator. Low levels of glucose increase levels of cyclic 
adenosine monophosphate (cAMP) which also aids in lac/tac promoter repression (Sorensen 
and Mortensen, 2004). As IPTG, a metabolite of lactose, is added, it binds LacI allowing 
expression of T7 RNA polymerase from the E. coli BL21(DE3) genome and hence expression 
of the recombinant protein (Schumann and Ferreira, 2004; Sorensen and Mortensen, 2004). 
Alternate promoters such as lacIq and lacIqI have been used in the pET expression system, 
which result in higher LacI levels and thus reduce “leaky” expression (Schumann and 
Ferreira, 2004).   
Native PfLDH is around 34.4 kD in size (PlasmoDB). Berwal et al., (2008) expressed PfLDH 
with a single His6-tag and found it to be approximately 36.3 kD in size. Hurdayal et al., 
(2010) found that rPfLDH expressed with 2 His6-tags to be approximately 39 kD in size.  
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Western blots using both anti-rPfLDH as well as anti-His-tag antibodies detected a major 
band of approximately 36 kD in this study. A second minor band of around 75 kD was also 
detected which may have been as a result of dimer formation. Zocher et al., (2012) observed 
dimers of recombinant P. falciparum glutamate dehydrogenase 1 on reducing SDS-PAGE 
gels which were detected by Western blotting, similar to what was seen here with rPfLDH. 
Detection of a second band just below the 35 kD band in the PfLDH Western blots was 
similar to the result found by Berwal et al., (2008); Hurdayal et al., (2010) and Turgut-Balik 
et al., (2004) and is thought to be a truncated form of the protein. This was due to an internal 
Shine Dalgarno sequence (GGAGGA) between bases 46 to 51 in the coding sequence for 
rPfLDH. The reason it was also detected in the anti-His blots was as the rPfLDH was 
expressed with two His6 tags, thus the C-terminal His6-tag would still have been detected. 
A major band around 39 kD was detected on the rPfGAPDH Western blots with both the anti-
rPfGAPDH and anti-His-tag antibodies. Both Satchell et al., (2005) and Daubenberger et al., 
(2003) expressed recombinant forms of around 36.6 kD in size.  
Both recombinant proteins were shown to form tetramers in solution, despite the additional 
His6-tags, estimated to be around 140 kD in size. This was similar to the results found by 
Satchell et al., (2005) who estimated the tetramer for rPfGAPDH to be approximately130 kD 
in size. The His6-tag did have an effect on the quality of crystal in their study, however 
enzyme activity was not affected in a study by Daubenberger et al., (2000). Similarly Berwal 
et al., (2008) found rPfLDH with a single His6-tag to be approximately 145 kD in size and 
also enzymatically active. 
In conclusion the coding sequences for both proteins were of the expected sizes and the 
sequence identity was confirmed by sequencing. The expressed proteins were detected by 
specific antibodies against the whole recombinant antigens as well as with anti-His6-tag 
antibodies. An additional control for identification of the recombinant proteins would be to do 
N-terminal sequencing. Both proteins formed tetramers without removal of the His6-tags 
being required, however to further assess the overall conformations of GAPDH and LDH, 
enzyme activity could be assessed as described by (Daubenberger et al., 2000; Ferdinand, 





Identifying malarial peptide epitopes on lactate dehydrogenase and glyceraldehyde-
3-phosphate dehydrogenase, and assessing PheroidsTM as an adjuvant in chickens 
 
4.1 Introduction 
Rapid diagnostic tests (RDTs) are lateral flow immunochromatographic tests which make use 
of monoclonal antibodies for diagnosis. The monoclonal antibodies are typically selected 
rather than starting with a unique epitope. As a result epitope mapping is done to determine 
the epitope target (Saravanan and Kumar., 2009). Knowing the target epitope is useful as 
often antigenic variation may affect detection of certain antigens. Histidine rich protein 2 
(HRP2) is a common RDT target for diagnosis of Plasmodium falciparum malaria (Baker et 
al., 2010, Lee et al., 2006) and the target protein undergoes antigenic variation leading to 
false negative results. An alternative approach to monoclonal antibodies, and employed here, 
was to raise polyclonal antibodies against specific peptides from the target protein.  
Tomar et al., (2006) have validated the use of polyclonal antibodies raised against the 
peptides of malarial target proteins for diagnosis, and Hurdayal et al., (2010) demonstrated 
this for differentiation between malarial lactate dehydrogenases. Peptides used in diagnostics 
are typically 12 to 15 amino acids in length and are not large enough to elicit an immune 
response by themselves and so are coupled to a carrier protein such as rabbit albumin. 
Alternatively multiple antigenic peptides (MAPs) have been used. MAPs consist of an amino 
acid, usually alanine, linked to a resin bead, followed by several layers of lysine residues. The 
lysines then facilitate binding of multiple peptides and as a result coupling of peptides to 
carrier proteins is not required (Saravanan and Kumar 2009). 
In a normal infection the malaria pathogen would provide various co-stimulatory signals such 
as pathogen associated molecular patterns (PAMPs) which promote the immunogenicity of 
antigenic proteins or peptides usually via Toll like receptors (De Gregorio et al., 2009; 
Morein et al., 2004; Palm and Medzhitov, 2009; Reed et al., 2008). In the absence of the 
pathogen the individual proteins are not as immunogenic and an additional stimulant is 
required for the host to produce sufficiently high yields/titres of antibodies. For this purpose 
adjuvants are added to the antigens for immunisation. 
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Adjuvants are immune-enhancing substances, meaning that they promote an immune 
response to a particular antigen but don’t have any antigenic effect themselves. There are 3 
basic mechanisms by which adjuvants function, the first being by a depot effect (Reed et al., 
2008). This describes the slow release of antigen from the immunisation site (Herbert, 1968) 
as adjuvants usually consist of a poorly degradable substance such as mineral oil in the case 
of Freund’s adjuvant. The second function is to stimulate antigen uptake by antigen 
presenting cells (APCs) by providing stimulatory signals such as PAMPs which stimulate 
phagocytosis. The third mechanism is to promote the immune bias caused by the antigen 
alone, that is either humoral or cell mediated immunity (Wilson-Welder et al., 2009).  
Two of the most common adjuvants used for raising antibodies are Freund’s adjuvant, first 
described in 1937 (Gupta and Siber, 1995), and alum first described in 1926 (Glenny et al., 
1926). Freund’s adjuvant has become a popular choice for use in research, as unlike alum, it 
is able to induce an immune response against peptide antigens coupled to protein carriers 
(Johansson et al., 2004) making it ideal for this study. The antigen is encapsulated into the 
mineral oil component of the adjuvant via a surfactant mannide mono-oleate (Arlacel A). This 
makes up the incomplete adjuvant (FIA), where a second form, complete adjuvant (FCA), 
combines heat-killed Mycobacterium in the formulation (Gupta and Siber, 1995). Freund’s 
falls under the vehicle type adjuvants as described by Reed et al., (2008), promoting either 
cellular or humoral immunity, depending on whether or not the Mycobacterium component is 
present (Johansson et al., 2004). Due to the low purity mineral oil and emulsifier used in 
Freund’s adjuvant, as well as the presence of Mycobacterium in the complete adjuvant 
formulation, site-specific hypersensitivity and granuloma formation are often observed. This 
makes it an unsuitable adjuvant for use in humans and it is being withdrawn for use in 
animals. Use of purer mineral and biodegradable oils such as squalenes and plant oils have 
been tested and showed reduced hypersensitivity (Johansson et al., 2004; Reed et al., 2008; 
Wilson-Welder et al., 2009).  
For a long time alum was the only adjuvant certified for use in humans (Lindblad, 2004), and 
a standard research formulation, AlhydrogelTM, was chosen in 1988 (Gregoriadis et al., 1989). 
Alum’s ability to induce a strong humoral immune response as opposed to cell mediated 
immunity made it favourable for use in humans as it did not cause tissue hypersensitivity 
reactions. However, recent recordings of hypersensitivity reactions have been made (Gupta 
and Siber, 1995; Rimaniol et al., 2004; Goldman and Lambert, 2004). Another drawback of 
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alum is that it is ineffective for use with peptide antigens, as well as DNA based vaccines 
(Wilson-Welder et al., 2009). This has therefore placed pressure on finding better adjuvant 
formulations for use in humans as well as in experimental animals. 
This chapter describes the selection of specific peptide epitopes of target proteins that were 
identified for malaria diagnosis, namely glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) and lactate dehydrogenase (LDH). The target proteins are conserved in all malarial 
species and epitopes were selected to be either a shared epitope (pan-malarial) or a species-
specific epitope. Antibodies were raised in chickens against both whole recombinant proteins 
to evaluate the antibody responses using a potential new adjuvant called PheroidsTM compared 
to Freund’s. PheroidsTM was developed by the University of the North West and is a liposome 
type delivery system composed of fatty acids, using nitrous oxide as an active ingredient (US 
Patent Application number 12280880).  
 
4.2 Results 
4.2.1 Peptide selection for raising species-specific and pan-malarial IgY 
Two malarial proteins lactate dehydrogenase (LDH) and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) were chosen as target antigens for malaria diagnosis. Alignments of 
the amino acid sequences were used to identify any potential peptides that could be used as 
target epitopes and included the P. falciparum, P. vivax and P. yoelii sequences as shown in 
Figures 4.1 and 4.4. To ensure that these sequences were unique to malaria, human (Homo 
sapiens) and mouse (Mus musculus) GAPDH and LDH were included. As the anti-peptide 








Figure 4.1 Alignment o f L DH a mino acid sequences t o s elect peptides for raising s pecies-specific 
and pan-malarial antibodies in chickens. 
A multiple sequence a lignment o f t he P. fa lciparum (PfLDH); P. viva x (PvLDH); P. y oelii (PyLDH), human 
heart (HuLDHh), human muscle (HuLDHm), chicken (GallusLDH) and mouse (MouseLDH) LDH amino acid 
sequences was done us ing ClustalW. P ercentage identity (ID) was t he first cr iterion for peptide selection and 
residues were annotated as follows: “*” identical residues; “:” conserved residues; “.” semi-conserved residues 
and blank spaces represented no identity between the sequences. Percentage identity was assessed between the 3 
malaria sequences (P. spp ID) and between all  7 LDH sequences (Overall ID). Specific peptides were selected 
based on lowest percentage identity and common peptides on 100 % identity between the malaria sequences. The 
three peptide sequences of interest were underlined in green and blue for the specific peptides and red for the 
common peptide. Sequence accession numbers are PfLDH: PlasmoDB ID: PF13_0141; PvLDH: PlasmoDB ID: 
PVX_116630; PyLDH: PlasmoDB ID: PY03885; Human heart LDH and muscle LDH respectively: NCBI ID: 
1IOZ_B an d 1 I1O_H; C hicken ( Gallus gallus) L DH: NCBI I D: NP_989508.1; Mouse LDH: NC BI I D: 
NP_038608.1. 
PfLDH           -----------------MAPKAKIVLVGSGMIGGVMATLIVQKNLG-DVVLFDIVKNMPH  42   
PvLDH           -----------------MTPKPKIVLVGSGMIGGVMATLIVQKNLG-DVVMFDVVKNMPQ  42 
PyLDH           -----------------MAPKAKIVLVGSGMIGGVMATLIVQKNLG-DVVLFDIVKNMPH  42 
P.spp ID                         *:**.************************ ***:**:*****: 
HuLDHh          -ATLKEKLIAPVAEEEATVPNNKITVVGVGQVGMACAISILGKSLADELALVDVLEDKLK  59 
HuLDHm          -ATLKDQLIYNLLKE-EQTPQNKITVVGVGAVGMACAISILMKDLADELALVDVIEDKLK  58 
MouseLDH        MSTVKEQLIQNLVPE-DKLSRCKITVVGVGNVGMACAISILLKGLADELALVDADTNKLR  59 
GallusLDH       MATLKEKLITPVAAG-STVPSNKITVVGVGQVGMACAISILGKGLCDELALVDVLEDKLK  59 
Overall ID                         .  **.:** * :* . *  *: *.*  ::.:.*   :  : 
PfLDH           GKALDTSHTNVMAYSNCKVSGSNTYDDLAGADVVIVTAGFTKAPGKSDKEWNRDDLLPLN 102 
PvLDH           GKALDTSHSNVMAYSNCKVTGSNSYDDLKGADVVIVTAGFTKAPGKSDKEWNRDDLLPLN 102 
PyLDH           GKALDTSHTNVMAYSNCKVSGSNTYDDLKDADVVIVTAGFTKAPGKSDKEWNRDDLLPLN 102 
P.spp ID        ********:**********:***:**** .****************************** 
HuLDHh          GEMMDLQHG-SLFLQTPKIVADKDYSVTANSKIVVVTAGVRQQEGES-----RLNLVQRN 113 
HuLDHm          GEMMDLQHG-SLFLRTPKIVSGKDYNVTANSKLVIITAGARQQEGES-----RLNLVQRN 112 
MouseLDH        GEALDLLHG-SLFLSTPKIVFGKDYNVSANSKLVIITAGARMVSGET-----RLDLLQRN 113 
GallusLDH       GEMMDLQHG-SLFLQTHKIVADKDYAVTANSKIVVVTAGVRQQEGES-----RLNLVQRN 113 
Overall ID      *: :*  *   :   . *:  .: *    .:.:*::***     *::     * :*:  * 
PfLDH           NKIMIEIGGHIKKNCPNAFIIVVTNPVDVMVQLSHQHSGVPKNKIIGLGGVLDTSRLKYY 162 
PvLDH           NKIMIEIGGHIKNLCPNAFIIVVTNPVDVMVQLLFEHSGVPKNKIIGLGGVLDTSRLKYY 162 
PyLDH           NKIMIEIGGHIKNNCPNAFIIVVTNPVDVMVQLLHQHSGVPKNKIVGLGGVLDTSRLKYY 162 
P.spp ID        ************: ******************* .:*********:************** 
HuLDHh          VNVFKFIIPQIVKYSPDCIIIVVSNPVDILTYVTWKLSGLPKHRVIGSGCNLDSARFRYL 173 
HuLDHm          VNIFKFIIPNVVKYSPNCKLLIVSNPVDILTYVAWKISGFPKNRVIGSGCNLDSARFRYL 172 
MouseLDH        VAIMKAIVPGIVQNSPDCKIIIVTNPVDILTYVVWKISGFPVGRVIGSGCNLDSARFRYL 173 
GallusLDH       VNVFKFIIPQIVKYSPNCTILVVSNPVDILTYVTWKLSGLPKHRVIGSGCNLDTARFRYL 173 
Overall ID        ::  *   : : .*:. :::*:****::. :  : **.*  :::* *  **::*::*  
PfLDH           ISQKLNVCPRDVNAHIVGAHGNKMVPLKRYITVGGIPLQEFINNK--LISDAELEAIFDR 220 
PvLDH           ISQKLNVCPRDVNALIVGAHGNKMVLLKRYITVGGIPLQEFINNK--KITDEEVEGIFDR 220 
PyLDH           ISQKLNVCPRDVNAHIVGAHGNKMVLLKRYITVGGIPLQEFINNK--KITDQELDAIFDR 220 
P.spp ID        ************** ********** *******************   *:* *::.**** 
HuLDHh          MAEKLGIHPSSCHGWILGEHGDSSVAVWSGVNVAGVSLQELNPEMGTDNDSENWKEVHKM 233 
HuLDHm          MGERLGVHPLSCHGWVLGEHGDSSVPVWSGMNVAGVSLKTLHPDLGTDKDKEQWKEVHKQ 232 
MouseLDH        IGEKLGVNPTSCHGWVLGEHGDSSVPIWSGVNVAGVTLKSLNPAIGTDSDKEHWKNVHKQ 233 
GallusLDH       MAERLGIHPTSCHGWILGEHGDSSVAVWSGVNVAGVSLQELNPAMGTDKDSENWKEVHKQ 233 
Overall ID      :.::*.: * . :. ::* **:. * :   :.*.*:.*: :         . . . :..  
PfLDH           TVNTALEIVNLHASPYVAPAAAIIEMAESYLKDLKKVLICSTLLEGQYGHS-DIFGGTPV 279 
PvLDH           TVNTALEIVNLLASPYVAPAAAIIEMAESYLKDIKKVLVCSTLLEGQYGHS-NIFGGTPL 279 
PyLDH           TVNTALEIVNLHASPYVAPAAAIIEMAESYIRDLRKVLICSTLLEGQYGHK-DIFAGTPL 279 
P.spp ID        *********** ******************::*::***:***********. :**.***: 
HuLDHh          VVESAYEVIKLKGYTNWAIGLSVADLIESMLKNLSRIHPVSTMVKGMYGIENEVFLSLPC 293 
HuLDHm          VVESAYEVIKLKGYTSWAIGLSVADLAESIMKNLRRVHPVSTMIKGLYGIKDDVFLSVPC 292 
MouseLDH        VVEGGYEVLNMKGYTSWAIGLSVTDLARSILKNLKRVHPVTTLVKGFHGIKEEVFLSIPC 293 
GallusLDH       VVESAYEVIRLKGYTNWAIGLSVAELCETMLKNLYRVHSVSTLVKGTYGIENDVFLSLPC 293 
Overall ID      .*: . *::.: . .  * . :: :: .: :::: ::   :*:::* :* . ::* . *  
PfLDH           VLGANGVEQVIELQLNSEEKAKFDEAIAETKRMKALA--- 316 
PvLDH           VIGGTGVEQVIELQLNAEEKTKFDEAVAETKRMKALI--- 316 
PyLDH           VIGGNGVEQVIELQLNADEKKKFDEAVAETSRMKALI--- 316 
P.spp ID        *:*..***********::** *****:*********  
HuLDHh          ILNARGLTSVINQKLKDDEVAQLKKSADTLWDIQKDLKDL 333 
HuLDHm          ILGQNGISDLVKVTLTSEEEARLKKSADTLWGIQKELQF- 331 
MouseLDH        VLGQSGITDFVKVNMTAEEEGLLKKSADTLWNMQKDLQL- 332 
GallusLDH       VLSASGLTSVINQKLKDDEVAQLKKSADTLWSIQKDLKDL 333 
Overall ID      ::.  *: ..::  :. :*   :.::      ::       
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Based on the data in Figure 4.1 a species-specific peptide sequence was identified (amino 
acids 208 to 219) for both P. falciparum and P. vivax LDH. These were highlighted in green 
and blue in the figure respectively. The common sequence was underlined in red (amino acids 
85 to 98) and was 100% conserved across all the malaria sequences. A BLASTp search in 
PlasmoDB with the peptide sequence also confirmed its conserved sequence across all 3 
additional species of malaria affecting man, namely P. ovale, P. malariae and P. knowlesi, 
where the only difference was in the P. malariae sequence with the alanine residue being 
replaced by a valine which is a semi-conservative substitution (Table 4.1).  The peptide 
included a 5 amino acid insert that was unique to the malarial LDH sequences, with a low 
overall identity with the rest of the non-malarial sequences shown. BLASTp searches in 
PlasmoDB revealed that the P. vivax peptide had 91 % identity with a P. knowlesi sequence, 
where the rest of the species-specific peptides had no identity with other human malaria 
species.  
In addition to sequence alignment, the amino acids of the chosen peptide sequences were 
evaluated in an epitope prediction program Predict7TM to assess hydrophilicity, surface 
probability, antigenicity and flexibility as shown in Figure 4.2. All three peptides were 
synthesised with an additional cysteine residue at the C-terminus (as indicated by “C” in the 
figure) to facilitate coupling to rabbit albumin via M-maleimidobenzoil acid N-hydroxy 
succinimide ester (MBS). 
 
The common APGKSDKEWNRDDL peptide with an identical sequence in all Plasmodial 
LDH proteins (Figure 4.2 (A)) showed good hydrophilicity and surface probability as the 
majority of the plots were above 0, with the highest values toward the N-terminal end of the 
peptide. As a result the cysteine was added to the C-terminus. The flexibility plot was poor 
with all values being ≤ 0, where the antigenicity prediction had the majority of values just 
above 0, with a slight peak toward the C-terminus of the peptide. 
The P. vivax specific peptide KITDEEVEGIFD showed an increase toward the N-terminus 
for all plots except flexibility, therefore the cysteine was added to the C-terminus. The 
hydrophilicity and surface probability plots were similar with the majority of values above 0. 
Antigenicity had no residues above 0 where flexibility values remained around 0 with a slight 
dip toward the middle of the sequence. 
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A multiple sequence alignment of the P. falciparum; P. vivax; P. malariae; P. ovale and P. knowlesi LDH amino acid sequences was done using ClustalW. Percentage 
identity (ID) was annotated as follows: “*” identical residues; “:” conserved residues; “.” semi-conserved residues and blank spaces represented no identity between the 
sequences. Sequence accession numbers are as follows: PfLDH: ABH03417.1; PvLDH: EDL45893.1; PmLDH: AAS77572.1; PoLDH: AAS77571.1; PkLDH: 
XP_002260092.1; PfGAPDH: XP_001348772.1; PvGAPDH: ABU50378.1; PmGAPDH: ABU50375.1; PkGAPDH: ABU50374.1; PoGAPDH: sequence was not yet 
available on NCBI or PlasmoDB (accessed 15.05.2012). 
  Peptide name 
Plasmodium species LDH specific LDH common GAPDH specific 1 GAPDH specific 2 GAPDH common 
falciparum LISDAELEAIFD APGKSDKEWNRDDL ADGFLLIGEKKVSVFA AEKDPSQIPWGKCQV KDDTPIYVMGINH 
vivax KITDEEVEGIFD APGKSDKEWNRDDL GDGCFTVGNKKIFVHS SEKDPAQIPWGKYEI KDDTPIYVMGINH 
malariae KITDAELDAIFD VPGKSDKEWNRDDL GDGKIIVGNKTINIHN NEKEPSQIPWGKYGI KDDTPIYVMGINH 
ovale KITDAELDAIFD APGKSDKEWNRDDL - - - 
knowlesi KITDEEVEAIFD APGKSDKEWNRDDL GDGFFTIGNKKIFVHH HEKDPANIPWGKYGI KDDTPIYVMGINH 

































































































Figure 4.2 Predict7TM analysis of three selected malaria LDH peptides. 
Predict7TM plots o f th e three LDH p eptides illustrating h ydrofilicity, s urface p robability, flexibility a nd 
antigenicity (key in the bottom right). The common peptide was plotted in (A), the P. vivax specific peptide in 
(B) and the P. fa lciparum specific peptide in (C).  Flexibility and antigenicity were plotted on the secondary 
axes in each graph. The amino acid sequences were shown along the bottom of the graphs, with the first and last 
amino acid residues shown in superscript and the addition of a C-terminal cysteine was indicated with a “C” in 
each case.  
 
The P. v ivax specific pe ptide (Figure 4.2 ( B)) and the P. fal ciparum specific pe ptide 
LISDAELEAIFD (Figure 4.2(C) ) had v ery sim ilar plots. This was expected due to the 
sequence sim ilarity shar ed be tween these  two p eptides. The P. fal ciparum specific pe ptide 




208 LISDAELEAIFD219 C 
three plots decreased toward the C-terminus, thus the cysteine was added to  this end of  the 
peptide. Hydrophilicity and surface probability plots had values above 0 for  the majority of  
the sequence, whereas antigenicity was below 0. 
The pa n-malarial (APGKSDKEWNRDDL) a nd P. fal ciparum specific ( LISDAELEAIFD) 
peptides (Figure 4.2 (A  and C) respectively) were loca ted on the surface of  the 3D c rystal 
structure model o f PfLDH published by (Dunn et al ., 1996) as shown in Figure 4.3 and are 









Figure 4.3 Location o f the P. falciparum specific and the pan-malarial epitopes o n the 3 D crystal 
structure model of PfLDH. 
The s elected peptide sequences were located o n th e surface o f th e 3D structure of PfLDH (monomer) an d 
highlighted in their corresponding colours (specific peptide in green and the pan-malarial peptide in red) on the 
structure using Swiss-Pdb viewer 4.0.1 (http://www.expasy.org.spdbv/). The amino acid sequences were shown 
alongside of the structure, with the first and last amino acid residues shown in superscript and the addition of a 
C-terminal cysteine indicated with a “C” in each case. Structural data (1t2d) obtained from swiss pdb.  
 
The se lection of  c ommon a nd spec ific peptides from the GAPDH se quence wa s shown in 
Figures 4.4 to 4.6 starting with the alignment of the sequences. Based on the data in Figure 
4.4 two P. falciparum specific peptide sequences were identified, the first (amino acids 63 to 
78), underlined in green a nd the second (a mino a cids 78 to 92) underlined in blue. The 
specific peptides showed no identity with any other human malaria species using a BLASTp 
search in PlasmoDB, where the pan-malarial peptide (amino acids 126 to 138) was common 

















Figure 4.4 Alignment of GAPDH amino acid sequences to select peptides for raising species-specific 
and pan-malarial antibodies in chickens. 
A multiple sequence alignment of the P. falciparum (PfGAPDH); P. vivax (PvGAPDH); P. yoelii (PyGAPDH), 
human (HuGAPDH), chicken (GallusGAPDH) and mouse (MouseGAPDH) GAPDH amino acid sequences was 
done using ClustalW. Percentage identity (ID) was the first criterion for selection and residues were annotated 
as follows: “*” identical residues; “:” conserved residues; “.” semi-conserved r esidues and b lank s paces 
represented n o id entity b etween th e sequences. Percentage id entity was as sessed b etween t he 3 malaria 
sequences (P. spp ID) and between all 6 GAPDH sequences (Overall ID).  Specific peptides were selected based 
on lowest percentage identity and common peptides on 100% identity between the malaria sequences. The three 
peptide sequences of interest were underlined in green and blue for the specific peptides and red for the common 
peptide. Sequence ac cession n umbers ar e PfGAPDH: PlasmoDB I D: P F14_0598; PvGAPDH: NCBI I D: 
ABU50378.1; PyGAPDH: PlasmoDB I D: P Y03280; Human GAPDH: NCBI I D: C AA25833.1; Chicken 
(Gallus gallus) GAPDH: NCBI ID: AAA48774.1; Mouse GAPDH: NCBI ID: NP_032110.1. 
 
PfGAPDH          MAVTKLGINGFGRIGRLVFRAAFGRKDIEVVAINDPFMDLNHLCYLLKYDSVHGQFPCEV  60 
PvGAPDH          MAVTKLGINGFGRIGRLVFRAAYERSDIEVVAVNDPFMDIKHLCYLLKYDSIHGVFPAEV  60 
PyGAPDH          MAITKVGINGFGRIGRLVFRSAQERSDIEVVAINDPFMDINHLIYLLKHDSVHGKFPCEV  60  
P.spp ID         **:**:**************:*  *.******:******::** ****:**:** **.** 
HuGAPDH          MAITKVGINGFGRIGRLVFRSAQERSDIEVVAINDPFMDINHLIYLLKHDSVHGKFPCEV  60 
MouseGAPDH       --MVKVGVNGFGRIGRLVTRAAICSGKVEIVAINDPFIDLNYMVYMFQYDSTHGKFNGTV  58 
GallusGAPDH      --MVKVGVNGFGRIGRLVTRAAVLSGKVQVVAINDPFIDLNYMVYMFKYDSTHGHFKGTV  58 
Overall ID         :.*:*:********** *:*    .:::**:****:*:::: *::::** ** *   * 
 
PfGAPDH          THADGFLLIGEKKVSVFAEKDPSQIPWGKCQVDVVCESTGVFLTKELASSHLKGGAKKVI 120 
PvGAPDH          TPGDGCFTVGNKKIFVHSEKDPAQIPWGKYEIDVVCESTGVFLTKELSNAHLKGGAKKVI 120 
PyGAPDH          TPTEGGIMVGSKKVVVYNERDPAQIPWGKHAIDVVCESTGVFLTKELSNAHIKGGAKKVI 120 
P.spp ID         *  :* : :*.**: *. *:**:******  :***************:.:*:******** 
HuGAPDH          TPTEGGIMVGSKKVVVYNERDPAQIPWGKHAIDVVCESTGVFLTKELSNAHIKGGAKKVI 120 
MouseGAPDH       KAENGKLVINGKPITIFQERDPTNIKWGEAGAEYVVESTGVFTTMEKAGAHLKGGAKRVI 118 
GallusGAPDH      KAENGKLVINGHAITIFQERDPSNIKWADAGAEYVVESTGVFTTMEKAGAHLKGGAKRVI 118 
Overall ID       .  :* : :. : : :. *:**::* *..   : * ****** * * :.:*:*****:** 
 
PfGAPDH          MSAPPKDDTPIYVMGINHHQYDTKQLIVSNASCTTNCLAPLAKVINDRFGIVEGLMTTVH 180 
PvGAPDH          MSAPPKDDTPIYVMGINHDKYDPKQLIVSNASCTTNCLSPIAKVLHDNFGIVEGLMTTVH 180 
PyGAPDH          MSAPPKDDTPIYVMGINHEKYNSSQTIVSNASCTTNCLAPIAKVIHENFGIVEGLMTTVH 180 
P.spp ID         ******************.:*:..* ************:*:***:::.************ 
HuGAPDH          MSAPPKDDTPIYVMGINHEKYNSSQTIVSNASCTTNCLAPIAKVIHENFGIVEGLMTTVH 180 
MouseGAPDH       ISAP-SADAPMFVMGVNHEKYDNSLKIVSNASCTTNCLAPLAKVIHDNFGIVEGLMTTVH 177 
GallusGAPDH      ISAP-SADAPMFVMGVNHEKYDKSLKIVSNASCTTNCLAPLAKVIHDNFGIVEGLMTTVH 177 
Overall ID       :*** . *:*::***:**.:*: .  ************:*:***:::.************ 
 
PfGAPDH          ASTANQLVVDGPSKGGKDWRAGRCALSNIIPASTGAAKAVGKVLPELNGKLTGVAFRVPI 240 
PvGAPDH          ASTANQLVVDGPSKGGKDWRAGRCALSNIIPASTGAAKAVGKVLPELNGKLTGVAFRVPI 240 
PyGAPDH          ASTANQLVVDGPSKGGKDWRAGRSALLNIIPASTGAAKAVGKVLPELNGKLTGVAFRVPI 240 
P.spp ID         ***********************.** ********************************* 
HuGAPDH          ASTANQLVVDGPSKGGKDWRAGRSALLNIIPASTGAAKAVGKVLPELNGKLTGVAFRVPI 240 
MouseGAPDH       AITATQKTVDGPS--GKLWRDGRGAAQNIIPASTGAAKAVGKVIPELNGKLTGMAFRVPT 235 
GallusGAPDH      AITATQKTVDGPS--GKLWRDDRGAAQNIIPASTGAAKAVGKVIPELNGKLTGMAFRVPT 235 
Overall ID       * **.* .*****  ** ** .* *  ****************:*********:*****  
 
PfGAPDH          GTVSVVDLVCRLQKPAKYEEVALEIKKAAEGLLKGVLGYTEDEVVSQDFVHDNRSSIFDM 300 
PvGAPDH          GTVSVVDLVCRLEKPAKYEEIAAQMKKAAEGPLKGILGYTEDEVVSQDFVHDKRSSIFDL 300 
PyGAPDH          GTVSVVDLVCRLEKPAKYEDVAKKIKEASEGPLKGILGYTDEEVVSQDFVHDSRSSIFDL 300 
P.spp ID         ************:******::* ::*:*:** ***:****::**********.******: 
HuGAPDH          GTVSVVDLVCRLEKPAKYEDVAKKIKEASEGPLKGILGYTDEEVVSQDFVHDSRSSIFDL 300 
MouseGAPDH       PNVSVVDLTCRLEKPAKYDDIKKVVKQASEGPLKGILGYTEDQVVSCDFNSNSHSSTFDA 295 
GallusGAPDH      PNVSVVDLTCRLEKPAKYDDIKRVVKAAADGPLKGILGYTEDQVVSCDFNGDSHSSTFHA 295 
Overall ID        .******.***:*****:::   :* *::* ***:****:::*** **  :.:** *.  
 
PfGAPDH          KAGLALNDNFFKLVSWYDNEWGYSNRVLDLAVHITNN- 357 
PvGAPDH          KAGLALNDNFFKIVSWYDNEWGYSNRVLDLAVHITKH- 357 
PyGAPDH          KAGLALNDNFFKIVSWYDNEWGYSNRLLDLAIHITKH- 357 
P.spp ID         ************:*************:****:***::  
HuGAPDH          KAGLALNDNFFKIVSWYDNEWGYSNRLLDLAIHITKH- 357 
MouseGAPDH       GAGIALNDNFVKLISWYDNEYGYSNRVVDLMAYMASKE 353 
GallusGAPDH      GAGIALNDHFVKLVSWYDNEFGYSNRVVDLMVHMASKE 353 































































The GA PDH pe ptides were a nalyzed usin g P redict7TM as shown in Figure 4.5. All the 
peptides were synthesized with an additional cysteine residue at the N-terminus (as annotated 
















Figure 4.5 Predict7TM analysis of three selected malaria GAPDH peptides.  
Predict7TM plots o f the th ree GAPDH p eptides illustrating h ydrofilicity, s urface probability, f lexibility an d 
antigenicity (key in the bottom right). The two P. falciparum specific peptides were plotted in (A and B) with 
the common p eptide plotted in ( C). Flexibility a nd a ntigenicity were p lotted o n t he s econdary a xes in ea ch 
graph. The amino acid sequences were shown along the bottom of the graphs, with the first and last amino acid 







The fir st P. fal ciparum specific pe ptide AD GFLLIGEKKVSVFA (Figure 4.5  (A )) h ad 
similar fle xibility a t both e nds. The h ydrophilicity a nd su rface p robability plot s increased 
toward the C-terminus however, with most points above 0 a nd therefore coupling to the N-
terminus was chosen. The antigenicity plot  had a similar trend, however, most values were 
below 0. 
The se cond P. falciparum specific peptide AE KDPSQIPWGKCQV (Fig ure 4.5 ( B)) had 
similar plots for a ll p arameters except flexibility, with values around 0 throu ghout. 
Hydrofilicity and surf ace probability show ed minor peaks toward the N-terminus, however 
flexibility was greatest toward the C-terminus, thus coupling to the N-terminus was chosen. 
The pan-malarial peptide KDDTPIYVMGINH (Figure 4.5 (C))  showed high hydrophilicity 
and surf ace pr obability values toward the N-terminus. The a ntigenicity plot  showe d the  
majority of  values be low 0, wh ereas the flexibility ha d an inc reasing t rend towa rd the C-
terminus with the majority of values above 0, thus coupling to the N-terminus was chosen. 
All 3 pe ptide se quences we re loca ted on the surface of  the 3D crystal structure model of  
PfGAPDH publi shed by (Satchell et al ., 2005)  as shown in Figure 4.6  a nd a re the refore 









Figure 4.6 Location o f the P. falciparum specific and the pan-malarial epitopes o n the 3 D crystal 
structure of PfGAPDH. 
The selected p eptide sequences were located o n t he surface of t he 3 D structure of PfGAPDH (tetramer) a nd 
highlighted i n their co rresponding co lours o n th e structure using S wiss-Pdb v iewer 4. 0.1 
(http://www.expasy.org.spdbv/). The amino acid sequences were shown alongside of the structure, with the first 
and last amino acid residues shown in superscript and the addition of an N-terminal cysteine indicated with a 
“C” in each case. Structural data (1ywg) obtained from swiss pdb. 
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4.2.2 Anti-LDH peptide antibody production and final yields of affinity-purified IgY 
Antibodies against the malaria LDH peptides coupled to rabbit albumin (RA) were raised in 
chickens using Freund’s adjuvant. Antibody production against the peptides was measured 
and shown in Figure 4.7, followed by affinity purification of the respective anti-peptide 
antibodies shown in Figure 4.8. The chickens immunised with the P. falciparum specific 
peptide were named FDC1 and 2. Those immunised with the pan-malarial peptide were 
named APG 1 and 2 and those immunised with the P. vivax specific peptide were named KIT 
1 and 2. Chicken APG2 stopped laying eggs completely and FDC2 stopped laying eggs from 
week 4 to 8. The chicken names and their respective anti-LDH peptides were shown in Table 
4.2. 
Table 4.2 Chickens immunised with the respective anti-LDH peptides. 
 
 
In Figure 4.7 antibody titres against the carrier rabbit albumin was followed as a control. The 
titre of anti-albumin IgY followed a similar trend to the anti-peptide IgY titres for the 3 
experiments except in the case of the APG group, where the anti-albumin antibody titres 
increased before the anti-peptide IgY titres. Anti-peptide IgY titres seemed to rise latest in the 
APG 1 chicken in comparison to all other groups, with a peak observed as late as week 8. In 
comparison the KIT 1 and 2 chickens produced anti-peptide antibodies the earliest of the 
groups, with initial peaks observed at weeks 6 and 4 for the two chickens respectively. The 
FDC1 chicken showed an initial anti-peptide IgY peak at week 6, where FDC2 only started 
laying eggs again at week 9, and showed high antibody production through to week 12. IgY 
isolated between weeks 4 to 12 were pooled and affinity purified using the specific peptide-
coupled SulfoLink® affinity matrix. 
 
 
Chicken names Peptide sequence Peptide description 
FDC 1 and 2 208LISDAELEAIFD219 C P. falciparum specific 
APG 1 and 2 85APGKSDKEWNRDDL98 C Pan-malarial 


















Figure 4.7 Measuring anti-LDH peptide and anti-RA carrier antibody production in chickens. 
Peptides were coupled to rabbit albumin (RA) for immunisation and two chickens were immunised per peptide 
on weeks 0, 2, 4 and 6 using Freund’s adjuvant. Crude IgY was isolated from each from weeks 0 to 12. Titres of 
specific anti-peptide IgY was measured by direct ELISA. Plates were coated with the respective peptides at 1 
µg/ml and rabbit albumin at the same concentration as a control (RA). Crude primary IgY samples were added 
at 100 µg/ml and detected with a rabbit-anti-chicken-IgY-HRPO secondary antibody at 1/15000 dilution. Weeks 
showing high antibody titres against the peptide were pooled for affinity purification. The titres shown in (A) 
were for chicken APG 1; (B) was for chickens KIT 1 and 2 and (C) was for chickens FDC 1 and 2. 
 










































































Figure 4.8 Elution profiles after affinity purification of anti-LDH peptide antibodies (IgY). 
Crude IgY was isolated from weeks showing high specific antibody titres. Pooled IgY from weeks 4 to 12 post 
immunisation were affinity purified by passing over peptide-linked SulfoLink® columns.  The elution profile in 
(A) was f or th e pan-malarial ( APGKSDKEWNRDDL) peptide; ( B) w as f or th e P. viva x-specific 
(KITDEEVEGIFD) peptide and (C) was for the P. falciparum-specific (LISDAELEAIFD) peptide.  
 
A high yield of  18.1 mg was obtained for the anti-APGKSDKEWNRDDL IgY (Figure 4.8 
(A)), followed by the anti-KITDEEVEGIFD IgY (Figure 4.8 (B)) with 11.4 mg and the anti-


































































Table 4.3: Yields of affinity purified IgY raised against the selected LDH peptides. 
LDH sequence origin 
Accession number 
(PlasmoDB) Peptide sequence 
Yield of affinity 
purified IgY (mg) 
P. falciparum (3D7) PF13_0141 208 LISDAELEAIFD219 C 2.6 
P. vivax (Sal1) PVX_116630 208 KITDEEVEGIFD219 C 11.4 
Pan-malarial 
 
85APGKSDKEWNRDDL98 C 18.1 
 
The antibodies against the selected GAPDH peptides were raised previously and for that 
reason the data was omitted. However antibodies against the C63ADGFLLIGEKKVSVFA78 
peptide have not been raised and will be raised and affinity purified in future work. 
4.2.3 Comparison of PheroidsTM and Freund’s adjuvants 
PheroidsTM and Freund’s adjuvants were compared and to do this, chickens were immunised 
with recombinant PfLDH or PfGAPDH (rPfLDH or rPfGAPDH). From the alignments of the 
respective amino acid sequences in Figures 4.1 and 4.4 the GAPDH sequences were more 
conserved than the LDH sequences sharing 64 % identity, whereas the LDH sequences 
shared only 32 % identity with the chicken sequences. 
The resulting antibody titres in chickens following immunisation with the respective 
recombinant proteins and adjuvant were shown in Figure 4.9 and 4.10. Chicken 2 in the 
Freund’s + rPfLDH group stopped laying eggs from week 3 to 9, and chicken 3 in the PBS + 
rPfGAPDH control group stopped laying eggs from week 3 onwards.  
All the immunised chickens with antigen-adjuvant preparations showed an earlier initial rise 
in antibody titres in comparison to the antigen alone (Figure 4.9). The initial peaks reading 
were observed around weeks 2 to 4. The highest titres were observed for the Freund’s + 
rPfLDH group, with the titres ranging from 0.8 to 1.4. This was followed by the PBS + 
rPfLDH control group with peaks ranging from 0.8 to 1.2 and then the PheroidsTM + rPfLDH 
group with the majority of the values ranging from 0.4 to 0.7. The chickens immunised with 
antigen-adjuvant preparations had sustained antibody titres over the 12 week period, 






















Figure 4.9 Antibody titres in eggs from chickens immunised with rPfLDH using either Freund’s or 
PheroidsTM as adjuvant, or the recombinant protein alone in PBS. 
All chickens were immunised on the same day (week 0) and antibody titres were measured post immunisation. 
Three ch ickens were immunised p er g roup an d b ooster im munisations were given on weeks 2,  4 a nd 6. A ll 
groups were immunised with rPfLDH as the antigen, and the groups were based on the adjuvant used, showing 
(A) the Freund’s adjuvant group, (B) the PheroidsTM group and (C) the PBS group. Chickens immunised with 
Freund’s adjuvant were immunised with the complete adjuvant for primary immunisations and the incomplete 
adjuvant for booster immunisations. Crude IgY was isolated from eggs at the end of each week from weeks 0 to 
12. I gY titres a gainst r PfLDH w ere m easured by d irect E LISA using a  rabbit-anti-chicken-IgY-HRPO 






















































































Figure 4.10 Antibody titres in eggs from chickens immunised with rPfGAPDH using either Freund’s 
or PheroidsTM as adjuvant, or the recombinant protein alone in PBS. 
All chickens were immunised on the same day (week 0) and antibody titres were measured post immunisation. 
Three ch ickens were immunised p er g roup an d b ooster im munisations were given o n weeks 2 , 4  an d 6. A ll 
groups were immunised w ith rPfGAPDH as the a ntigen, and the groups were based on th e ad juvant used, 
showing (A) the Freund’s adjuvant group, (B) the PheroidsTM group a nd ( C) t he PBS group. Chickens 
immunised with Freund’s adjuvant were immunised with the complete adjuvant for primary immunisations and 
the incomplete adjuvant for booster immunisations. Crude IgY was isolated from eggs at the end of each week 
from weeks 0 to 12. IgY titres against rPfGAPDH were measured by direct ELISA using a rabbit-anti-chicken-





























































The resulting titres for chickens immunised with the rPfGAPDH antigen followed a similar 
trend to rPfLDH (Figure 4.10). All chickens showed rapid increase in antibody titres with an 
initial peak between weeks 2 to 3. The A405 values were highest for the chickens immunised 
with PheroidsTM + rPfGAPDH (0.6 to 1.0). This was followed by the group immunised with 
Freund’s + rPfGAPDH (0.3 to 0.5) and finally the PBS + rPfGAPDH control group (0.3 to 
0.4). The PBS + rPfGAPDH control group again showed a decrease antibody titre earlier in 
the experiment than the adjuvant-antigen groups. 
Antibodies isolated from eggs for weeks 3 to 7 and 8 to 12 were pooled for affinity 
purification of the anti-rPfLDH and anti-rPfGAPDH antibodies. The elution profiles of the 
specific anti-recombinant antibodies off their respective AminoLink® affinity columns were 
shown in Figures 4.11 and 4.12.  
Elution peaks within the group of chickens immunised with rPfLDH were highest for the 
chickens immunised with Freund’s, followed by the PheroidsTM and the control group (Figure 
4.11).  
Chickens immunised with rPfGAPDH (Figure 4.12) also showed highest elution peaks when 
immunised with Freund’s, followed by the PheroidsTM and the antigen control group 
respectively. 
To compare total antibody yields, eluents from the affinity matrix with A280 values greater 
than 0.1 were pooled and the final IgY yield was determined per chicken and evaluated 
against initial yolk volume, since the number of eggs laid per chicken varied, the yields were 
expressed as mg IgY / ml yolk and the results shown in Figure 4.13. As a control an ELISA 
was performed with the unbound samples after affinity purification and showed little or no 
A405 above background (data not shown). 
Chickens in each group showed varied IgY responses. Chickens immunised with Freund’s 
adjuvant showed a significant difference in IgY yields compared to the control group 
immunised with antigen alone. There was an increased IgY yield for the chickens immunised 























































































Figure 4.11 Affinity pu rification o f anti-rPfLDH IgY from c hickens i mmunised with Freund’s, 
PheroidsTM or antigen alone. 
Crude Ig Y isolated from eg gs co llected b etween weeks 3 -7 a nd 8 -12 were pooled and cir culated o ver a 
recombinant PfLDH AminoLink® matrix overnight. The columns were then washed with PBS until A280 values 
of the eluents were between 0.01-0.02, at which p oint t he b ound an ti-rPfLDH-IgY was elu ted using Gl ycine 
HCl at pH 2.8, and fractions were collected. (A to C) show antibodies raised using Freund’s or PheroidsTM as 





















Figure 4.12 Affinity pu rification of a nti-recombinant GAPDH I gY from chic kens i mmunised with 
Freund’s, PheroidsTM or antigen alone. 
Crude Ig Y isolated from eg gs co llected b etween weeks 3 -7 a nd 8 -12 were pooled and cir culated o ver a 
recombinant PfGAPDH Am inoLink® matrix overnight. The columns w ere then w ashed w ith PBS until A280 
values of the eluents were between 0.01-0.02, at which point the bound anti-rPfGAPDH-IgY was eluted using 
Glycine HCl at pH 2.8, and fractions were collected. (A to C) show antibodies raised using Freund’s or 

































































































Figure 4.13 Final y ields o f a ffinity purified IgY raised a gainst r PfLDH o r rPfGAPDH a s a ntigens, 
from chickens immunised with Freund’s, PheroidsTM or PBS. 
Chickens were immunised with either rPfLDH or rPfGAPDH and were separated into groups of 3 depending on 
whether t hey were immunised with Freund’s adjuvant (FCAL/G) or PheroidsTM (PHEL/G) o r an tigen alo ne 
(LDH/GAPDH). Final affinity purified IgY yields against the respective antigens were presented as mg IgY / ml 
yolk due to a variation in egg production per chicken. A significant increase in yield with respect to the control 
group (p < 0.05) was annotated with “*”. 
 
 
Antibodies were raised against recombinant P. falciparum heat shock protein 70 ( PfHsp70) 
for use as a loading control in enhanced chemiluminescence work. The antibody production 
was measured ( Figure 4.15 (A )) a nd the resulting e lution profile of  a ffinity purif ied a nti-
rPfHsp70 IgY was shown in (B) of the same figure. The overall yield of affinity purified anti-



























































Figure 4.14 Measure of anti-rPfHsp70 IgY titres and affinity purification of anti-rPfHsp70 IgY. 
Two chickens were immunised with rPfHsp70 on weeks 0, 2, 4 and 6 using Freund’s complete and incomplete 
adjuvant. Crude IgY was then isolated from single eggs at the end of each week from weeks 0 to 12. Specific 
IgY responses were measured b y d irect ELISA a nd p lotted in  ( A). P lates were coated with recombinant 
PfHsp70 at 1µg/ml. Crude primary I gY samples were added at 100µg/ml and d etected with a rabbit-anti-
chicken-IgY-HRPO secondary antibody at 1/15000 dilution. Weeks showing specific antibody production were 
then p ooled an d af finity p urified o n a recombinant PfHsp70 A minoLink® matrix. T he elution p rofile was 












In this chapter both anti-peptide as well as anti-recombinant (whole protein) chicken 
antibodies were raised against PfLDH and PfGAPDH. Antibodies were raised against 
recombinant proteins for use as the capture antibody in diagnostics, and to compare a new 
adjuvant, called PheroidsTM. 
To identify appropriate peptide targets, multiple sequence alignments, an epitope prediction 
program (Predict7TM) and the 3D crystallographic data of both target proteins were used. 
From the sequence alignments, regions of conserved amino acids were identified between the 
Plasmodium species which would allow detection of all Plasmodium orthologs of the target 
proteins. These were designated pan- or common peptides. Alternatively regions of variable 
amino acid sequences, which were not conserved between the Plasmodium species, were 
identified as species-specific peptides. The chosen peptides ranged in size from 13 to 17 
amino acids including the additional cysteine residues added during synthesis.  
The potential peptide targets were then analysed using Predict7TM. This program overlaps 7 
amino acids of the protein primary sequence at a time. Each amino acid side chain has unique 
properties and these are compared in an algorithm in the Predict7TM program (Cármenes et 
al., 1989). The algorithm predicts secondary structure, such as alpha-helix or beta-sheet 
(Chou and Fasman, 1978); surface probability (Kyte and Doolittle, 1982; Emini et al., 1985); 
hydrophilicity (Hopp and Woods, 1981) and antigenicity (Jameson and Wolf, 1988).  
Hydrophilicity and surface probability are indicators of likely peptide location within the 
overall protein structure.  All peptides had values above 0 for these two parameters indicating 
that they were likely to be located on the surface and are also likely to be soluble for use in an 
ELISA. Surface location of the peptides is essential in order for antibodies to easily recognise 
and bind their epitopes on the native proteins in solution (Saravanan et al., 2009). The 
Predict7TM results were also used to decide on the orientation of coupling, either N- or C-
terminal to rabbit albumin. This was done with the aim of exposing the end of the peptide 
with highest antigenicity to the immune system. To support the Predict7TM data all the P. 
falciparum peptides were found to be on the surface of the 3D crystal structure models of 
their respective proteins. Experimental confirmation of the surface antigenicity of the peptide 
antigens is shown in chapter 5.  
Overall the polarity of the peptide structures seemed to correlate with the antibody yields, 
where the order was APGKSDKEWNRDDL > KITDEEVEGIFD > LISDAELEAIFD. The 
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APGKSDKEWNRDDL peptide had 7 charged polar amino acid side chains, followed by 
KIT with 6 and FDC with 4. 
The LDH amino acid sequence contained a 5 amino acid insert which was not found in the 
non-malarial sequences in the alignment, but was conserved across all human malarial 
species as confirmed using a BLASTp search. This sequence is found within the active site of 
Plasmodial LDH and affects the substrate and cofactor specificity of the enzyme (Gomez et 
al., 1997). BLASTp searches in PlasmoDB with the P. falciparum LDH specific peptide 
(LISDAELEAIFD) showed no identity with other human malaria species, where the P. vivax 
sequence (KITDEEVEGIFD) showed 91 % identity with the P. knowlesi sequence, 
suggesting cross reactivity may occur and will have to be assessed. P. knowlesi infections 
have been detected with LDH and aldolase based RDTs (Kawai et al., 2009; van Hellemond 
et al., 2009). BLASTp searches with the GAPDH peptides showed the common Plasmodial 
GAPDH peptide to be 100 % conserved, within the Plasmodium sequences sequenced to 
date. The P. falciparum sequences showed no identity with any other human malaria 
sequences. P. vivax specific sequences can be identified as the corresponding sequence to the 
P. falciparum specific peptides in the GAPDH alignment, however they should still be 
assessed using Predict7TM. 
The European Centre for the Validation of Alternative Methods in 1993 outlined the 3 R’s 
associated with the use of experimental animals in research, these are: refine, reduce and 
replace. Choosing the chicken as the experimental animal for antibody production has an 
advantage due to the higher yields of antibody, with approximately 7 times greater yields 
from egg yolk in comparison to rabbit serum for example (Schade et al., 1991). This also 
eliminates the need to bleed the animals. Finding an alternative to Freund’s adjuvant would 
address the hypersensitivity reactions associated with its use (Wilson-Welder et al., 2009). 
Freund’s is often associated with granuloma formation at the site of immunisations and these 
have been recorded to last up to 2 years in humans (Chapel and August, 1976). Granulomas 
were also observed in this study within the Freund’s groups, with none observed in the 
PheroidsTM and no-antigen control groups, but these disappeared over the course of the 
experiment. 
Sustained antibody titres were observed in chickens immunised with Freund’s and 
PheroidsTM where, in comparison, titres in the control groups decreased rapidly. This was 
suggestive of the depot effect for both adjuvants which is a function of adjuvants (Reed et al., 
90 
 
2008). The depot effect was first described as a possible mode of action for Freund’s adjuvant 
by Herbert in 1968, who observed the slow and sustained release of ovalbumin from the site 
of immunisation in mice. These findings were similar to those seen in a study by Sun et al., in 
2008 between adjuvant and no-adjuvant control groups. In the same study Sun et al., 
observed a one week lag in specific IgY production, where our results showed similar trends 
between weeks 2 and 3. 
The final antibody yields against the whole recombinant proteins showed Freund’s to be 
superior to PheroidsTM. Yields were expressed in relation to egg yolk volume as yolk volume 
has been shown to be directly proportional to antibody yield (Li et al., 1998). There was a 
statistically significant difference between the yields for the chickens immunised with 
Freund’s adjuvant and the control groups. The results for the chickens immunised with 
PheroidsTM were slightly higher than those for antigen alone, but were not statistically 
significant. This showed that Freund’s stimulated a more aggressive humoral immune 
response than PheroidsTM. This may be due to the strong initial stimulation caused by the 
Freund’s complete adjuvant due to the presence of the heat killed Mycobacterium. To 
improve the immune stimulation by PheroidsTM alternate methods may be used such as 
mannosylation. This has been used in conjunction with similar microsphere delivery systems 
to target mannose receptors in macrophages (Jiang et al., 2007). Another alternative may be 
the addition of a saponin such as Quil A (Demana et al., 2004).  
PheroidsTM has been used as a drug delivery system, similar to other liposome or lipid based 
systems that have been used as adjuvants such as immunostimulatory complexes (ISCOMs) 
(Demana et al., 2004; Fernando et al., 1995; Reed et al., 2008; Wilson-Welder et al., 2009). 
Liposome delivery systems function by fusing with the host cell membrane after 
phagocytosis and releasing the antigen into the cell cytoplasm. Particle size is important as it 
affects phagocytosis and antigen delivery (Demana et al., 2004). This may have had an effect 
in this study and alternate methods of preparation as opposed to trituration may result in 
increased antibody yields. 
The method of antigen delivery is important as it determines the presentation pathway used 
by antigen presenting cells. Internal antigens are processed and presented by the major 
histocompatibility complex I (MHC I), whereas external antigens are presented by MHC II. 
This in turn affects the host immune response bias. The delivery mechanism employed by 
PheroidsTM suggests an MHC I biased response whereas Freund’s should promote an MHC II 
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response. Presentation with MHC I promotes a cell mediated immune response where 
presentation with MHC II promotes a humoral immune response (Delves et al., 2006; 
McNeela and Mills, 2001; Reed et al., 2008; Wilson-Welder et al., 2009). Cross-presentation 
is where an MHC I presentation may result in humoral and an MHC II in cell mediated 
immunity responses are also possible (Guermonprez et al., 2003; Houde et al., 2003). Future 
studies could thus focus on the effect of PheroidsTM on cytokine expression by monocytes 
and perhaps inclusion of additional stimulatory substances such as quil A or mannose. 
Assessing possible differences in affinities between antibodies raised using the two adjuvants 
should also be done. 
Although not suited to antibody production, comparison of PheroidsTM to other lipid-based 
adjuvants such as ISCOMs may be warranted as these can potentially be used in oral vaccines 
(Demana et al., 2004; Reed et al., 2008). In developing a malaria vaccine, a school of thought 
is to elicit a cell mediated immune response as opposed to a humoral-dominated response 
(Friesen et al., 2010). PheroidsTM may offer an alternative adjuvant in such an instance. 
Further comparison and characterisation of the anti-recombinant and anti-peptide antibodies 
raised would also be of interest. In the following chapter both antibodies are used for 














Detection and quantitation of native PfGAPDH and PfLDH using both anti-peptide 
and anti-recombinant chicken antibodies 
 
5.1 Introduction 
Throughout its lifecycle the malaria parasite requires different proteins in order to carry out 
various functions. According to the central dogma of molecular biology (Crick, 1970), genes 
are transcribed into messenger RNA (mRNA) and then translated into protein. Various 
studies have been performed on the malaria transcriptome (Bozdech et al., 2003; Le Roch et 
al., 2003), and the data has been used to identify protein targets for drug assays, vaccine 
development and molecular markers.  
According to Bozdech et al., (2003), the majority of Plasmodium proteins are instantly 
translated from their respective transcripts. It has since been shown that parasite mRNA 
levels are not always directly proportional to protein levels due to posttranscriptional and 
posttranslational regulation of gene expression (Foth et al., 2008; Hall et al., 2010; Jackson et 
al., 2011; Nirmalan et al., 2004). A study by Mackinnon et al., in 2009 showed that there 
were variations between levels of gene expression in long-term laboratory cultured 
Plasmodium isolates compared to field isolates (Mackinnon et al., 2009). The studies by Le 
Roch et al., and Bozdech et al., in 2003 were both done using the P. falciparum 3D7 and 
HB3 strains laboratory isolates respectively. As a result the transcriptional data are used as a 
starting point for identifying target genes. Plasmodium falciparum glyceraldehyde-3-
phosphate dehydrogenase (PfGAPDH) was chosen as a potential new target for malaria 
diagnosis as it was shown to be between 2.4 to 8 times more abundant than Plasmodium 
falciparum lactate dehydrogenase (PfLDH) from transcription data (Le Roch et al., 2003). 
The Plasmodium proteome has been studied using semi-quantitative protein analyses 
involving two-dimensional gel electrophoresis and mass spectrometry (Aebersold and Mann, 
2003; Lasonder et al., 2002; Nirmalan et al., 2004; Smit et al., 2009). These methods allow 
for the quantification of relative amounts of protein, usually with respect to the initial ring 
stage of the parasite and thus give an idea of up- or down-regulation of protein levels 
throughout the life cycle. This can be compared to mRNA levels and gives an idea as to 
whether the gene is regulated after transcription. In the case of PfGAPDH and PfLDH, both 
transcript and protein expression levels showed increasing  trends from the ring to 
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trophozoite stages of the parasite life cycle (Smit S. et al., 2009, Nirmalan et al., 2004) 
supporting the initial transcription data from Le Roch et al., (2003). 
Quantitation of individual proteins still relies on specific methods. A popular strategy uses 
antibodies for the detection of antigens, in an ELISA assay (van Weemen and Schuurs, 
1971). The antibodies have to be characterised to establish affinities or avidities for target 
antigens (Pereira Arias-Bouda et al., 2003; Ferreira and Katzin, 1995). 
An antigen generally contains a number of potential epitopes which are each recognised by 
an individual B-cell clone. Each B-cell clone in turn produces an epitope specific antibody, 
hence the name monoclonal antibody (Pluschke et al., 1998). The strength of the interaction 
between a single antibody and its specific epitope is defined as its affinity, which is also used 
to describe the strength of a monoclonal antibody binding its epitope. Alternatively 
polyclonal antibodies are raised from an entire subset of B-cells (hence the term polyclonal). 
As a result the polyclonal antibodies produced may all be specific to the same antigen, but 
recognise different epitopes and therefore have different individual affinities for the same 
antigen. The sum of the individual affinities of a group of polyclonal antibodies for the same 
antigen is defined as avidity (Delves et al., 2006; Ferreira and Katzin, 1995; Pereira Arias-
Bouda et al., 2003). 
A typical IgG antibody molecule is divalent and has the ability to bind two epitope regions on 
an antigen and can, in theory, bind two antigen molecules or alternatively bind strongly to a 
single antigen if the epitope is repeated. As a result the antigen binding capacity of an 
antibody in solution is dependent on the antibody concentration and the binding efficiency is 
dependent on the affinity/avidity of that antibody as well as its valence (Delves et al., 2006). 
Malaria rapid diagnostic tests (RDTs) capture and detect malarial antigens from infected 
blood lysates using antibodies (Murray and Bennett, 2009; Murray et al., 2008). As a result 
RDT sensitivity is a function of: 1) antibody affinity/avidity for its target antigen; 2) antibody 
valence and 3) the concentration of the target antigen within the test sample.  
As with any antibody based test, however, RDTs also have limits of detection. HRP-2 based 
tests have been shown to be affected by a phenomenon called the prozone effect (Gillet et al., 
2009), where LDH and aldolase based tests were unaffected. The prozone effect describes the 
appearance of faint positive or even false negative results due to high antigen concentration 








Figure 5.1 A simplistic representation of the prozone effect on antibody-based antigen capture and 
detection assays. 
A defined concentration o f capture antibody (  ) and detection antibody (  ) are used to  detect antigen (   ). 
Signal intensity is  r epresented b y t he blue line and i s d ependent on t he ratio o f an tigen to  antibody 
concentrations. 
 
From Figure 5.1 too little antigen (far left) gives a  fa int signal and equal concentrations of 
antigen to antibody gives the strongest signal (middle). As the antigen becomes excessive, the 
detection a ntibody-antigen ra tio be comes diluted and a  fa int sig nal results (far right). This 
phenomenon (far right) is known as the prozone effect (Gillet et al., 2009). The concentration 
of HRP-2 to LDH has been quantified as approximately 6:1 (Martin et al., 2009), explaining 
the se nsitivity of the HRP-2 ba sed tests to the prozone e ffect, which is  e asily rectified b y 
simple dilution of test samples. 
Direct quantitation and comparison of PfLDH and PfGAPDH proteins have not been made to 
date. The aim in this section was to compare their concentrations in parasite lysate material 
using antibody based detection methods. Such detection would mimic that of a malarial RDT 
format and would allow for more accurate conclusions about PfGAPDH as a new RDT target 

















PfGAPDH and PfLDH both have sim ilar molecular masse s of a round 35 kD therefore not  
allowing for their differentiation based on size on reducing SDS-PAGE gels. Since the aim 
was to compare the concentrations of both native proteins in P. falciparum lysate samples, it 
had to be e nsured that t he a ntibodies used were not cross-reactive. C ontrol Western blot s 
were ther efore run  using  both  a nti-peptide a nd a nti-recombinant whole pr otein antibodies 
raised previously.  
 
5.2.1 Characterising antibodies 
Both a nti-recombinant a s well a s anti-peptide a ntibodies were teste d for  c ross-reactivity 






Figure 5.2 Anti-recombinant protein a nd a nti-peptide a ntibodies det ected t he re spective 
recombinant proteins on Western blots. 
Affinity p urified rPfGAPDH or rPfLDH were run in lanes 1  and 2  respectively, on 12.5 % SDS-PAGE gels. 
Panel (A i) ) was a r eference g el stained with C oomassie R-250 w ith m olecular weig ht markers (Mw). 
Recombinant PfGAPDH or r PfLDH were detected b y W estern b lotting using an ti-recombinant whole p rotein 
antibodies (1 µg/ml) in (A ii)) and iii)) respectively; or using anti-peptide antibodies (5 µg/ml) as indicated in 
(B) and (C). The molecular weight marker (Mw) in  (B and C) was the 35 kD marker. A rabbit anti-chicken-
HRPO secondary antibody at 1/12000 dilution was used for all sets of Western blots.  
 
The result in Figure 5.2 showed the specificities of the anti-recombinant antibodies for their 
respective antigens. Recombinant PfGAPDH was detected by the anti-rPfGAPDH antibodies 
as a major  band a round 39 kD with minor pr oducts smaller than 35 kD. The anti-rPfLDH 
antibodies detected a minor band around 75 kD as well as a major band of approximately 36 
kD as expected for rPfLDH. These patterns were similar to those detected in chapter 3 fo r 
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antibodies also showed specificity for their respective antigens as shown in (B) of the same 
figure, detecting major bands just above the 35 kD molecular weight marker as expected.  
The anti-recombinant antibodies were then used to detect PfGAPDH and PfLDH on Western 











Figure 5.3 Detection of PfLDH and PfGAPDH in in vitro P. falciparum (D10) culture lysates using 
anti-rPfLDH or anti-rPfGAPDH IgY. 
Infected h uman r ed b lood ce ll l ysates were run o n a 12.5% SDS-PAGE gel, transferred to  n itrocellulose and 
stained with Ponceau S (A i)) and (B i)) or probed with anti-rPfLDH (A ii)) or anti-rPfGAPDH (B ii)) IgY and 
detected with a rabbit anti-chicken-HRPO secondary at 1/12000 d ilution. Lane 1 contained the lysate of a P. 
falciparum (D10) culture at 15 % parasitemia; lane 2 contained uninfected human type “O” blood and molecular 
weight markers were run in the (Mw) lane.  
 
Both a nti-recombinant antibodies de tected their respective a ntigens on W estern blot s of 
Pf(D10) lysate samples and did not cross react with any human red blood cell proteins. The 
native proteins both had similar molecular weights of around 35 kD, with native PfLDH at 
around 34 kD and native PfGAPDH around 36 kD.  
Anti-recombinant PfHsp70 IgY antibodies were a lso tested a nd showe d spec ificity for  a 
major protein around 73 kD within a Pf(D10) lysate sample as shown in Figure 5.4, with no 
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Figure 5.4 Detection o f PfHsp70 on a Western blo t o f in vitr o Plasmodium f alciparum (Pf(D10)) 
lysate with anti-rPfHsp70 IgY. 
Samples were run on a 12.5% SDS-PAGE gel. Lane 1  Pf(D10) lysate at 15 % parasitemia, lane 2 uninfected 
lysed human type “O” blood. The gel on the left was stained with Coomassie R250 and served as a reference for 
the Western blot on the right. PfHsp70 was detected with an anti-rPfHsp70 IgY primary (1 µg/ml) and a rabbit 
anti-chicken-HRPO secondary antibody at 1/12000 dilution.  
 
All three anti-recombinant antibodies were tested in an enhanced chemiluminescence format 
and each antibody detected a band at the expected sizes (Figure 5.5). Uninfected red blood  
cell l ysates were e xcluded a s haemoglobin gives false signals on film paper when re acted 







Figure 5.5 Detection o f native PfGAPDH, PfLDH a nd PfHsp70 in Pf(D10) lysate with a nti-
recombinant antibodies. 
Lysate samples (20 µg) of Pf(D10) infected human red blood cell lysates were run on 12.5 % SDS-PAGE gels 
as shown in the reference gel stained with Coomassie R-250 (A). Molecular weight markers (Mw) were labelled 
alongside in k ilo Dalto ns (kD). ECL b lots were probed with a nti-rPfHsp70 (B); an ti-rPfGAPDH (C) o r a nti-
rPfLDH ( D), all using p rimary an tibody co ncentrations of 1 µg/ml and a  r abbit anti-IgY-HRPO s econdary 
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5.2.2 Immunoprecipitation of native proteins 
The next approach was to “pull down” or immunoprecipitate native PfGAPDH and PfLDH 












Figure 5.6 Immunoprecipitation of native PfGAPDH and PfLDH from Pf(D10) lysates. 
All samples were run on 12.5 % SDS-PAGE gels. A lysate protein concentration range of 5 mg/ml (lane 1); 2.5 
mg/ml (lane 2); 1.25 mg/ml (lane 3) and 0.625 mg/ml (lane 4) were precipitated with 25ug anti-rPfGAPDH or 
anti-rPfLDH IgY, 10ug s econdary r abbit anti-IgY antibodies and p rotein G.  A s co ntrols n on-
immunoprecipitated parasite lysate (5 mg/ml) as well as uninfected red blood cell lysate (5 mg/ml) were run in 
lanes 5 a nd 6  r espectively. Silver stained r eference g els were shown o n t he left with t he respective anti-
rPfGAPDH (A) or anti-rPfLDH (B) Western blots on the right. Western blots were probed with anti-rPfGAPDH 
or anti-rPfLDH IgY antibodies at 1 µg/ml and a rabbit anti-IgY-HRPO secondary antibody at 1/12000 dilution. 
 
Both native proteins were detected at around 35 kD as was expected, but what was interesting 
was a second minor band just below the 35 kD band detected in the 5 mg/ml Pf(D10) lysate 
sample precipitated with anti-rPfLDH antibodies. This was similar to the doublet obtained in 
the rPfLDH samples seen previously (Figure 3.5). The intensity of the bands decreased with a 
decrease in the lysate concentration.  
In a  s econd im munoprecipitate e xperiment, the na tive pr oteins were d etected using anti-
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Figure 5.7 Native PfLDH a nd PfGAPDH prec ipitated f rom Pf(D10) l ysate with anti-recombinant 
protein IgY were detected with specific anti-peptide IgY antibodies on Western blots. 
Native PfLDH an d PfGAPDH were precipitated f rom Pf(D10) ly sate material at  5  mg/ml u sing a nti-
recombinant I gY at 25 µg/ml, 1 0 µg/ml s econdary r abbit anti-IgY antibodies and p rotein G.  Sa mples 
precipitated using anti-rPfLDH IgY were run in lane 1 and those precipitated with anti-rPfGAPDH IgY in lane 2 
on 12.5 % reducing SDS-PAGE gels. These were then probed with anti-peptide IgY at 5 µg/ml, where anti-FDC 
and an ti-APG ar e PfLDH specific and co mmon p eptides respectively an d an ti-WGK and an ti-VMG ar e 
PfGAPDH specific and common peptides respectively.  A rabbit anti-IgY-HRPO secondary antibody was used 
at 1/12000 dilution throughout. 
 
The anti-FDC (PfLDH specific) and anti-APG (pan LDH) peptide antibodies only detected 
the proteins precipitated using the anti-rPfLDH antibodies (Figure 5.7), both also detecting a 
band of approximately 34 kD. Similarly the anti-WGK (PfGAPDH specific) and anti-VMG 
(pan GA PDH) peptide antibodies only de tected the proteins precipitated with the anti-
rPfGAPDH antibodies, again around 36 kD as expected. The smear in lane one of the anti-
APG Western blot  and the horizontal line across the anti-FDC and anti-APG Western blots 
were Ponceau S stain and were not as a result of antibody detection. 
Sequential precipitation of both native PfGAPDH and PfLDH was also performed using the 
anti-recombinant IgY antibodies. First PfGAPDH was precipitated, followed by PfLDH from 
the sa me Pf(D10) lysate. The n PfLDH, f ollowed b y PfGAPDH fr om a separate Pf(D10) 
lysate. The resulting Western blots were shown in Figure 5.8. 
This result (F igure 5.8) served a s a control for a ntibody spe cificity again showin g that the  
anti-recombinant antibodies each bound and precipitated a separate antigen of approximately 
35 kD within the same lysate sample. Dilut ions of pa rasite l ysates were made , while the 
antibody c oncentrations used remained the same for e ach dil ution. This ensured that the 
antibody concentration was not limiting, therefore the proteins “pulled down” in the 


















Figure 5.8 Sequential immunoprecipitation o f native PfGAPDH a nd PfLDH f rom Pf(D10) l ysate 
samples. 
All samples were run on 12.5 % SDS-PAGE gels. Lysates were prepared to give a total protein concentration 
range of 5  mg/ml (lane 1 ); 2.5 mg /ml (lane 2 ); 1. 25 mg/ml (lane 3 ) and 0. 625 m g/ml (lane 4 ) and w ere 
precipitated with 25 µg/ml anti-rPfGAPDH or anti-rPfLDH IgY, 10 µg/ml secondary rabbit anti-IgY antibodies 
and p rotein G . The l ysates were r etained a nd a sequential round o f p recipitations was p erformed. Sa mples 
incubated with anti-rPfGAPDH (A i)) were then incubated with anti-rPfLDH (A i i)) and vice versa. In lane 5 
uninfected human blood lysate (5 mg/ml) replaced the infected parasite lysate. Western blots were probed with 
either an  anti-rPfGAPDH o r anti-rPfLDH I gY (1 µg/ml) as shown in the figure and a rabbit an ti-IgY-HRPO 
secondary antibody at 1/12000 dilution. 
 
The immunoprecipitation experiments using the anti-recombinant antibodies were repeated in 
triplicate. Using densitometry the band intensities observed for native PfGAPDH and PfLDH 
on Western blots were compared and summarised in Figure 5.8.  
 
 
A i) Precipitated and probed 
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B i) Precipitated and probed 
with anti-rPfLDH 
ii) Sequentially precipitated and 

























Figure 5.9 Densitometry a nalysis o f t he immunoprecipitation results f or PfGAPDH a nd PfLDH 
from Pf(D10) lysate samples.  
Lysate samples were diluted to give protein concentrations of 5; 2.5 and 1 .25 mg/ml and were incubated with 
25ug a nti-rPfGAPDH or an ti-rPfLDH I gY; 10ug secondary rabbit an ti-IgY antibodies an d p rotein G . After 
separation o n 1 2.5 % SDS-PAGE gels, samples were assessed b y W estern b lotting with the r espective a nti-
rPfGAPDH or a nti-rPfLDH antibodies a t 1 µg/ml a nd d etected with a rabbit a nti-IgY-HRPO secondary a t 
1/12000 dilution. The blots were analysed using Quantity One® Version 4.6.0 (Bio-Rad Laboratories © 2005) 
and densitometric values were assigned to the bands detected as intensity (INT) per mm2. The results show the 
mean values of experiments done in triplicate (n = 3), with standard deviations.  
 
Band intensities are subject to the polyclonal antibody avidities and antigen concentration, so 
without a standard curve to associate band intensity with approximate protein concentration, 
the results in Figure 5.8 ma y b e mi sleading. The re sults suggest a hig her concentration of  
native PfGAPDH to PfLDH within the lysate samples. The increasing absorbance values for 
all thre e sa mples suggest that the antibody concentrations were in excess, as incr easing 
protein leve ls were de tected with each incr ease in lysate c oncentration, with the same 
antibody concentration used throughout.   
 
5.2.3 Detection of native proteins using a direct ELISA 
A dire ct ELISA wit h pa rasite l ysate was used to c oat the wells and PfLDH or  PfGAPDH 
were detected using the respective anti-recombinant IgY antibodies. Since separate antibodies 
were used for e ach pr otein, standa rd curves ha d to be pr epared whi ch would a llow for 
quantitation of  the proteins. These were shown in Figure 5.10 and were prepared using the  






































































Figure 5.10 Standard curves showing limits of detection of rPfLDH and rPfGAPDH using anti-
recombinant IgY.  
ELISA plates were coated with a range of concentrations of recombinant protein from 0.15 µg (1 µg/ml) to 
0.0003 µg. Anti-recombinant IgY antibodies were used as the primary antibodies at 6.25 µg/ml and a 1/15000 
dilution of a rabbit anti-chicken HRPO secondary antibody. An average of triplicate readings with standard 
deviations was shown. 
 
Both anti-recombinant protein antibodies detected their target antigens. The anti-rPfLDH 
curve seemed to have a steeper initial increase compared to the anti-rPfGAPDH curve. The 
slope of the curve suggests that the anti-rPfLDH antibodies have higher avidity for the target 
antigen than the anti-rPfGAPDH antibodies.  
Using the standard curves, the approximate concentrations of native PfLDH and PfGAPDH 





































Figure 5.11 Detection of native PfLDH and PfGAPDH in Pf(D10) lysate using anti-recombinant IgY. 
ELISA plates were co ated with a r ange o f Pf(D10) l ysate p rotein f rom 7 5 µg (0.5 mg/ml) t o 0. 15 µg. T he 
antigens w ere detected with an ti-rPfLDH or an ti-rPfGAPDH IgY an tibodies at 6 .25 µg/ml and a rabbit an ti-
chicken HR PO labelled s econdary a ntibody at  1 /15000 d ilution. T he A405 values were converted to  
concentrations of native antigen using the antigen specific standard curves. All data points were average values 
of triplicate readings.  
 
The anti-rPfGAPDH antibodies detected an increasing concentration of native PfGAPDH as 
the lysate concentration increased (Figure 5.11) . The anti-rPfLDH antibodies, however, did 
not detect native PfLDH within the ELISA. The above experiment was repeated using double 
the lysate concentration, starting at 150 µg of total lysate protein (1 mg/ml), however, there 
was no change in the de tection of  native PfLDH. The detection of  PfGAPDH increased as 
expected with approximately 0.059 µg of  na tive PfGAPDH de tected at a pa rasite l ysate 
concentration of  150 µg ( data not shown), therefore just  more  than double that de tected in 
Figure 5.11, as was expected.  
Not a ll pr oteins bind equally w ell t o E LISA plates. Since pr otein bi nding c an be  pH  
dependent, an experiment was performed using either PBS pH 7.4 or carbonate buffer pH 9.6 
(data not shown), where PBS gave the best result.  
There are a number  of  pr oteins within a  l ysate, whic h e ach h ave dif ferent affinities for  
binding to the ELISA wells. It was hypothesized that the proteins in the lysate samples were 
out-competing native PfLDH and PfGAPDH for binding to ELISA wells. This would explain 
the poor absorbance re adings for  PfLDH in  F igure 5.11.  To a ssess this hypothesis an 
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“spiked” with rPfLDH or rPfGAPDH protein and detected in a direct ELISA (Figures 5.12 








Figure 5.12 Lysates “spiked” with rPfGAPDH to assess competitive binding between lysate proteins 
and PfGAPDH. 
Malaria Pf(D10) lysate samples and uninfected type “O” blood samples at 15 µg were spiked with rPfGAPDH. 
The samples were diluted for a total of 6 doubling dilutions and detected with anti-rPfGAPDH IgY and a rabbit 
anti-chicken-HRPO secondary antibody at 1/15000 dilution. All data sets were done in triplicate and standard 
deviations are displayed. 
 
Approximately 0.01 µg of native PfGAPDH was detected in the Pf(D10) lysate sample 
without the addition of rPfGAPDH, as seen in Figure 5.12, which correlated to levels 
detected in Figure 5.11 at a similar lysate concentration. As a general trend the concentration 
of PfGAPDH detected declined with increasing dilution of the samples as was expected.  
Detection of rPfGAPDH in the PBS control sample showed highest levels of antigen. In 
comparison lower readings with the “spiked” infected red blood cell lysate and “spiked” 
uninfected red blood cell lysate samples suggested there were other proteins present in lysates 
that were competing for binding to the ELISA wells, thus reducing the detected level of 
PfGAPDH.  
A similar result was obtained for PfLDH (Figure 5.13). Samples “spiked” with rPfLDH in 
this case also showed increased detection of recombinant antigen, but a similar lack of 
detection of the native antigen as seen previously in Figure 5.11. There seemed to be a 
sharper decline in the detection of the recombinant antigen in the lysate samples in 
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Figure 5.13 Lysates “spiked” with rPfLDH to assess competitive binding between lysate proteins and 
PfLDH. 
Malaria lysate samples and uninfected type “O” blood samples at 15 µg w ere “spiked” with rPfLDH. T he 
samples were diluted for a total of 6 doubling dilutions and detected with anti-rPfLDH IgY and a rabbit anti-
chicken-HRPO s econdary antibody at 1/ 15000 dilution. All d ata sets were done in t riplicate and standard 
deviations are displayed. 
 
Detection of native protein using a direct ELISA approach would thus be an underestimation 
of the real concentration present within the lysate samples due to an apparent competition in 
binding of proteins within a lysate sample for the ELISA plate. An immune-capture method 
in the form of a double antibody sandwich ELISA (DAS-ELISA) was then evaluated.  
 
5.2.4 Development of a d ouble antibody san dwich (D AS) ELISA for d etection of 
native PfGAPDH and PfLDH 
The a nti-recombinant IgY antibodies raised against both protein tar gets were used as 
detection antibodies, with anti-peptide antibodies used as the capture antibodies in the DAS 
ELISA. The detection antibodies were thus labelled with HRPO and the concentration to be 






















































Figure 5.14 ELISA to optimise the concentration of HRPO-labelled anti-recombinant IgY to use in 
the DAS-ELISA. 
96-well ELSIA plates were coated with rPfLDH or rPfGAPDH at an initial concentration of 25 µg/ml and 
diluted for 7 doubling dilutions across the plate. Doubling dilutions of the anti-rPfLDH-HRPO or anti-
rPfGAPDH-HRPO were prepared separately starting at a 1 in 50 dilution to a 1 in 800 dilution. These were then 
tested across the range of antigen concentrations coated on the plates.  
 
The chosen antibody dilution was a compromise between conserving the amount of antibody 
used to get a good signal. A 1 in 200 dilution (5 µg/ml) of HRPO coupled antibody was 
chosen for both anti-rPfLDH and anti-rPfGAPDH as these gave good A405 readings across 
the antigen range tested in Figure 5.14.  















































Figure 5.15 Standard curv es indicating li mit o f detection o f the DAS-ELISA assay, us ed f or 
estimating levels of native proteins. 
96-well ELISA p lates were coated w ith t he pan-malarial an ti-peptide antibodies at 1 µg/ml as th e capture 
antibodies. The anti-APG (pan LDH) antibody was used for the capture of PfLDH (A) and the anti-VMG (pan 
GAPDH) antibody for PfGAPDH (B). Standard curves were prepared using rPfLDH or rPfGAPDH at starting 
concentrations o f 0 .75 µg and double diluted a  to tal o f 9  times. The prepared HRPO-labeled anti-rPfLDH or 
anti-rPfGAPDH was then added as the detection antibody at a 1/200 dilution. The resulting standard curves are 
average values of triplicate samples with standard deviations shown.  
 
The anti-rPfLDH-HRPO standard curve show ed a fa r more p ronounced i ncrease in A405 at 
low rPfLDH concentration, reaching saturation a t approximately 0.2 µg. In comparison the 
anti-rPfGAPDH-HRPO standard curve sti ll showe d incr easing d etection a t 0.8 µg of  
rPfGAPDH ( Figure 5.15 ). No c ross reactivity w as detected in a c ontrol experiment where 
rPfGAPDH was added t o PfLDH and the  sa me for r PfLDH added to PfGAPDH (da ta not  
shown). Standard c urves and de tection of  n ative PfLDH a nd PfGAPDH withi n Pf(D10) 
lysates were run on the same plate to avoid inter-plate inconsistencies. The resulting detection 
of the native pr oteins was shown in Figure 5.16 , whe re th e corresponding stand ard curves 


































Figure 5.16 Detection of native PfLDH and PfGAPDH in Pf(D10) lysate material. 
Separate ELISA p lates were coated w ith t he pan-malarial an ti-peptide an tibodies at 1 µg/ml as the ca pture 
antibodies. T he anti-APG antibody was used for the ca pture o f PfLDH and t he anti-VMG an tibody for 
PfGAPDH. Total parasite lysate was then added at an initial concentration of 750 µg and double diluted 3 times. 
The resulting A405 values were converted to protein concentration values using prepared standard curves and the 
average values of triplicate readings were plotted with standard deviations shown.  
 
PfGAPDH was consistently detected at higher l evels than PfLDH, b eing pr esent at 4 to 8 
times the amount of PfLDH (Figure 5.16) . The concentrations determined b y DAS-ELISA 
correlated with those using the direct ELISA method for PfGAPDH. At a pproximately 150 
µg a nd 75 µg Pf(D10) lysate the respective c oncentrations were a round 59 a nd 17 ng o f 
PfGAPDH for  the direct ELISA approach. F or the DAS-ELISA re sults, the a pproximate 
concentrations were 36  and 15 ng of  PfGAPDH a t lysate c oncentrations of  approximately 
187.5 and 93.75 µg respectively. As for the detection of PfLDH, this was not the case. With 
the DAS-ELISA the  concentrations of PfLDH were higher than those  in the direct ELISA. 
The leve ls were around 1 ng in the dire ct ELISA regardless of the l ysate c oncentration, 
whereas they inc reased fr om 4 to 13 ng in the DA S-ELISA a ssay for Pf(D10) l ysate 
concentrations of 93.75 to 750 µg. These r esults translate to an e stimated 259.5 ng /ml of 
PfLDH withi n the original 15 %  l ysate and 2.1  µg/ml of  PfGAPDH. F or c omparison to a  
paper by Martin et al., (2009) the levels in a 1 % lysate would be approximately 17.3 n g/ml 





Antibody specificity is important for the detection of antigens. Both the anti-peptide and anti-
recombinant chicken antibodies raised in chapter 4 were used and characterised here. The aim 
was to compare the concentrations of the two target antigens PfLDH and PfGAPDH within 
P. falciparum lysate samples. Since both target antigens shared similar molecular masses of 
around 35 kD, differentiation based on size was not possible. It was important to show that 
the antibodies detected two separate antigens in solution and not the same 35 kD protein 
before further analysis was done. Western blotting, immunoprecipitation and ELISA assays 
were used to assess antibody specificity. 
The anti-recombinant as well as anti-peptide antibodies detected only their respective 
recombinant antigens on a Western blot. In Western blots of Pf(D10) lysate samples bands of 
around 35 kD were detected using the anti-recombinant antibodies, with no proteins detected 
in uninfected blood samples. Using enhanced chemiluminescence both anti-recombinant 
antibodies also showed specificity by detecting only a single band. The PfLDH band (around 
34 kD) was slightly lower than that of PfGAPDH (around 36 kD). This would correlate with 
PlasmoDB values predicted to be 34.4 kD for PfLDH and 36.6 kD for PfGAPDH based on 
the amino acid composition. With respect to the ECL results, the samples were prepared 
differently to the immunoprecipitation and ELISA samples. This was due to signal 
development between haemoglobin and the ECL substrate, as luminol is known to react with 
metal ions (Hartkopf and Delumyea, 1974), hence haemoglobin had to be removed by several 
wash steps. 
With Western blotting proteins are detected in their fully denatured states, thus antibodies 
recognise linear epitopes of their target antigens (Towbin et al., 1979). Both PfLDH and 
PfGAPDH share similar tertiary structures forming tetramers in solution (chapter 3). They 
also bind the same cofactor NAD+(H); both have Rossmann fold motifs (Daubenberger et al., 
2000; Gomez et al., 1997; Granchi et al., 2010) and share 47 % identity. The antibodies may 
therefore still cross react by detecting conformational epitopes on PfLDH and PfGAPDH. 
Through immunoprecipitation antibodies have the opportunity of binding antigens in their 
native conformation and could potentially recognise and bind conformational epitopes. The 
proteins precipitated using the anti-recombinant antibodies were recognised by their 
respective anti-peptide antibodies on Western blots with no cross reaction. To add to this 
sequential precipitations were also performed and showed that two separate antigens of 
around 35 kD were being precipitated from the same initial Pf(D10) lysate sample using the 
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anti-recombinant antibodies. These results support the specificity of the antibodies for their 
antigens, showing no cross-reaction with linear or conformational epitopes.  
Detection of higher molecular weight bands around 65 to 68 kD in immunoprecipitation 
Western blots were not dimers of the native proteins, as the bands were also present in the 
uninfected red blood cell control lanes. These bands match the estimated size of the IgY 
heavy chain (Schade et al., 1993), which would have been detected by the secondary rabbit 
anti-IgY-HRPO antibody used in the Western blots. These were not seen before in Figure 5.6 
possibly because a new secondary antibody was used in these Western blots and may have 
been more reactive in this case. The smaller band around 50 kD may be a dimerization of IgY 
light chains. 
In a direct ELISA format, ELISA plates were coated with the target antigen which was then 
detected with a specific antibody. Coating plates with a target protein causes slight 
denaturation of the protein due to protein-plastic interactions (van Regenmortel, 1988). PBS 
pH 7.4 was optimal for coating, however for some reason native PfLDH appeared not to bind 
well to ELISA plate wells under these conditions and from spiked ELISAs it seemed that 
other proteins in solution were competing with native PfLDH. This also showed that 
quantitation by direct ELISA is not ideal due to such competition and would likely result in 
an under estimation of the actual protein concentration. For this reason a double antibody 
sandwich ELISA was used (DAS-ELISA) for quantitation of native PfLDH and PfGAPDH.  
The standard curves for the direct ELISA did suggest a higher avidity between the anti-
rPfLDH antibody and rPfLDH than the avidity between anti-rPfGAPDH and rPfGAPDH. 
This result was similar for the DAS-ELISA standard curves. The higher avidity suggests that 
the detection of higher levels of native PfGAPDH to PfLDH in immunoprecipitation 
experiments may be more significant than observed in Figure 5.8, since the antibody 
concentrations used were the same. According to transcription data from Le Roch et al., 
(2003) the relative levels of PfGAPDH should be approximately 4 times greater than the 
corresponding level of PfLDH (see appendix). This is clearly greater than that observed for 
the immunoprecipitation results. Nirmalan et al., (2004) showed the relative protein levels of 
both PfLDH and PfGAPDH to exceed those of the mRNA levels at the trophozoite and 
schizont stages of the parasite red blood cell cycle. A similar finding was made by Smit et al., 
(2009), which both support the transcription data and suggest there to be posttranscriptional 
regulation of these genes. The DAS-ELISA data thus far suggest there to be between 4-8 
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times more PfGAPDH than PfLDH, which corresponds with the mRNA levels from Le Roch 
et al., (2003). It was concerning that the levels detected were still very low, and further 
optimisation of this assay will be done to allow more accurate quantitation. It would be 
interesting to quantify the levels of these protein targets at each stage of the parasite red blood 
cell cycle for comparison to the transcription data. 
A study by Martin et al., (2009) quantified the levels of LDH and histidine rich protein within 
the P. falciparum Dd2 strain. This strain does not express HRP-2, but they measured the 
levels of HRP-1 and HRP-3. The concentration of PfLDH was estimated at 28.9 ng/ml for a 1 
% parasite culture. The DAS-ELISA data shown here suggest there to be 17.3 ng/ml of 
PfLDH in a 1 % parasitemia lysate. The DAS-ELISA data in this study suggest there to be 
approximately 138.5 ng/ml PfGAPDH within a 1 % parasitemia lysate.  
These results showed the anti-recombinant as well as the anti-peptide antibodies to be 
specific to their respective target antigens. They did not cross-react with any human blood 
proteins or any other parasite proteins. These antibodies consistently detected greater levels 
of PfGAPDH to PfLDH except in ECL results, where sample preparation may have played a 
role. In a DAS-ELISA assay approximately 4 times greater levels of PfGAPDH in 
comparison to PfLDH were detected. These results support PfGAPDH as a possible 















6.1 Brief review 
Malaria causes severe disease and is often fatal, especially in children under the age of 5 
(WHO The Global Burden of Disease, 2008; WHO malaria fact sheet no. 94, January 2009). 
With no vaccine currently available, disease control and prevention relies on vector control 
methods, diagnosis and anti-malarial treatment (Betson et al., 2009; Kappe et al., 2010; 
Moody, 2002). Developing countries in the tropics, which often lack the required 
infrastructure and funding to effectively control malaria are the worst affected (Hay et al., 
2009). Field hospitals in rural areas therefore require diagnostic tests that are rapid, easy to 
perform and interpret, yet sensitive and specific at the same time (Makler et al., 1998; 
Moody, 2002; Perkins and Bell, 2008). Microscopy using Giemsa staining has served as and 
still is the gold standard for malaria diagnosis, detecting around 50 parasites per microliter. 
Preparation of samples for microscopy is cheap and infections can be quantified, however 
expertise is required to specifically identify the infecting species of Plasmodium (Moody, 
2002; Suh et al., 2004). Various alternate methods have been developed in attempts to 
improve diagnosis, such as PCR, which can detect infections below 5 parasites per microliter 
(Demas et al., 2011). Most of these methods including microscopy require either expensive 
equipment or laboratory conditions to perform optimally (Makler et al., 1998; Moody, 2002; 
Perkins and Bell, 2008). Malaria immunochromatographic or rapid diagnostic tests (RDTs) 
have been developed to simplify malaria diagnosis and to be implemented in the field. The 
current tests target histidine rich protein 2 (HRP-2), lactate dehydrogenase (LDH) and 
aldolase and take between 15 to 20 minutes to perform with a detection limit of around 100 
parasites per microliter (Ashley et al., 2009; Khairnar, 2009; Makler et al., 1998; Murray et 
al., 2008, Perkins and Bell, 2008). In order for RDTs to detect asymptomatic infections 
which would act as reservoirs of infection, the limits of detection will have to be improved to 





6.2 The aims and objectives of this study 
The main aims of this study were first to find a new Plasmodium falciparum protein target 
glyceraldehyde-3-phosphate dehydrogenase (PfGAPDH) and to compare it to a current 
diagnostic target lactate dehydrogenase (PfLDH). A second aim was to detect PfGAPDH and 
PfLDH within parasite lysate material using polyclonal chicken antibodies (IgY). To do this 
both proteins were recombinantly expressed, affinity purified and used to raise IgY. 
Additional IgY against specific peptide epitopes identified on the surface of PfLDH and 
PfGAPDH were also raised.   
 
6.3 Main findings, conclusions and future work 
The gene inserts used for expression of PfLDH and PfGAPDH were confirmed by size and 
PCR, where the PCR amplicons were sequenced, and had between 96 to 98 % homology with 
their respective DNA coding sequences. Both recombinant proteins were expressed at sizes 
slightly larger than the predicted native protein sizes due to additional His6-tags similar to 
results from other groups (Berwal et al., 2008; Daubenberger et al., 2003; Satchell et al., 
2005; Turgut-Balik et al., 2004). This did not seem to affect their quaternary structure as 
assessed by molecular exclusion chromatography (gel filtration chromatography) and was 
also demonstrated by Berwal et al., (2008) and Satchell et al., (2005), however enzyme 
activity assays for PfGAPDH (Daubenberger et al., 2000; Ferdinand et al., 1964) and PfLDH 
(Berwal et al., 2008; Gomez et al., 1997) would be useful to confirm the correct folding of 
the respective enzymes. 
Peptide epitopes were identified on both PfLDH and PfGAPDH by sequence alignment and 
using an epitope prediction program Predict7TM. The locations of the individual peptides 
identified were shown to be on the surface of their respective 3D protein crystal structure 
models (Dunn et al., 1996; Satchell et al., 2005). This approach allowed for in silico 
assessment of the target epitopes ensuring their specificity prior to the immunisation of 
experimental animals. This avoids the selection process involved in raising monoclonal 
antibodies (Pluschke et al., 1998) saving time, money and experimental animals. It would be 
interesting to compare the sensitivity of the polyclonal anti-LDH-peptide antibodies raised 
here to the monoclonal antibodies against Plasmodial LDH currently used in RDTs.  
Isolation of IgY yields approximately 7 times more specific antibodies than comparative 
yields of IgG from rabbits and avoids bleeding of experimental animals (Schade et al., 1991). 
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In addition IgY lacks an Fc portion and does not cross react with mammalian complement 
proteins, Rheumatoid factors and anti-nuclear antibodies (Schade et al., 1991), which has 
been a cause of false positives in malaria RDTs using mammalian antibodies (Iqbal et al., 
2000). Chicken antibodies (IgY) were raised against both the selected peptide epitopes for 
both PfLDH and PfGAPDH as well as both recombinant proteins. The antibodies were 
specific and did not cross react with other human blood proteins. Further work needs to be 
done to compare the sensitivities of the respective antibodies, as well as assessing their 
specificity using LDH and GAPDH from other malaria species. The anti-peptide antibody 
sensitivities will be assessed using a direct ELISA approach as was done with the anti-
recombinant antibodies, as well as in a DAS-ELISA format, where the recombinant antigens 
will be captured by the anti-peptide antibodies and detected using an anti-His6 tag antibody. 
Native PfLDH and PfGAPDH were successfully “pulled down” using the anti-recombinant 
whole protein antibodies and also detected in DAS-ELISA experiments in Pf(D10) lysates. 
PfGAPDH was consistently detected at higher levels than PfLDH. The rapid saturation of the 
PfLDH standard curve for the DAS-ELISA assay was concerning and this could be tested by 
using the other anti-peptide antibody as the capture antibody. By comparing the level of 
PfGAPDH with the level of PfLDH detected in this study as well as by Martin et al., (2009), 
PfGAPDH in these assays appears to be present at a higher level than PfLDH. This correlated 
with transcription data from Le Roch et al., (2003), however, it would be interesting to 
quantify protein levels at each stage within the red blood cell cycle, as Kuss et al., (2012) and 
Lasonder et al., (2002) have shown that protein levels may not necessarily correlate with 
mRNA levels due to posttranscriptional or posttranslational regulation. Semi-quantitative 
analyses of protein levels by Nirmalan et al., (2004) and Smit et al., (2009) have shown 
increasing trends in PfLDH and PfGAPDH levels from ring to schizont stages, however, 
therefore supporting the Le Roch et al., (2003) data. 
The antibodies raised here remain to be tested in an RDT format. This would not only allow 
for comparison with other RDTs, but at the same time the heat stability of the IgY in an RDT 
format could be assessed. IgY antibodies have been shown to be stable at 4 ºC for prolonged 
periods (Goldring and Coetzer, 2003). Chiodini et al., (2007) highlighted the need for a cold 
chain to ensure RDTs remain of a high functional quality in the field. The recombinant 
proteins and the peptides used in this study could also be used for quality assurance of RDTs 
as described by Lon et al., (2005). 
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In order to eliminate malaria, RDTs would have to detect asymptomatic infections at parasite 
loads below 100 / µl (Faechem et al., 2009). By identifying and targeting proteins expressed 
at higher levels than the current RDT targets, the limits of detection of RDTs may be 
lowered. Alternatively targeting a pool of malarial antigens may also improve RDTs and this 
could also be tested using the antibodies and recombinant proteins available in this study. 
Another school of thought is that RDTs should not only be focused on detecting low 
parasitemia levels. In malaria endemic regions the adult population often develop natural, 
non-sterilizing immunity against malaria, therefore they remain susceptible to infection but 
are asymptomatic (Hafalla et al., 2011; Miller et al., 1994). As a result detecting and treating 
an asymptomatic malaria infection in such patients does not necessarily treat the cause of the 
disease which may be due to a different pathogen and thus require alternate drug treatment to 
treat the disease. 
The ultimate aim with RDTs would be to quantify the extent of infection, as this will allow 
clinicians to monitor patients during drug treatment and will allow them to determine whether 
alternate drug treatments are necessary to clear infections. By targeting glycolytic proteins for 
malaria diagnosis in this study we hope to allow RDTs to do this. It was shown that LDH 
based RDTs return to negative between 2 to 7 days after drug clearance of infections (Iqbal et 
al., 2004; Murray et al., 2008). This will have to be assessed in an RDT format using 
GAPDH as the target antigen. 
Future studies concerning the application of this research for the improvement of rapid 
diagnostic malaria kits can be broken down into three criteria: 
1) Comparative studies of the newly identified diagnostic target PfGAPDH to the known 
target PfLDH can be conducted.  
This would include the further optimisation of the double antibody sandwich assay 
described in this study, as well as the use of enhanced chemiluminescence for 
comparison of the relative levels of the protein targets to each other. Comparison of 
PfLDH and PfGAPDH gene transcription and expression levels at the different stages 
of the malaria parasite red blood cell cycle would also be interesting.  
2) Comparative studies of the antibodies raised in this study to each other as well as to 
the commercial antibodies used in current RDTs would be interesting. 
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The antibodies raised in this study could be evaluated for their affinity for their target 
antigens by measuring their affinity constants (KD). This can be done to compare the 
affinities of the anti-peptide antibodies to each other, and to assess which target 
peptide has greatest antigenicity which would also assess the Predict7TM data used 
here. This could also be done for monoclonal antibodies used in current RDTs.  
The antibodies raised here could also be tested for their specificity for their target 
antigens, especially in the case of the species specific anti-peptide antibodies. To add 
to this it would be interesting to assess the possibility of targeting P. knowlesi specific 
peptides. 
3) The antibodies raised here will have to be assessed in an RDT format, as the 
antibodies may perform differently under RDT conditions than they do in optimised 
laboratory settings.  
RDT specificity and sensitivities could be assessed. The heat stability of these RDTs 
would also be of interest in comparison to commercial RDTs using monoclonal 
antibodies. This is a concern raised in the literature for current RDTs used in the field.  
The use of RDTs targeting PfGAPDH for monitoring infections also has to be 
assessed, possibly with the use of a mouse model in which infections are cleared with 
drug treatment.  
Further studies which are of interest are to address the possibility of using RDTs to 
detect the severity of infections in terms of % parasitemia. This may involve a larger 
number of test lines on RDTs detecting antigen, and in this way relating amount of 
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